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Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a complex 
disease, characterised by progressive airflow obstruction and is a major cause of 
morbidity, mortality and healthcare usage in the UK. Quadriceps muscle dysfunction 
is a key cause of exercise intolerance in patients with COPD, manifested by reduced 
muscle mass and strength. This problem also imposes a burden to the health system 
as quadriceps dysfunction is an independent predictor of hospitalisation and 
mortality. Importantly, the quadriceps may provide a target for therapy in an 
otherwise irreversible lung disease and changes in strength after resistance training 
(RT) are well documented. Protein supplementation has been successfully used as 
an adjunct to RT in healthy populations. However the role of this therapeutic 
combination has not before been studied in a COPD population.
Methods: This thesis describes a randomised controlled trial (RCT) which aims to 
explore the role of protein supplementation given immediately after RT, upon 
functional outcomes, in patients with COPD. The hypothesis was that RT, in 
combination with protein ingestion (at the time of training) will have greater effects on 
functional outcomes than RT alone (chapter 4). Secondary aims were to precisely 
explore the training intensity progression, fatigue profile (chapter 5) and cardio-
respiratory load imposed by the RT (chapter 6) and to examine the measurement 
properties of the ActiTrac® physical activity (PA) monitors (chapter 7). In all 
chapters the response to the intervention in patients with COPD, is compared to 







Results: The overriding message from this thesis is that protein supplementation 
can not be routinely recommended as an adjunct to RT for patients with COPD. All 
groups made significant improvements in quadriceps strength and thigh mass after 
RT but protein did not augment the outcome. Subjects with evidence of muscle 
wastage (based on fat-free mass criteria) responded less well to RT, although the 
study was underpowered to draw meaningful conclusions in this group. Subjects with 
COPD made comparable improvements to healthy age-matched controls, despite 
training at much lower intensities and experiencing greater decay in muscle force 
during a training session. Moreover, the RT programme was able to sufficiently 
activate the cardio-pulmonary system and led to significant improvements in whole-
body exercise performance. PA did not change after the 8-week RT programme; 
suggesting that changes after RT are not routinely translated to increased habitual 
activity, particularly when the educational component of rehabilitation is missing.
Conclusions: The RT programme utilised in this thesis was able to significantly 
improve both strength and endurance-related outcomes in patients with COPD. 
However, the provision of additional protein at the time of training did not enhance 
the benefits. The isokinetic RT programme provided a unique opportunity to 
precisely explore the training intensity progression, fatigue profile and cardio-
respiratory load imposed by the training; comparing patients with COPD and healthy 
controls. The findings from this work provide some important considerations for 
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and symbols used in this Thesis
σ sigma 
° degrees 
°/sec degrees per second 
/ divided by
< less than 
≤ less than or equal to 
> more than 
≥ more than or equal to 
multiplied by
% percent or percentage 
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1.1 Defining the burden of COPD 
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term that 
describes several abnormalities of the lung often caused by tobacco smoking, 
including chronic bronchitis and emphysema (Anthonisen 2002) . It is a 
complex disease, characterised by progressive airflow obstruction, which isn’t 
fully reversible but does not change markedly over several months (National 
Institute for Clinical Excellence 2010). COPD is a major cause of morbidity, 
mortality and healthcare usage in the United Kingdom (Britton 2003;National 
Institute for Clinical Excellence 2010) and therefore represents a huge burden 
to the individual, their family and the healthcare system. This burden is set to 
increase in line with tobacco usage, as COPD is projected to become the 3rd 
leading cause of death in the world by 2030 (World Health Organization 
2008). Symptoms include dyspnoea, cough and sputum production 
(Anthonisen 2002). However, exercise intolerance is a key feature of 
advancing COPD, with patients reporting dyspnoea and leg fatigue among the 
most frequent symptoms which limit exercise (Killian et al. 1992) . 
The clinical manifestations of COPD are not confined solely to the lungs and 
the systemic consequences of the disease are now well documented 
(Decramer et al. 2005). One extra- pulmonary feature of the disease is 
skeletal muscle dysfunction (American Thoracic Society/ European 








strength (American Thoracic Society/ European Respiratory Society 
1999;Gosselink et al. 1996). The mechanisms underlying skeletal muscle 
dysfunction in this population are not fully understood; however 
deconditioning through inactivity is undoubtedly involved (Decramer et al. 
1994;Morgan 2005). 
Whatever the cause, muscle weakness has important prognostic and 
functional consequences for the individual, independent of their lung function 
(Decramer et al. 1997a;Gosselink, Troosters, & Decramer 1996;Marquis et al. 
2002;Swallow et al. 2007b) and leg fatigue negatively contributes to whole 
body exercise performance (Steiner et al. 2005a). These skeletal muscle 
alterations indicate that muscle training should play an important role in the 
treatment of this patient group (O'Shea et al. 2004). For many patients with 
COPD, the pulmonary pathology underlying their disease is irremediable. 
Therefore, therapies to combat the secondary consequences of the disease 
may be effective and warrant further investigation. With this in mind, the 
skeletal muscles may provide a potential target for therapy in an otherwise 
irreversible lung disease and this is a key aim of Pulmonary Rehabilitation 
(PR). 
We know that resistance training (RT) in isolation can improve muscle mass 
and strength in patients with COPD (O'Shea, Taylor, & Paratz 2004;Spruit et 
al. 2002). Increases in quadriceps strength are well documented (O'Shea et 
al. 2009a) and improvements after training are generally in the region of 20% 





this population. Furthermore changes in mass after exercise tend to be much 
lower than changes in strength (only 5-6% improvements); suggesting that 
other factors (besides increased mass) are involved in producing muscle force 
(Jones et al. 2004). Whether these improvements in muscle strength and 
mass translate into functional benefits for patients is inconclusive (O'Shea, 
Taylor, & Paratz 2009). 
RT has generally been prescribed quite crudely for practical purposes within 
rehabilitation settings, using equipment which is locally available and 
transportable. Isokinetic dynamometry represents the gold standard in the 
observation of muscle performance for testing and training. The presence of 
an accommodating resistance during isokinetic testing allows for the safe 
measuring of torque, total work and power at constant speed throughout the 
full range of movement and therefore gives a comprehensive picture of 
muscle function. Isokinetic testing is rarely used in the evaluation of strength 
for patients with COPD and has not been used as a RT device in this 
population. The unique RT programme used in this thesis was based upon 
some novel research by Jones conducted at the University of Nottingham in 
2004. They found that by immobilising healthy young men in a limb cast for 2 
weeks, a 5% decrease in quadriceps mass occurred. Following a carefully 
controlled isokinetic RT programme at 180 degrees per second (°/ sec); 
muscle mass and strength returned to basal levels. The rapid training velocity 
chosen targets type II muscle fibres and was found to be feasible and 
acceptable to our frail patients in a pilot study which took place prior to 








Skeletal muscle mass is determined by varying rates of protein synthesis and 
protein degradation. Therefore muscle atrophy may be expressed in terms of 
decreased protein synthesis and/ or increased protein degradation resulting in 
net protein loss. Evidence suggests that there is increased whole body protein 
turnover in underweight patients with COPD (Engelen 2000), although the 
mechanisms are poorly understood. Dietary protein has been shown to induce 
protein synthesis in healthy young adults. However there is an impaired 
response in healthy elderly subjects and merely providing dietary protein may 
not be effective in increasing protein synthesis (Cuthbertson et al. 2006). It 
may be that an anabolic stimulus, such as exercise is needed. The timing of 
supplementation in relation to resistance exercise may also be an important 
factor in the response for older people. Data from Denmark found that muscle 
hypertrophy only occurred in the group receiving protein immediately after 
resistance training and not in those receiving the protein 2 hours later
(Esmarck et al. 2001). The aim of this thesis was to translate these 
observations to a group with COPD as the role of protein in combination with 
RT has not before been studied in this population. 
1.2 Research Aim and Research Objectives
This thesis aims to address gaps in the existing field of knowledge. We 
currently do not know what the effects of this therapeutic combination (RT and 
protein supplementation) will be. Furthermore we do not know if the results 
will translate into functional benefits for patients. This was a mechanistic 
study, examining the role of protein as an adjunct to RT. It was not a study of 



















study hypothesis was that: RT, in combination with protein (at the time of 
training), will have greater effects on functional outcomes than RT alone.
Furthermore, the nature of the RT programme chosen presented unique 
opportunities to precisely explore the training intensity progression, fatigue 
profile and cardio-respiratory load imposed by the training; comparing patients 
with COPD and healthy controls.
Specific objectives were to measure the functional response to the 
intervention by observing changes in muscle function (muscle strength and
mass) and physical performance [whole-body exercise capacity and physical 
activity (PA)]. The effects in patients with COPD are compared with healthy, 
age-matched controls.
The following research objectives were formulated:
1. To observe the changes in muscle function and physical performance after 
a RT programme.
2. To then determine whether the addition of a nutritional supplement has 
increased benefits on muscle function and physical performance in 
patients with COPD; compared to RT alone.
3. To describe the trajectory of training intensity progression and fatigue 
profile of the isokinetic RT programme over an 8-week period and to 










4. To analyse the cardio-respiratory load imposed by the RT programme. 
5. To explore the test re-test reliability, reproducibility and sensitivity of the 
ActiTrac® accelerometers, used to assess PA in this thesis. 
1.3 Structure and Setting of the Thesis 
This thesis forms part of a larger Medical Research Council (MRC) funded 
study which was designed to explore the molecular mechanisms underpinning 
the restorative effects of RT and protein supplementation on muscle mass in 
patients with COPD (‘Molecular approaches to reversing skeletal muscle 
wasting in COPD. The role of resistance training and nutritional 
supplementation’). Dr Manoj Menon obtained vastus lateralis muscle biopsies 
to examine the molecular responses to the intervention for his PhD thesis. My 
thesis focuses on the functional outcomes from the randomised controlled trial 
(RCT) of RT and nutritional supplementation, in patients with COPD. The RCT 
is described in chapter 3 (materials and methods). Both myself and Dr Menon 
recruited and consented patients, performed cycle ergometry tests and carried 
out DEXA (dual energy x-ray absorptiometry) scans. I, independently, 
supervised RT and assessed muscle strength. My thesis was therefore 
limited, in part, due to the design of the study which was beyond my control 
(e.g. timings, duration of programme, interventions delivered).
Chapter 2 presents a comprehensive review of the available literature and 
contextualises this thesis. Chapter 4 presents the main outcomes from the 

















function and physical performance after the 8-week intervention. As protein 
supplementation did not augment the benefits of RT, after this chapter, the 
data from the subgroups are pooled.
Chapters 5 and 6 explore the profile of the RT programme; comparing 
training trajectories, fatigue/ force decay and the cardio-respiratory load in 
patients with COPD and healthy controls. The relationship between training 
intensity and functional outcomes at 4 and 8-weeks is also analysed.
Chapter 7 is a methodological chapter relating to PA. The reliability properties 
of the ActiTrac® activity monitors, used to measure PA in this thesis, are 
interrogated. The changes in PA (measured using the ActiTrac® and 
questionnaires), following RT in a sub-group of patients are also presented. 
Finally chapter 8 discusses the key findings, implications for clinical practice, 












This chapter helps to contextualise the thesis by exploring the main themes. 
Firstly the disease pathology, epidemiology and clinical features of Chronic 
Obstructive Pulmonary Disease are introduced. A major cause of exercise 
limitation in this population is skeletal muscle dysfunction. The possible 
causes and consequences of this problem are discussed. Current treatments 
used to slow disease progression, improve symptoms, exercise tolerance and 
quality of life are appraised. Finally the chapter concludes by outlining the two 
interventions explored (resistance training and protein supplementation) and 
the outcome measures used in this thesis. 
2.2 Chronic Obstructive Pulmonary Disease 
2.2.1 Definition 
Chronic obstructive pulmonary disease (COPD) is an umbrella term that 
describes several abnormalities of the lung including chronic bronchitis and 
emphysema (Anthonisen 2002). COPD is a preventable and treatable disease 
characterised by progressive airflow obstruction. This obstruction is not fully
reversible but does not change markedly over several months (Department of 
Health 2010;National Institute for Clinical Excellence 2010). 
COPD is diagnosed by an objective measure of airflow obstruction; 







         
   
 
    
     
 
   
       
 
   
       
 
   




FEV1 is forced expired volume in one second and FVC is forced vital 
capacity). An FEV1/FVC ratio of less than 0.7 (70%) indicates COPD (National 
Institute for Clinical Excellence 2010). The FEV1 is also commonly reported as 
an independent measure of airflow obstruction which can be expressed as a 
percentage of the value predicted for that individual [based on age, height and 
gender (Department of Health 2010;Global Initiative for Chronic Obstructive
Lung Disease (GOLD) 2009)]. GOLD classify disease severity in four stages 
based on FEV1 and FEV1/FVC ratio criteria, these stages are heavily cited 
[table 2.1 (Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
2009)]. 
Table 2.1 GOLD classification of COPD severity by spirometry
Classification Spirometry values
I: Mild • FEV1/FVC <70%
• FEV1 ≥ 80% predicted
II: Moderate • FEV1/FVC <70%
• FEV1 ≥ 50 and < 80% predicted
III: Severe • FEV1/FVC <70%
• FEV1 ≥ 30 and < 50% predicted
IV: Very Severe • FEV1/FVC <70%
• FEV1 < 30% predicted OR < 50% predicted plus
respiratory failure
2.2.2 Pathology and clinical features 
In the past, distinctions were made between the individual diseases which are 
now incorporated by the term COPD. This section discusses those individual 
diseases in more detail. However, for practical purposes, these conditions 












individual and the management is much the same (Department of Health 
2010). 
Chronic Bronchitis 
Chronic bronchitis is defined as the presence of a cough, which is productive 
of sputum, occurring on most days for at least 3-months of at least two 
successive years. The disease is characterised by inflammation of the large 
airways, mucous gland hypertrophy and hyperplasia, resulting in an over 
production of mucous (Kon & Brame 2008). This provides the ideal 
environment for infections to thrive. The combination of inflammation and 
sputum plugging causes airway narrowing.
Emphysema 
Emphysema is described when the alveolar walls are destroyed, resulting in 
permanent dilatation of the airways, distal to the bronchioli, without obvious 
fibrosis. It is thought that this destruction occurs because of inflammation 
within the lung parenchyma (Kon & Brame 2008). 
Patients with emphysema also have increased lung volumes because of air
trapping which occurs as a result of expiratory flow limitation (Man and Kon 
2008). This ‘air trapping’ is known as hyperinflation which is apparent on both 
physical examination and imaging, and is particularly evident during exercise 






        
    
 
         
 
            
 
          
      
 
               
 
 





Clinical features of COPD 
The symptoms of COPD include dyspnoea, cough and sputum production 
(Anthonisen 2002), which may be worse during winter months (Department of 
Health 2010). Initially, dyspnoea does not inhibit daily tasks and these 
symptoms are often not present until the disease is relatively well advanced.
The severity of breathlessness can be classified using the modified Medical 
Research Council (MRC) grade [table 2.2- (Flectcher et al. 1959)].
Table 2.2 Modified Medical Research Council dyspnoea grades
Grade Level of breathlessness
1 Not troubled by breathlessness except on strenuous exercise
2 Short of breath when hurrying or walking up a slight hill
3 Walks slower than contemporaries on level ground because of
breathlessness, or has to stop for breath when walking at own pace
4 Stops for breath after walking about 100m or after a few minutes on level
ground
5 Too breathless to leave the house, or breathless when dressing or
undressing
COPD is a systemic disease which affects organs outside of the lungs 
(Decramer et al. 2005). A key problem is skeletal muscle dysfunction 
(weakness and atrophy), leading to exercise intolerance (Killian et al. 1992). 
The resultant inactivity from avoiding uncomfortable symptoms leads to 
worsening exercise tolerance and progressive disability (American Thoracic 
Society/ European Respiratory Society 1999;Rochester 2003). These 
changes are associated with a reduced quality of life and are often described 
as a ‘vicious cycle’ of physical and psychosocial decline (Agusti 2005). 








which has been linked to increased arterial stiffness (Sabit et al. 2007). The 
arterial stiffness found in this population is greater in those with evidence of 
osteoporosis and is associated with inflammation (Sabit et al. 2007). 
COPD is also characterised by acute exacerbations (AE) or ‘flare ups.’ This 
describes periods of the illness where there is a rapid and sustained 
worsening of symptoms beyond normal day-to-day variations (National 
Institute for Clinical Excellence 2010;Rodriguez-Roisin 2000). During an AE, 
dyspnoea is generally worse and sputum expectoration may change (more 
than usual, more viscous or more purulent). These symptoms often 
necessitate a change in treatment [e.g. antibiotics and/or oral steroids 
required (Rodriguez-Roisin 2000)]. Disease exacerbations are associated with 
worsening quality of life (Seemungal et al. 1998), speedier disease 
progression (Donaldson et al. 2002), increased mortality (Soler-Cataluna et al. 
2005) and are a significant cause of hospitalisations and health care costs
(Garcia-Aymerich et al. 2003). On average, 15% of those admitted to hospital 
die within three months, and around 25% die within a year of admission. 
Recent data published by the office for UK National Statistics show that one in 
three people with COPD are being readmitted within 28 days of discharge
(British Lung Foundation and British Thoracic Society 2010).  
2.2.3. Aetiology and natural history 
Tobacco smoking is the single most important and preventable cause of 
COPD development (Department of Health 2010;van Durme et al. 2009), 








[one pack year= 20 cigarettes smoked per day for one year (Bloch and Kon 
2008)]. Over time, cigarette smoking causes cycles of inflammation and 
repair. These cycles are associated with protein degradation, airway and 
parenchymal remodelling. However, non-smokers can also develop COPD 
due to other causes. These include exposure to pollution, occupational dusts/ 
fumes/ solvents and previous respiratory infections. The disease is also more 
prevalent in those with a poor diet and low socio-economic status 
(Department of Health 2010;Hansel and Kon 2008). Some individuals may 
additionally have a genetic deficiency of alpha-1-antitrypsin. This is an anti-
protease which opposes the protease elastase. Without opposition, elastase 
attacks the alveolar sacs of the lungs (Stoller and Aboussouan 2005). 
Measuring the annual rate of loss of FEV1 is the classic way of recording the 
natural history of COPD. The decline in FEV1 can be slowed by smoking 
cessation (Scanlon et al. 2000). In addition to lung function, it is also important 
to measure the systemic effects of the disease. The BODE index is a useful 
prognostic indicator and incorporates body mass (B), airflow obstruction (O), 
dyspnoea score (D) and exercise performance [E (Celli et al. 2004)]. 
2.2.4. Prevalence, burden of disease and mortality 
An estimated 210 million people have COPD worldwide (World Health 
Organization 2009). This burden is set to increase in line with tobacco usage, 
as COPD is projected to become the third leading cause of death in the world 
by 2030 (World Health Organization 2008). In the UK, around 900,000 people 









disease but this is yet to be diagnosed (Healthcare Commission 2006). These 
people are referred to as ‘the missing millions’ in the COPD strategy 
consultation document, launched in February 2010 (Department of Health 
2010). Recent data from Canada suggests that one in four people are likely to 
be diagnosed and receive medical attention for COPD during their lifetime 
(Gershon et al. 2011). 
Whilst other major causes of death have been declining, mortality due to 
COPD continues to rise. One person every 20 minutes dies from COPD in 
England and Wales, attributing to 25,000 deaths per year (UK National 
Statistics 2008). Mortality data may underestimate the impact of COPD as it is 
often listed as a contributory cause of death or not listed at all on death 
certification (Pauwels et al. 2001b). 
COPD is a major cause of morbidity, mortality and healthcare usage in the 
United Kingdom (Britton 2003;National Institute for Clinical Excellence 2010)
and therefore represents a huge burden to the individual, their family and the 
healthcare system in terms of long-term management and disability-related 
costs The direct cost of COPD to the UK health system is estimated to be 
between £810 and £930 million per year (Department of Health 2010). 
2.3 Skeletal muscle dysfunction 
Prior to considering the problem of skeletal muscle dysfunction in patients with 










2.3.1 Healthy muscle structure, function and response to training 
Muscle structure 
Skeletal muscle tissue makes up over one-third of total body mass 
(Palastanga et al. 2006). Skeletal muscle consists of several individual cells 
which are long multinucleated fibres. Muscle fibres can shorten to around half 
of their original resting length, therefore the arrangement of fibres within a 
muscle determines how much the muscle will shorten during a contraction 
(Palastanga, Field, & Soames 2006). The arrangement of fibres within a 
muscle will either be parallel (fusiform) or oblique (pennate) to the line of pull 
for the whole muscle (Palastanga, Field, & Soames 2006). Muscles are 
attached to bones and other structures via dense connective tissue, namely 
tendons. When a muscle or tendon passes over a bone it is usually separated 
from the bone surface by bursae (fluid filled sacs); which help to reduce 
friction (Palastanga, Field, & Soames 2006).  
Muscle fibres which are collectively supplied by one motor endplate (neurone)
make up a ‘motor unit’. The motor unit comprises the alpha motor neurone 
and all of the muscle fibres which this innervates. The electrical impulse from 
this nerve ending is transmitted along the fibre by the sarcolemma, a thin 
membrane encasing the muscle fibre. This membrane also conducts fuels and 
waste products in and out of the muscle cell from the surrounding capillaries 
(Sherwood 1993). Each muscle cell contains specialised contractile elements; 








Amino acids are the building blocks of proteins and skeletal muscle is the 
body’s main protein store. In extreme conditions, such as starvation, muscle 
can supply amino acids to other tissues (Jagoe and Engelen 2003). 
Muscle contraction mechanism and contraction types 
Each myofibril is made up of a uniform arrangement of thick (myosin) and thin 
(actin) protein filaments. Excitation of the skeletal muscle fibre by its motor 
neurone brings about a contraction by a series of events that result in the thin 
filaments sliding closer together between the thick filaments. This ‘sliding-
filament’ mechanism of muscle contraction is switched on by calcium release 
which binds to the protein complex troponin on the actin filaments and 
uncovers actin’s cross bridge binding sites. After the exposed actin binds to 
the myosin cross bridge; energy is released which powers the rowing action of 
the thick and thin filaments as they slide past each other. Inward sliding of all 
the thin filaments causes the whole muscle to shorter (Sherwood 1993). This 
cycle continues as long as calcium is still present and energy is available 
[from the breakdown of adenosine tri-phosphate (ATP)]. 
Muscle contractions may occur both when the muscle is at a static length and 
when the length changes (shortens or lengthens under tension). See table 
2.3. The two outcomes of interest in isokinetic contractions are peak torque 
and total work. These are described in more detail in section 2.6.1 
(quadriceps muscle strength). 
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The length of the muscle fibres remain constant during the 
contraction and no movement occurs at the joint.
Dynamic Joint movement occurs during contraction. This can consist of
either isotonic or isokinetic contractions.
Isotonic There is a shortening (concentric action) and lengthening (eccentric
action) of a muscle throughout its range of motion around a joint.
Isokinetic The speed of muscle contraction is fixed within a range of motion,
and the force generated by the muscle encounters an opposing 
force relative to that applied to the testing device.
Quadriceps Femoris muscle group
The muscles of interest in this thesis are the quadriceps (femoris); a group of 
four muscles which contract to extend the knee joint (rectus femoris, vastus 
lateralis, vastus medialis and vastus intermedius). The rectus femoris also
plays a role in hip flexion, as its tendon originates above the hip joint. The 
other three muscles originate along the shaft of the femur (thigh) and all four 
join together around the patella to form the ligamentum patellae, which inserts 
into the tibial tuberosity (figure 2.1). Each muscle within the quadriceps 





          
 
Figure 2.1 Line drawing of the Quadriceps femoris group of muscles
Two of the four muscles, rectus femoris and vastus intermedius, give central 
power to knee extension, working through the patella as a lever. Vastus 
lateralis and vastus medialis assist in knee extension but also give peripheral 
support to both movement and the joint itself (Backhouse 2012).The 
quadriceps is of particular importance because it is heavily utilised in daily 
function (e.g. standing from a chair, climbing stairs) and is known to be more 
affected by the systemic consequences of COPD, compared to other muscles 











and mass rapidly (within days) if disused or injured (Di Monaco et al. 
2007;Ferrando et al. 1996a;Rittweger et al. 2005;Visser et al. 2000)Normal 
values for quadriceps strength have been reported for young and middle aged 
adults (American College of Sports Medicine 2009). However data from older 
individuals is sparse. 
Table 2.4 summarises normal values for both isometric and isokinetic 
quadriceps strength in two studies which have evaluated these measures in a 
range of age groups (Borges 1989;Phillips et al. 2000a). These values are 
interesting when comparing values in patients with COPD to healthy controls 
of various ages. It should be noted, however, that variations exist between the 
knee joint angles and speeds for testing in this thesis and these studies. This 
should be taken into account when considering the results from this thesis in 
comparison to these studies.
Energy metabolism 
ATP is required during the following three steps of contraction-relaxation:  
1. To provide the energy for the power stroke of the cross bridge.
2. Permits detachment of the myosin bridge from the actin filament so that 
the cycle can be repeated.
3. The transport of calcium at the end of the contraction depends on the 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































        





      
     
      
     
     
    
      
 
      
 
 
ATP is the single energy source that can be used for these processes and 
must be continuously supplied for activity to continue. There are three types of 
muscle fibres present in skeletal muscle which are classified by which of the 
three pathways they use for ATP synthesis. The characteristics of these fibre 
types are summarised in table 2.5.  







Speed of contraction Slow Fast Fast
Endurance/Fatigue Resistance High Medium Low
Power of contraction Low High High
Metabolism Oxidative Oxidative,glycolytic Glycolytic
Mitochondrial Density High Medium Low
Capillary Density High Medium Low
Colour of fibre Red Red White
Adapted from (Maughan et al. 1997;Sherwood 1993).
Metabolites, such as lactate (lactic acid) and ammonia are the end products of 
anaerobic glycolysis and are associated with fatigue (Tesch et al. 1978). 
Determining muscle strength 
Muscular strength is defined as ‘the amount of force an individual can produce 
during a single maximum effort’. The term power is often used 
interchangeably but actually refers to the rate of force production (Costill et al. 








motor units recruited, fibre cross-sectional area (CSA) and two important 
relationships, which are: 
1. The length-tension relationship: tension or force produced by a muscle is 
dependent upon the length of the muscle and each muscle has an optimal 
length for maximal force generation (Rack and Westbury 1969). This 
represents a function of the amount of overlap between actin and myosin
filaments. If a muscle length changes, shorter or longer, force is reduced 
(Gaines and Talbot 1999). 
2. The force-velocity relationship: The power of a contraction is dependant on 
the velocity at which the muscle fibres shorten and the load to be moved. 
Power is equal to load multiplied by velocity. With a large load, the speed of 
fibre shortening is slow (Gaines & Talbot 1999). Also torque exerted during 
isokinetic testing decreases with increasing pre-set angular velocity (PAV). 
Therefore more force is generated at a speed of 60 °/sec compared to 180 
°/sec (Baltzopoulos and Brodie 1989). 
Muscle quality also plays a role in force development as well as the factors 
outlined above. Quality relates to force produced per muscle area and can be 
related to fibre type, fatigability, blood supply to the muscle, neural activity and 
ability to produce/ efficiency of use of muscle energy substrates. Neural drive 
is particularly important in strength development and relates to motor unit 
recruitment, motor unit firing rate and synchronisation of motor unit firing.










hypertrophy and should therefore be considered when measuring strength
(Broughton 2001). 
Motivation will also have an influence on muscle strength and is discussed 
further in section 2.5.1 (resistance training). 
Fatigue 
Muscle fatigue is an important area of research as it is essential for daily living 
tasks, sporting activities and has been implicated as a possible cause of 
musculo-skeletal injuries (Corin et al. 2005). However it is a challenging area 
as the term ‘fatigue’ has been poorly defined in the literature and is used to 
describe a variety of processes related to muscle strength (Crowther et al. 
2007). In simple terms, it is ‘an exercise-induced reduction in maximal 
voluntary muscle force which is reversed by rest’ (Gandevia 2001). Other 
authors describe fatigue in terms of ‘task failure’ (Maluf and Enoka 2005). 
Exercise or task-induced fatigue can be described as: muscular (accumulation 
of metabolites and depletion of energy reserves), neuromuscular (unable to 
sustain neural stimuli, i.e. reduced neural motor drive) or central 
[psychological due to motivation (Sherwood 1993)] and will depend upon the 
demands of the exercise or task [i.e. intensity, muscle groups involved (Maluf 
& Enoka 2005)]. 
The optimal measurement of fatigue has not been established. Therefore the 
tools to measure muscle fatigue have often not been assessed or validated 









isokinetically (Corin, Strutton, & McGregor 2005) and is frequently measured 
after a fatiguing task by recording force/ torque decay, by assessing changes 
in electromyography (EMG) signals or a combination of the two (Abdalla et al. 
2007). The fatigue index (FI) was originally proposed by Thorstensson and 
Karlsson in 1976. This calculates the amount of muscle fatigue using the 
following equation:
FI= final force/ initial force x 100
(Thorstensson & Karlsson 1976). 
It is therefore a ratio measure or percentage and may be more appropriately 
described as force decay. In this approach, the decline in torque output of the 
quadriceps after 50 contractions was expressed as a percentage of the 
highest of the first three torques to the last three torques. A high fatigue index 
indicates high fatigue resistance (FR), i.e. an increased ability to sustain 
muscular contraction. If the value is greater than or equal to100%, no fatigue 
has occurred. Variations on this FI have also been reported e.g. initial force – 
final force/ initial force x 100. Using this equation, a lower score indicates 
better FR. Authors since have adapted the index to look at the difference 
between the first and last third of the test or the first and last five repetitions, 
for instance (Davies et al. 2000). An endurance protocol may also look to test 
individuals until they produce a pre-defined reduced in peak torque, 50% 







Corin and co-workers have found that isometric testing is better (the most 
valid) at evoking fatigue in the trunk flexors and extensors than isokinetic 
testing (Corin, Strutton, & McGregor 2005). Using four different protocols, the 
authors were observing for the greatest reduction in maximal muscle force in 
16 university rugby players. The ‘best’ protocol (at evoking fatigue) reduced 
flexor peak torque by an average of 16.2% and extensor peak torque by 
8.8%, compared to before fatigue testing using the FI described above 
(Thorstensson & Karlsson 1976). 
Fatigue may also be expressed as time until exhaustion/ task failure using 
repeated contractions (Maluf & Enoka 2005;Patton et al. 1978). However, this 
methodology can be time consuming and impractical. Several authors 
propose the use of RT to fatigue or failure to enhance strength gains. There is 
an argument that fatigue may, in itself, provide the stimulus to improve 
strength by activating muscle repair processes in response to mechanical 
stress (Izquierdo et al. 2006;Rooney et al. 1994). Abdalla and colleagues 
found that there was a rise in back extensor torque following a one minute 
maximal fatigue protocol (Abdalla, McGregor, & Strutton 2007). They argued 
that this could be attributed to post-activation potentiation (prior muscle 
loading induces central nervous system stimulation). 
Fatigue resistance (FR) is another frequently occurring term in the literature 
and is defined as ‘the capacity to resist fatigue in conditions of prolonged 
strength use’ (Salvador et al. 2009).  FR is required during exercise and many 










(Dipla et al. 2009). Generally, fatigue and FR are measured during strength 
testing (during one session). However it may be important to look at these 
factors serially, during a RT programme. One study by Salvador and 
colleagues analysed FR in young healthy subjects (mean age 21 years) over 
an 8-week RT programme (Salvador et al. 2009). The RT included 3 sets of 8-
12 repetitions for bench press, squat and arm curl. Strength and FR improved
in both males and females after training (p<0.05 compared to baseline). The 
increases in strength were accompanied by a mean percentage change in FI 
of - 17.3% in males and - 31.3% in females; when the three RT exercises 
were combined. This study used the alternative FI were a lower score 
indicates greater FR. Other studies have supported this notion that RT can 
improve FR (Campos et al. 2002;Izquierdo et al. 2006;Kemmler et al. 2004) 
and that women are more fatigue resistant than men at baseline and after 
training (Clark et al. 2005;Pincivero et al. 2003). The fact that men exhibit a 
higher tendency for muscle fatigue may be related to their ability to produce 
greater peak muscle force initially (Pincivero, Gandaio, & Ito 2003), as the FI 
is a ratio based on the initial force generated.
The majority of studies exploring fatigue, derived from isokinetic methods, 
have focused on peak torque (maximal strength) as an outcome, rather than 
total work (cumulative). Therefore the fatigue characteristics of isokinetic work 










Long-term adaptive changes occur in skeletal muscles, depending on the 
demands placed on the muscle. These demands must be greater than 
habitual levels of activity (principle of overload). 
Anaerobic RT increases the diameter of glycolytic (type II) fibres and the 
number of muscle cells [hyperplasia (Sherwood 1993)]. Hypertrophy following 
RT requires net protein synthesis within the muscle fibres and that the 
exercise stimulus be sufficiently intense (Esmarck et al. 2001). The transient 
increase in protein synthesis after an acute bout of RT persists for up to 48 
hours after training (Phillips et al. 1997). Protein synthesis rates are greater at 
three hours post-exercise, when compared to 24 and 48-hours (Phillips et al. 
1997). Muscle glycogen and phosphocreatine stores are also increased with 
RT. In addition, each muscle fibre is linked with a population of satellite cells.
These cells are capable of dividing and fusing with existing fibres. This fusion 
appears to be an essential part of fibre hypertrophy and therefore muscle 
growth. The type and magnitude of these changes will depend upon the 
frequency, intensity and duration of training and will only take place in the 
mode of performance by which the training occurs [principle of specificity 
(Maughan, Gleeson, & Greenhaff 1997)].
Outside of the individual fibres; neural adaptation after RT has been inferred 
because several studies report increases in muscle strength with little or no 
change in cross sectional area of the muscle (Bandy et al. 1990). This 








producing muscle force (Jones et al. 2004). Neural adaptations describe the 
development of more efficient neural pathways along the route to the muscle 
to improve contraction quality. The increases in muscle strength during the 
initial periods of a RT programme are more associated with these neural 
adaptations (Moritani & deVries 1979), rather than changes in fibre size which 
occur later (Sale 1988). 
Isokinetic training will increase maximum torque at the training velocity. It has 
been noted by several authors that peak torque also improves at velocities 
above and below the training velocity. Several studies have shown that 
training at peak angular velocity (PAV’s) of 60, 120, 180 and 240°/sec 
produce equitable improvements in isokinetic peak torque. The carry over 
may be as great as 210°/sec below and up to 180°/sec above the training 
velocity (Kraemer et al. 2000). However, carry over does decrease as the 
difference between the training and testing velocity increases. Training at 60 
and 240°/sec also produces equivalent gains in isometric strength (Kraemer 
et al. 2000). A speed of 180°/sec sits in the middle of the spectrum of speeds 
available on isokinetic machines and, as such, represents the centre of the 
muscular strength to endurance continuum (Kraemer et al. 2000). Bearing in 
mind the carry over effect, training at 180°/sec could produce strength gains 
over a wide range of velocities (Kraemer et al. 2000). 
FR or the ability to sustain maximal muscular force can also be improved with 
RT (see section above ‘Fatigue’), generally this is measured using the FI (ratio 







2.3.2 Changes in muscle structure and function in healthy elderly
subjects 
Sarcopenia describes the age-related changes in muscle morphology that 
occur with ageing which lead to decreased muscle strength and mass 
(Cuthbertson et al. 2006;Dutta 1997). Muscle strength is known to decrease 
by 30-40% between the ages of 30 and 80 years (Young et al. 1984;Young et 
al. 1985) and this correlates with decreased mass (reduced fibre cross-
sectional area). This decline may be associated with decreased physical 
activity (PA) during ageing (Jubrias et al. 1997). 
There is some discrepancy in the literature regarding the effects of ageing on 
muscle fatigue. Some investigators suggest that older people experience 
greater muscle fatigue than younger counterparts (Cupido et al. 1992;Petrella 
et al. 2005). Petrella et al. found that peak isokinetic force fell by 24% after 
just 10 knee extensions in older adults [mean age 64 years (Petrella et al. 
2005)]. This deficit persisted even after adjustment for muscle mass (lower in 
old age) and suggested that the force-velocity relationship changes with 
ageing (Petrella et al. 2005). Callahan and co-workers observed FR in young
(24 years on average) and old (mean of 69 years) healthy individuals during 
three muscle fatigue protocols of the quadriceps (isometric, intermediate and 
high PAV contractions). The older subjects showed greater FR during the 
isometric test, less FR at the high PAV (240°/sec) and there was no difference 
between the age groups for the intermediate PAV contractions (Callahan & 
Kent-Braun 2011). Again this supports the notion that contractile velocity has 







subjects exhibit more fatigue at high velocity strength testing and this affects 
muscle power [force x speed (Rawson 2010)]. 
However, there is the opposing argument that older people are more FR than 
the young because ageing muscle relays more heavily on oxidative rather 
than glycoltic pathways and therefore lactate production is reduced (Lanza et 
al. 2004). A recent study by Rawson et al. analysed fatigue for old (mean age 
66 years) and young healthy men using the same isokinetic RT protocol 
described in this thesis [five sets of 30 knee extensions at 180°/sec, one 
minutes rest between sets (Rawson 2010)]. This protocol took place on one 
testing session rather than in the context of a RT programme. Both groups 
had significant reductions in absolute torque generation for sets 2-5 
(compared to set one) and younger individuals produced significantly more 
torque on each set. The authors also calculated relative fatigue using a FI and 
found that relative fatigue was significantly greater in young subjects 
compared to the old (p<0.001). The overall relative fatigue (% decline in 
torque sets 2-5 compared to set 1) was 22.2% in the older men compared to 
38.1% in the younger men. The authors of this study concluded that older 
men demonstrated enhanced FR during their chosen testing protocol which 
included intermittent contractions (approximately 30 seconds), interspersed 
with 60 seconds of rest. They argued that this type of testing favours the 
oxidative preferences of ageing muscle, as intermittent contractions favour the 
replenishment of oxygen within the muscle. Therefore varying testing methods 










Previous research has demonstrated that aging also alters the neuromuscular 
response to short-term disuse (two weeks of limb-immobilisation) and 
recovery in humans. For older individuals, immobilisation had a greater impact 
on neural motor function, while young individuals were more affected at the 
muscular level (fibre size atrophy). None the less, in this study (Suetta et al. 
2009) and others, the age-related loss of strength and mass can be regained 
with exercise training and there is evidence that training adaptations may be 
greater in the elderly compared to younger individuals (Jubrias et al. 2001). 
Muscle weakness and reduced power contributes to difficulty in transferring 
[e.g. rising from a chair (Alexander et al. 1997)] and an increased falls risk in 
this age group (Schultz et al. 1997). As such, RT should be advocated to 
improve muscle strength, power and mass. However there is more 
susceptibility for muscle damage during heavy RT, in older adults, and 
investigations have shown that muscle recovery/ repair is slower in older 
persons after RT (Roth et al. 2000). 
The effects of ageing on the muscles of patients with COPD is largely 
unknown (American Thoracic Society/ European Respiratory Society 1999). It 
is unclear whether the decline in muscle function seen with normal ageing is 
more pronounced or accelerated in these patients.
2.3.3 Skeletal muscle dysfunction in COPD  
Skeletal muscle dysfunction describes the selective loss of skeletal muscle 







include a loss of contractile proteins, reduced capillarity, decreased fat free 
mass and lower myoglobin levels (American Thoracic Society/ European 
Respiratory Society 1999;Decramer et al. 2005). Muscle fibre type 
composition is also known to change [relative reduction in the proportion of 
type I (oxidative) fibres and increased proportion of type IIb (glycolytic) fibres] 
as well as a lower fibre-to-capillary ratio (Hurley et al. 1986;Whittom et al. 
1998). The reduction in type I fibres is associated with disease severity in 
terms of FEV1 percent predicted (Vogiatzis et al. 2011). As such, quadriceps 
endurance is reduced in patients with COPD, compared to controls (Swallow 
et al. 2007a) and premature metabolite accumulation occurs (Saey et al. 
2005). 
The molecular mechanisms responsible for regulating skeletal muscle growth 
and atrophy in this population are not fully understood. However 
deconditioning through inactivity is undoubtedly involved (Decramer et al. 
1994). Other proposed causes include systemic inflammation, nutritional 
depletion, hypoxaemia, oxidative stress and steroid-induced myopathy 
(American Thoracic Society/ European Respiratory Society 1999;Decramer et 
al. 2005). It may be that several mechanisms are responsible for skeletal 
muscle dysfunction in this population and that the relative contribution of 
factors may differ between patients. 
Skeletal muscle mass is determined by the relative rates of protein synthesis 
(anabolic process) and protein breakdown (catabolic process). Therefore, 







protein synthesis and/or an increase in protein breakdown (resulting in net 
protein loss). Several authors have found reductions in amino acid 
concentrations in patients with COPD when compared to control subjects 
(Pouw et al. 1998;Schols et al. 1993a;Schols et al. 1996;Yoneda et al. 2001)
and there is some evidence of increased whole-body protein turnover 
(increased rates of protein synthesis and breakdown) in this group of patients 
compared to healthy controls (Engelen 2000). The reasons for this are still 
being elucidated but it is likely that protein synthesis and degradation rates 
are altered in patients with COPD due to changes in protein signalling 
pathways (Jagoe & Goldberg 2001). 
Weight loss is an important feature in COPD, with many patients being 
undernourished. This has a negative influence on protein balance, particularly 
within the muscle (American Thoracic Society/ European Respiratory Society
1999). A commonly used definition of nutritional depletion is a body weight of 
less than 90% of ideal body weight. Based on this definition, 35% of patients 
entering pulmonary rehabilitation (PR) would be deemed nutritionally depleted 
(Schols et al. 1993b). Weight loss occurs when energy (caloric) expenditure 
(EE) exceeds energy intake from the diet (Kao et al. 2011). It should be 
remembered that for patients with COPD, their disability may present an 
obstacle in the purchase and preparation of food. This may also be related to 
social deprivation which is a risk factor for COPD (Hansel & Kon 2008). In 
addition, several investigators have shown that resting energy expenditure 
(REE) is elevated in patients with COPD (Creutzberg et al. 1998b;Schols et al. 







demands imposed by the increased work of breathing and certain medications 
(Creutzberg et al. 1998a;Palange et al. 1995). In acute exacerbations, REE is 
likely to be further increased (Vermeeren et al. 2004). 
Importantly, subjects of normal weight may show a relative loss of muscle (fat-
free) mass [FFM (Schols et al. 1991c)]. Reduced FFM is associated with the 
degree of airflow obstruction (Ischaki et al. 2007). Cachexia (defined as a low 
BMI and low FFM) is most prevalent in GOLD stage IV (Schols et al. 2005). A 
loss of FFM is associated with reduced muscle strength (Engelen et al. 1998) 
and increased morbidity (Bolton et al. 2004). Furthermore, FFM depletion 
correlates with walking performance (Schols et al. 1991b), maximal oxygen 
uptake (Baarends et al. 1997a) and adversely affects health status (Mostert et 
al. 2000;Shoup et al. 1997). The loss of bone mineral density (BMD) is also 
common in patients with COPD and this has been linked to reduced FFM 
(Bolton et al. 2004)
Alterations in muscle structure and function mirror that of other chronic 
diseases, such as heart failure (Gosker et al. 2000) and in immobilising 
conditions of healthy subjects. Disuse and unloading of the muscles is 
associated with reductions in protein synthesis and increases in degradation 
(Ferrando et al. 1996b;Gibson et al. 1987). Some novel research conducted at 
the University of Nottingham in 2004 found that by immobilising healthy young 
men in a limb cast for two weeks, a five percent decrease in quadriceps 
strength was linked to altered expression of several candidate genes [figure 





















   










            
        




muscle mass and strength returned to basal levels and again this was linked 
to changes in gene expression (figure 2.2).  
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Figure 2.2 Overview of changes in quadriceps lean mass and targeted gene
expression during 2 weeks of limb immobilisation and 6 weeks of prescribed
rehabilitation exercise in healthy male volunteers.
These study findings (Jones et al. 2004) suggested that at least part of the 
loss of muscle mass in immobilising conditions, such as COPD, may be linked 
to gene activation. This concept provided the basis of the larger MRC funded 
study, described in this thesis.
2.3.4 Consequences of skeletal muscle dysfunction 
Skeletal muscle dysfunction is now recognised as an important factor in the 
exercise limitations of this population (American Thoracic Society/ European 
Respiratory Society 1999;Decramer et al. 2005;Gosselink, Troosters, & 
Decramer 1996) and contributes to whole-body exercise performance 
(Gosselink, Troosters, & Decramer 1996;Steiner et al. 2005). We have known 








counterparts of the same age (Bernard et al. 1998;Hamilton et al. 1995). Both 
upper and lower-limb muscle force are reduced, although the muscles of 
ambulation are the most affected (Bernard et al. 1998;Man et al. 2003b). 
Muscle weakness and atrophy are important variables to measure because 
they are better prognostic indicators than lung function (Marquis et al. 2002;
Swallow et al. 2007b). Quadriceps weakness is also associated with higher 
health care utilisation (Decramer et al. 1997b). Furthermore, the skeletal 
muscles may provide a target for treatment in an otherwise irreversible lung 
disease. 
We are aware that patients with COPD experience greater muscle fatigue 
than healthy, age-matched controls (p<0.01) and that their rate of fatigue is 
more rapid (Allaire et al. 2004;Swallow 2007a), which causes patients to 
cease exercise prematurely. Fatigue has been defined in various ways in the 
literature for patients with COPD. This makes it difficult to compare studies
and to generate an agreed definition. Allaire and colleagues described 
isometric muscle endurance; this was significantly lower in patients with 
COPD compared to controls (p<0.001) and that this was linked to reduced 
markers of muscle oxidative metabolism [type I fibres and oxidative enzymes 
(Allaire et al. 2004)]. Using magnetic stimulation of the intramuscular branches 
of femoral nerve, Swallow and colleagues found that the time taken for 
quadriceps force to fall to 70% of baseline (their definition of fatigue) was 
significantly shorter in patients with COPD (55.6 seconds) compared to the 









quadriceps twitch force (TwQ) before and 10 minutes after this endurance 
protocol. Half of the patients with COPD showed evidence of fatigue using a 
15% reduction in TwQ force criteria. None of the control subjects met this 
criterion. Two previous studies also found that 50% of patients with COPD 
experience this post-exercise fall in TwQ (Mador et al. 2003;Saey et al. 
2003a). Saey et al found a significant relationship between the fall in TwQ with 
lactate levels and capillary/ fibre ratio; suggesting that the skeletal muscle 
changes which occur in COPD lead to a higher reliance on anaerobic 
glycolysis during exercise. This causes premature acidosis and is linked to 
aerobic muscle fatigue (Saey et al. 2005). 
Muscle fatigue, and particularly the FI, is seldom reported in studies of 
patients with COPD. In one study were the FI is reported, subjects were asked 
to perform the maximum number of knee extensions possible in one minute 
(at an isokinetic PAV of 70°/ sec) before and after a neuromuscular electrical 
stimulation (NMES) training programme (Neder et al. 2002). The FI was 
calculated as the ratio between the work performed in the last and first three 
contractions (%); therefore a lower number indicates greater fatigue 
resistance. There was a significant reduction in the FI from a mean of 113.7 % 
prior to the NMES programme, to 74.9% after NMES. However this study only 
included 9 subjects, therefore variation between individuals was high and 
subjects were not familiarised to the fatigue protocol, therefore a learning 














2.4 Treatments used in patients with COPD 
This section appraises current treatments for patients with COPD. These 
options are comprehensively described in the most recent NICE guidelines for 
COPD (National Institute for Clinical Excellence 2010).  
2.4.1 Pharmacology
Bronchodilators represent the basis of pharmacological COPD management. 
Three types are available: beta2 agonists, antimuscarinics and theophylline. 
All three relax airway smooth muscle but are activated via different pathways 
(Carrera et al. 2008). Short-acting versions of these drugs work quickly to 
relieve breathlessness and may increase exercise tolerance by improving 
inspiratory capacity (Newton et al. 2002). In patients with stable COPD who 
remain breathless, despite the use of a short-acting bronchodilator, the 
following maintenance options are available:
• if FEV1 is ≥ 50% predicted, offer either a long-acting beta2 agonist 
(LABA) or long-acting muscarinic antagonist (LAMA), 
• if FEV1 is <50% predicted, offer either a LABA with an inhaled 
corticosteroid (ICS) or LAMA (National Institute for Clinical Excellence 
2010). 
The same is true of those who experience frequent AE (National Institute for 







Surgery for individuals with COPD is rare and is only offered to a minority of 
patients who fulfil strict criteria. Lung Volume Reduction Surgery (LVRS) is 
becoming increasingly popular for patients with localised areas of 
emphysema. The procedure involves removing a poorly functioning area of 
lung so that the remaining lung has more ‘room’ to work efficiently 
(Department of Health 2010). Much of our knowledge around LVRS stems 
from the National Emphysema Treatment Trial (NETT) which compared 
optimal medical management (including rehabilitation= control) and optimal 
medical management plus LVRS (Weinmann et al. 2008).]. At long-term 
follow-up (median 4.3 years), total mortality rates were 0.11 deaths per person 
per year in the LVRS group and 0.13 in the control group [p=0.02 (Criner et al. 
2011)]. 
2.4.3 Oxygen therapy and ventilation 
The aim of oxygen therapy is to provide the necessary amount of oxygen to 
all bodily tissues (PaO2 of at least 8.0kPa or to improve oxygen saturation to 
at least 90%), this ensures perfusion of vital organs (Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) 2009). Oxygen can be delivered 
by concentrators, gas cylinders or in liquid form, depending on the patients’ 
requirements (Bradley et al. 2007;Lee and Kon 2010). Patients with chronic 
hypoxaemia (PaO2 <7.3kPa) benefit from long-term oxygen therapy (LTOT), 
delivered for at least 15 hours per day (Calverley and Walker 









hypoxic COPD patients (Calverley & Walker 2003), probably by reducing the 
rate of pulmonary arterial hypertension development (Lee & Kon 2010). 
Other patients may only require ambulatory oxygen therapy (AOT) if they 
have significant oxygen de-saturation on exertion (fall in oxygen saturation of 
4% to below 90%). AOT can acutely improve exercise tolerance and reduce 
dyspnoea at sub-maximal work rates (Bradley et al. 2007;Lee & Kon 
2010;Nonoyama et al. 2007). However, a recent paper has challenged the 
use of exercise de-saturation as the primary criterion for AOT prescription 
(Moore et al. 2011). Their results found that those with oxygen de-saturation 
after a six-minute walk test (6MWT) did not derive benefit from using oxygen 
on subsequent testing. 
Non-invasive ventilation (NIV) should be used as the treatment of choice for 
persistent hypercapnic ventilatory failure (American College of Chest 
Physicians 1999) and during AE which are not responding to conventional 
medical therapy (National Institute for Clinical Excellence 2010). NIV delivers 
positive airway pressure and works by ‘offloading’ the respiratory muscles 
during exercise, allowing patients to train at higher intensities and thereby 
enhancing performance (Garrod et al. 2000;Johnson et al. 2002). 
2.4.4 Pulmonary rehabilitation (PR) 
PR is defined as: ‘an evidence-based, multidisciplinary, and comprehensive 
intervention for patients with chronic respiratory diseases who are 





reduce symptoms, optimise functional status, increase participation, and 
reduce health-care costs through stabilising or reversing systemic 
manifestations of the disease’ (Nici et al. 2006). These goals are 
accomplished by helping patients become more physically active (Department 
of Health 2010) whilst learning more about their disease. Comprehensive PR 
programmes include patient assessment, exercise training, education, and 
psychosocial support’ (Nici et al. 2006a) and should be available to all COPD 
patients who have a functional limitation (Department of Health 2010), 
including those who have recently been hospitalised for an exacerbation 
(National Institute for Clinical Excellence 2010). 
PR programmes typically last between six weeks (UK) and 6-months (Europe) 
and can be effectively delivered within a variety of settings (Troosters & 
Decramer 2008). The benefit of supervised over unsupervised exercise has 
been demonstrated in controlled studies (Lacasse et al. 2006;Puente-Maestu 
et al. 2000) but for logistical reasons many programmes combine weekly or 
twice weekly supervised sessions with additional home exercises. In England, 
programmes typically run twice a week for six to 12-weeks (Department of 
Health 2010). However there is no real consensus about the optimum duration 
of a PR programme. Significant improvements in exercise tolerance and 
health related QoL (HRQoL) have been shown in programmes as short as ten 
days (Votto et al. 1996) and as long as 18-months (Wijkstra et al. 1995). 
Shorter programmes clearly decrease the cost per patient and disperse 
limited resources amongst more people (Clini et al. 2001) but long-term 








al. 2007). Sewell and colleagues (Sewell et al. 2006) observed that a 
shortened 4-week supervised PR programme was equivalent to a 7-week 
supervised PR programme at the comparable time points of 7-weeks and 6-
months. Outcomes assessed were exercise tolerance and disease-specific 
QoL. It may be that the duration of the programme can be dictated by the 
patients’ needs.
PR should include exercise training for the muscles of ambulation (Ries et al. 
2007). Lower-limb aerobic training (e.g. walking or cycling) should be at an 
intensity of between 60-80% of the peak work achieved on a maximal 
exercise test (Casaburi et al. 1991;Maltais et al. 1997). Training load 
progression can be achieved by increasing exercise duration whilst keeping 
intensity constant (Singh et al. 1998) or by increasing intensity when the 
optimum duration has been attained (Griffiths et al. 2000a); both approaches 
are effective. Training intensity can be monitored using Borg breathlessness 
and perceived exertion scales (Borg 1982). Typically, as patients improve, 
they will achieve the same Borg rating at a higher absolute work rate 
(Troosters & Decramer 2008). Heart rate (HR) may also be used to establish 
training intensity. Maximal HR is calculated as 220 – age, and a HR of 65 to 
85% of maximum relates to the target training zone for cardio-respiratory 
fitness (Tanaka et al. 2001). 
Modifications can be made to conventional whole-body exercise training to 
overcome ventilatory limitations in patients with severe disease. These include 









muscle mass at work (e.g. single leg cycling) and shortening the time of 
training bouts [interval training (Troosters & Decramer 2008)]. Interval training 
has been found to confer equivalent benefits to continuous training in a recent 
systematic review (Beauchamp et al. 2010). 
RT for the peripheral muscles should also be included to improve skeletal 
muscle function (Troosters & Decramer 2008). This approach is discussed 
further in section 2.5.1. 
Patient education is the other key component of PR. Discriminating between 
the effects of education and exercise is difficult as they are generally 
administered together (Nici et al. 2006b). Studies which have compared 
comprehensive PR with education alone demonstrate that education alone 
has no independent benefit (Ries et al. 2007). Education can be delivered in a 
number of ways and, in general, the topics covered are: disease education, 
exacerbation management, medications, managing breathlessness, chest 
clearance and lifestyle advice [smoking cessation, healthy diet, promoting PA, 
energy conservation]. Amongst the potential benefits of education are: active 
participation in healthcare and increased coping skills (Von et al. 1997). Two
disease-specific knowledge questionnaires have been developed which can 
help to identify knowledge deficits in patients with COPD and their carers. 
They are the LINQ [Lung Information Needs Questionnaire (Jones et al. 
2008)] and the BCKQ [Bristol COPD Knowledge Questionnaire (White et al. 
2006)]. By identifying gaps in knowledge; individualised education can be 








et al. 2008). There continues to be limited research about the impact of 
education on the outcomes of PR in patients with COPD, such as increased 
PA but expert opinion suggests that there are important benefits of patient 
education (Ries et al. 2007). 
The exercise component of PR has consistently been found to improve 
exercise tolerance, muscle strength and endurance. These impressive 
changes, in exercise performance, are seen in the absence of lung function 
improvements (American Thoracic Society/ European Respiratory Society 
1999) and support the notion that PR targets the extra-pulmonary 
consequences of COPD.
Bolton and co-workers found that quadriceps strength and FFM improved 
after an 8-week in-patient PR programme (Bolton et al. 2007). However the 
gains in FFM returned to basal levels 4-weeks after the cessation of PR, when 
the anabolic stimulus of exercise had stopped (Bolton et al. 2007). A recent 
study (Vogiatzis et al. 2011) has shown that PR [interval training (cycling)] can 
also influence fibre type distribution and capillary-fibre ratio within the muscle, 
as evidenced by sampling vastus lateralis muscle biopsies. The changes were 
comparable across the gold stages. Furthermore, PR helps to address the 
cardiovascular risk factors associated with COPD by reducing blood pressure 
(and therefore arterial stiffness) and cholesterol levels (Gale et al. 2011). 
PR also enhances HRQoL in patients with COPD (Ries et al. 2007), reduces 









exacerbation rates (Foglio et al. 2001). This may be potentially cost-effective 
(Griffiths et al. 2001). 
2.5 Interventions explored in this thesis 
2.5.1 Resistance training (RT) 
The skeletal muscle alterations displayed in patients with COPD, indicate that 
muscle training should play an important role in the treatment of this patient 
group (O'Shea, Taylor, & Paratz 2004). RT is appealing as it is the optimum 
form of exercise to increase muscle mass and strength in healthy and 
diseased populations (Brown et al. 1990a;Nici et al. 2006). Given the 
problems of muscle weakness and wastage in patients with COPD, guidelines 
recommend that RT should be included in a PR programme (Ries et al. 2007). 
Despite these recommendations, relatively few published studies have 
explored the role of RT in COPD (Alexander et al. 2008). 
The single systematic review on RT in COPD (O'Shea, Taylor, & Paratz 2004) 
yielded only 13 articles, four of which were previous reviews. In the nine 
experimental studies, training sessions generally included two to four sets of 
six to 12 repetitions of each strength exercise at 50% to 85% of an individuals’ 
one repetition-maximum [(1RM) defined later in this section. Training 
programmes were, on average, eight to 12-weeks in duration at a frequency 
of two or three times per week, with individual sessions lasting between 40 
and 90 minutes. These training regimes were generally in line with guidelines 










published in the ATS/ ERS Statement on PR (Nici et al. 2006c). Many of the 
programmes included combined endurance and RT; therefore the relative 
value of RT in isolation was difficult to establish. The authors of this review 
concluded that peripheral RT was feasible and safe for patients with COPD, 
even at intensities of 80% and beyond of the pre-training 1RM (Bernard et al. 
1998;Simpson et al. 1992). No adverse events were reported, although the 
teaching of the correct lifting technique is important to avoid breath holding in 
these patients (Storer 2001). 
We know that in healthy adults, symptom scores have a linear relationship 
with RT intensity [i.e. as intensity increases, symptom scores increase 
(Pincivero et al. 2001)]. The symptoms of dyspnoea and perceived exertion, in 
patients with COPD, are significantly lower during RT when compared to 
during whole-body exercise performance (Probst et al. 2006).  
This meta-analysis suggested that RT had a positive effect on both upper limb 
and knee extensor strength (p < 0.001) and lower-limb muscle mass (O'Shea, 
Taylor, & Paratz 2004). However, the impact of RT on other outcome 
measures, such as health status and PA, was less clear. For this reason, the 
authors later updated their review (O'Shea et al. 2009b) with an emphasis on 
activity and participation level outcomes. This second review yielded 10 
additional trials and again the authors were able to conclude that progressive 
RT lead to appreciable increases in muscle strength compared to control or 
aerobic training. Interestingly, meta-analyses found large effect sizes for 






p=0.006) and only small effect sizes for upper limb strength improvements. 
This can be expected as upper-limb strength is thought to be relatively well 
preserved in patients with COPD, compared to lower-limb strength (Bernard, 
Leblanc, Whittom, Carrier, Jobin, Belleau, & Maltais 1998;Gosselink 
2002;Hamilton, Killian, Summers, & Jones 1995) and would therefore have 
less scope to change. Four studies included in the review (Kongsgaard et al. 
2004;O'Shea et al. 2007a;Panton et al. 2004;Phillips et al. 2006) suggested 
that improvements in strength may carry over to daily task performance such 
as stair climbing and rising from a chair. However there were inconsistencies 
in the outcomes between the studies and a greater risk for bias which could
have overestimated the effect size (O'Shea, Taylor, & Paratz 2009b). Isolated 
RT can also lead to increases in whole-body exercise (endurance) 
performance, albeit to a lesser extent than endurance training (Vonbank et al. 
2011). 
RT may also offer advantages in patients with severe disease; where 
ventilatory limitation is often the main contributor to exercise intolerance. i.e. 
patients terminate exercise because they are unable to increase ventilation in 
response to growing metabolic demands (O'Donnell 2001). There is a school 
of thought, that for more disabled patients with COPD; RT of small muscle 
volumes may allow for higher training intensities at a muscle level than 
traditional whole-body exercise. This is important for patients disabled by 
COPD who are ventilatory limited (Simpson et al. 1992). Probst and co-
workers have shown that cardiopulmonary stress/ metabolic load is lower in 






and end of a 12-week training programme (Probst et al. 2006). This was
observed in both objective (e.g. minute ventilation, oxygen uptake derived 
from a portable breath by breath system) and subjective (i.e. symptom scores) 
parameters. The HR response after leg press exercise was significantly lower 
than walking, cycling (week 1 and 6 only) stair climbing and arm cranking. 
Subjects also experienced less dyspnoea during leg press exercise compared 
to cycling (weeks 1, 6 and 12 p<0.05).  More recently, Sillen et al found that 
the metabolic response was significantly lower still with neuromuscular 
electrical stimulation (NMES) compared to RT during a single session (Sillen 
et al. 2008). Peak oxygen uptake (as a percentage of the maximum) was 57% 
for RT and 34% for NMES (p<0.001 between RT and NMES) and Borg 
dyspnoea scores were 3 (RT) and 1 [(NMES) p<0.01 between groups]. 
However, the authors concluded that both NMES and RT resulted in 
acceptable metabolic responses and symptom scores for patients (Sillen et al. 
2008). 
Unlike endurance training, we do not know what the optimum ‘dose’ of RT is, 
to derive maximum benefit in terms of muscle strength and mass. The ‘dose’ 
comprises of training intensity and duration (Zuwallack et al. 2006). The 
relationship between RT intensity and outcome measures, such as strength 
and mass have been poorly described. Ideally, the optimum ‘dose’ of training 
should depend on the individuals’ needs and the ongoing measurement of 
outcomes during training (Ries et al. 2007). However the serial measurement 
of outcomes may be impractical in the context of a PR programme and 








ZuWallack and co-workers took serial measures every four sessions during a 
24 session rehabilitation programme [bi-weekly for 12-weeks (Zuwallack et al. 
2006)]. Outcomes assessed were: treadmill endurance time (at 85% of 
maximum work rate), upper-limb endurance lifts, Borg dyspnoea levels (at 
isotime on the treadmill test) and HRQoL. All outcomes improved significantly 
from baseline as early as session four. Upper- and lower-limb endurance 
outcomes continued to improve until session 20, when a plateau was noted. 
We do not know whether changes in muscle strength and mass, following RT, 
track the same trajectory as improvements in exercise tolerance and HRQoL 
derived from comprehensive PR, in patients with COPD. The dose-response 
relationship of RT has, however, been explored in healthy individuals (Rhea et 
al. 2003). The authors found, that for untrained individuals, 80% of the 1RM 
was the most effective to elicit changes in strength and training should include 
four sets per muscle group, three times per week. A meta-analysis, including 
1313 older subjects (age range 65-81 years) found that progressive RT 
improved maximal strength in a dose-dependant pattern (Steib et al. 2010). 
The authors concluded that more research was still required to refine the 
optimum training parameters in old/ frail populations.
RT can be prescribed in a number of ways and manipulation of training
variables (e.g. number of sets/ repetitions and level of resistance) can stress 
the muscles in different ways to produce specific adaptations. DeLorme was 
the first to suggest that a RT programme with low repetitions and high 
resistance would favour improvements in strength (DeLorme 1945). Most RT






training load; ≥ 70% would be typical for RT in all populations. The 1RM is 
defined as the maximum amount of weight that can be lifted with the proper 
technique for one repetition only (Baechle et al. 2008). Alternatively loads can 
be assigned by a given number of repetitions (Baechle et al. 2008). For 
example, if an individual can lift 20 kilograms (kg) for ten repetitions, their 
10RM is 20kg. Using RM training loads is appropriate for machine weights or 
free weights and three sets of eight repetitions is sufficient to elicit a training 
response in patients with COPD (Spruit et al. 2002). Clearly as the percentage 
of the 1RM decreases, the subject should be able to perform more repetitions 
(Baechle, Earle, & Wathan 2008). However other modes of resistance are 
available including isokinetic dynamometry (see section 2.3.1 muscle 
contraction mechanism and types of contraction), elastic resistance bands 
and using body weight (callisthenics). RT is generally progressed by 
increasing the resistance/ weight, whilst keeping the number of sets and 
repetitions the same (i.e. low).
Motivation for exercise (including RT), theoretically has a significant influence 
on exercise performance and progression. Motivation is defined as: ‘the 
process that initiates, guides and maintains goal-oriented behaviours.’ This 
can be intrinsic (from within, e.g. enjoyment of exercise) or extrinsic [e.g. 
financial rewards (Vallerand 1999)]. There are several questionnaires which 
aim to determine an individuals’ general motives for exercising. For example, 
the Exercise Motivations Inventory-2 [EMI-2 (Markland and Ingledew 1997)]. 
One assumes that motivation for RT, on a session by session basis, is 







with COPD using the Borg RPE scale (Borg 1982), outlined previously and 
displayed in appendix 9. There is a strong dose–response relationship 
between RT intensity and strength gains, therefore high-intensity (or high-
effort) training produces greater improvements in performance compared to
low-intensity (low-effort) training (Fatouros et al. 2005;Seynnes et al. 2004). 
We are aware, from previous literature, that high motivation and particularly 
high intrinsic motivation, is associated with greater exercise adherence. 
Furthermore, high post-exercise enjoyment ratings are also related to greater 
continued adherence with exercise (Ryan et al. 1997) which has a positive 
effect on training outcomes [e.g. strength (Winett et al. 2009)].
Preservation of strength following resistance training 
Although the short-term benefits of RT are clear (Lacasse et al. 2006;O'Shea, 
Taylor, & Paratz 2004;Ortega et al. 2002), we know very little about whether 
strength gains are sustained in the long-term for patients with COPD. In fact, 
even in healthy older adults there is limited information about how long the 
benefits from strength training are maintained. Various authors have proposed 
that strength may be sustained for anything from five to 32 weeks once 
training ceases in healthy older adults (American College of Sports Medicine 
1998;Fatouros et al. 2005;Hakkinen et al. 2000;Lemmer et al. 2000;Taaffe 
and Marcus 1997). 
A comprehensive literature search was undertaken as part of this thesis to 
establish the knowledge regarding the long-term preservation of strength 






extensive search of the literature, only four studies were located [(O'Shea, 
Taylor, & Paratz 2007a;Ortega et al. 2002;Troosters et al. 2000;van Wetering 
et al. 2010). Although RT is a key feature of many longitudinal PR studies, it 
appears that strength is rarely measured as an outcome at follow-up. One of 
the studies included in the review suggested that strength gains remain 
statistically higher than baseline, 12-months following graduation from a six-
month training programme (Troosters, Gosselink, & Decramer 2000). It was 
not possible to pool the results of the four studies statistically, as the study 
interventions and assessments were heterogeneous. Furthermore, the four 
papers reported conflicting findings. A PDF of the narrative review findings 
and details of the four included studies can be found in appendix 1 (the data 
from van Wetering et al. was published after the review publication).
The four studies included in the review measured the long-term sustainability 
of strength following fairly lengthy PR programmes (12-weeks to 6-months). 
The preservation of strength after a short course of RT (i.e. a 7-week 
programme) is unknown. Therefore, as part of this PhD programme, I 
analysed the 6-month follow-up strength data from a previous RCT conducted 
at the University Hospitals of Leicester (UHL) NHS Trust. Participants had 
attended a 7-week outpatient PR programme, enhanced with individualised 
RT (Deacon et al. 2008). This involved 21 sessions utilising multi-gym 
machines for leg extensions, step-up and sit-to-stand exercises (all 3x8 
repetitions). Isometric quadriceps strength was assessed at baseline (after 
familiarisation), immediately after rehabilitation and at 6-months using an 














7- week course of PR and remained significantly higher than baseline at 6- 
months. This was in the absence of a formal maintenance programme. The 
full PDF report can be found in appendix 2.
RT may prove more challenging to continue at home after PR (compared to 
endurance walking), due to lack of access to specific equipment (e.g. multi-
gym machines or free weights). Feasible ways to continue strength training 
within the home require further exploration.
2.5.2 Nutritional supplementation 
Nutritional supplementation in the context of COPD serves a dual purpose: to 
increase body weight and to enhance exercise performance. I shall discuss 
these two goals in the following section.
It is a widely accepted that under nourished patients with COPD should 
receive nutritional supplementation (American Thoracic Society/ European 
Respiratory Society 1999). Re-feeding trials in malnourished patients have
been shown to improve nutritional status and respiratory muscle strength 
(Whittaker et al. 1990;Wilson et al. 1986). Calorific supplementation, 
principally protein, may be particularly necessary during an exacerbation to 
prevent muscle wastage (Vermeeren, Wouters, Geraerts-Keeris, & Schols 
2004). Three placebo-controlled studies of oral nutritional support in stable 
patients were able to show improvements in body weight and functional 
performance at four to eight weeks (Efthimiou et al. 1988;Rogers et al. 








and a Cochrane review of nutritional supplementation in COPD came to 
disappointing conclusions (Ferreira et al. 2005). Studies in this remit have 
generally included small numbers and have been difficult to compare due the 
heterogeneity in the patient population, setting, supplementation composition 
and outcome measures. 
The overriding message appears to be that nutrition in isolation is not 
effective. In particular, those with evidence of systemic inflammation respond 
particularly badly (Creutzberg et al. 2000). Furthermore the effects of 
supplementation may be negated by patients who reduce their normal dietary 
intake (Knowles et al. 1988) or fail to comply due to the gastro-intestinal side 
effects of the supplement. It may be that a stimulus, such as exercise is 
needed to increase appetite and a few studies have explored the use of 
supplements alongside generic PR. Schols and colleagues investigated the 
effects of a daily nutritional supplement (mainly fat) alongside an 8-week 
rehabilitation programme (Schols et al. 1995). This study saw improvements 
in anthropometric measures (e.g. body weight, fat free mass) and respiratory 
muscle strength (maximal inspiratory pressure: PImax), but no additional 
increase in exercise performance. In post-hoc survival analysis, those who 
achieved significant weight gain (>2kg in 8-weeks) and had an increased 
PImax during PR, had a better chance of survival (Schols et al. 1998).  
A study by Steiner et al. utilised carbohydrate supplements. The authors 
found that only the well-nourished sub-group had significantly greater 






increase correlated with total carbohydrate intake [r=0.46, p=0.001 (Steiner et 
al. 2003)]. It may be that PA or exercise could be costly in terms of energy for 
COPD patients; contributing to a negative energy balance in weight-losing 
patients. A poor treatment response to nutrition in these weight-losing patients 
may be attributed to an inadequate assessment of their energy requirements 
(Baarends et al. 1997b), particularly when engaged in a rehabilitation 
programme. 
Recently, Pison and co-workers have investigated the efficacy of a multimodal 
nutritional rehabilitation programme in malnourished patients with respiratory 
failure [LTOT and/ NIV (Pison et al. 2011)]. 122 patients were assigned to the 
multimodal nutritional rehabilitation programme (rehab) or the home-based 
education (control) group. Rehab comprised of oral testosterone, three 
nutritional supplements per day (20% protein, 60% carbohydrate, 20% lipids) 
and exercise for 90 days. Exercise was endurance cycling and RT with 
elasticised bands. After the 90 day trial period, patients in the rehab group 
had significant improvements in body composition (BMI, FFM), peak 
workload, cycle endurance time and isometric quadriceps strength; compared 
to controls. After 450 days of follow-up, exacerbation rates and hospital 
admission rates were similar between groups but survival was significantly 
improved for the rehab group. The results of this multimodal intervention are 
encouraging but need to be confirmed in a larger study, in less severe 
patients and with a longer follow-up period. It appears that the combination of 
nutritional support with anabolic (muscle protein building) substances may be 










Dietary protein has been shown to induce protein synthesis in healthy young 
adults. However there appears to be an impaired response in healthy elderly 
subjects and merely providing dietary protein may not be effective in 
increasing protein synthesis (Cuthbertson et al. 2005), even when high doses 
of amino acids are ingested (highest titrated dose= 40 grams: g/ 500 millilitres: 
mls). Blood and biopsy markers were examined for evidence of protein 
synthesis in this study of 20 young and 24 elderly men. All subjects were 
mobile but not well trained (Cuthbertson et al. 2005). The authors found that 
the signal from protein ingestion is not ‘sensed or transduced’ as well by old 
muscle as it is in young muscle, resulting in a lower rate of protein synthesis 
to the same nutrient level delivered (Cuthbertson et al. 2005). It might be that 
an anabolic stimulus, such as exercise is needed. 
The timing of supplementation in relation to RT may also be an important 
factor in the response for older people. As stated previously, protein synthesis 
after a bout of RT is known to be greater three hours post-training when 
compared to 24 and 48-hours later (Phillips, Tipton, Aarsland, Wolf, & Wolfe 
1997). As protein availability is essential for optimum protein synthesis; the 
early intake of protein after RT is potentially important. Data from Denmark 
has shown that muscle hypertrophy (quadriceps CSA increase of 7%) only 
occurred in an elderly group receiving protein immediately after RT (36 
sessions) and not in those receiving the protein two hours later [p<0.001 
between timing groups (Esmarck et al. 2001)]. The supplement comprised of 














The role of protein given immediately after RT has not before been studied in 
the COPD population. 
2.6 Measures used to assess the response to resistance training and 
nutritional supplementation 
2.6.1 Quadriceps muscle strength 
The aims of measuring muscle strength are: to identify and quantify
impairment, to prescribe an appropriate exercise regime and to evaluate 
response to treatment (Storer 2001). Prior to measuring strength, several 
factors should be considered. One aspect to consider is familiarisation, which 
is, performing a practice of the actual testing manoeuvres before the actual 
testing. Otherwise, subjects who are naive to the testing method may improve 
strength scores on subsequent testing by simply getting better at doing the 
test (‘learning effect.’) This is particularly important when using unfamiliar/ 
unnatural testing methods (Brown & Weir 2001). After familiarisation, the 
actual testing should take place once muscle soreness is resolved [e.g. two-
three days later (Brown & Weir 2001)]. Correct subject positioning and 
stabilisation of other joints/ muscles will also help to improve the accuracy of 
strength testing (Brown & Weir 2001). To decrease between operator 
variability, standardised instructions should be given to all subjects. Ideally the 
same operator should perform all measurements at the same time of day, 






Strength can be measured using volitional or non-volitional techniques 
(Menon & Steiner 2009). Volitional techniques require maximum effort by the 
subject and can be affected by operator encouragement. Non-volitional 
testing using nerve stimulation is not effort dependant. Volitional strength can 
be assessed using static (isometric) or dynamic (isotonic/ isokinetic) 
contractions (see table 2.3) and measured manually, using resistance 
machines, with portable devices [e.g. handheld dynamometers (HHD), cable 
tensiometers] and using computerised dynamometers. 
When the length of a muscle changes in response to stimuli, the term for the 
contraction is isotonic (Davies, Heiderscheit, & Brinks 2000). There are two 
types of isotonic contractions: concentric, in which the muscle actively 
shortens whilst overcoming external resistance and eccentric, in which the 
muscle actively lengthens whilst being overcome by an external resistance 
(Dvir 2004). Eccentric contractions occur to control movement against an 
applied force. e.g. when the elbow flexors must be active to control the fall of 
an object (Davies, Heiderscheit, & Brinks 2000). 
When the length of the muscle doesn’t change because of an externally 
applied force; then tension in the muscle increases in an attempt to overcome 
resistance. These static contractions are termed isometric (Palastanga, Field, 
& Soames 2006). Isometric contractions are preferred when trying to minimise 
the influence of neural components associated with muscle strength 
(Broughton 2001). Isometric contractions are quick and easy to perform and 






0.99 (Abernethy et al. 1995)]. However the strength recorded is specific to the 
point in the range of movement (ROM) at which the contraction occurred. If 
the joint angle is changed, then isometric strength is likely to change (Brown & 
Weir 2001). Furthermore, isometric testing may not reflect the dynamic nature 
of everyday tasks. There are no specific guidelines outlining the correct joint 
angles, the number of repetitions, rest period or duration of contraction for 
isometric testing. However several authors have made recommendations on 
these factors. It has been suggested that testing should take place at the joint 
angle associated with the greatest force production. For knee extension, the 
angle of greatest force production would be midway between full knee flexion 
and extension [approximately 65 degrees (Kulig et al. 1984)]. Literature 
suggests that contractions with a one second transition period and a plateau 
of four to five seconds should be sufficient to observe a maximal isometric 
contraction. Rest between repetitions should be one to five minutes (Brown & 
Weir 2001). Edwards and colleagues were amongst the first to explore the 
number of isometric repetitions required (Edwards et al. 1977). They
suggested that three was sufficient given that the first was usually tentative 
and the last two were comparable to each other (coefficient of variation= 
2.8%). More repetitions clearly increases the chance of fatigue and injury 
(Brown & Weir 2001) 
Isokinetic contractions describe those in which there is an accommodating 
resistance and a fixed speed (Davies, Heiderscheit, & Brinks 2000). As the 
subject increases force, the dynamometer increases resistance to maintain 








can only be produced with specialised equipment (isokinetic dynamometers). 
The test re-test reliability of isokinetic testing is known to be very high from 
several studies (Frontera et al. 1993;Gleeson and Mercer 1992) and a wide 
range of variables can be analysed from the data collected. Peak torque is 
one variable of interest and is the product of mass, acceleration and level arm 
length (the peak of the torque versus the position curve- see figure 2.3). The 
maximum or peak torque can be produced anywhere within the range of ROM 
and is synonymous with the 1RM (Brown & Weir 2001). Work is a product of 
torque and distance travelled; this is the cumulative ability of the subject to 
produce torque throughout the ROM (the area under the curve- figure 2.3).  
Figure 2.3 Isokinetic torque versus position graph 
The number of repetitions chosen for isokinetic testing is dependant upon the 
outcome desired. Generally five repetitions are enough when measuring 
strength, as many as 50 may be performed when endurance is the outcome of 






Isokinetic testing is unfamiliar to most individuals and is rarely used in the 
assessment and training of individuals with COPD. Only 16 out of 139 articles 
relating to RT in patients with COPD used an isokinetic dynamometer to 
measure dynamic strength (Robles et al. 2011). This systematic review found 
that most studies measured quadriceps strength at 60°/sec. Reliability results 
from isokinetic testing in the healthy population can not be easily extrapolated 
to patients with COPD who have weaker muscles and are more prone to 
fatigue (American Thoracic Society/ European Respiratory Society 1999). The 
test re-test reliability of isokinetic muscle testing has therefore been explored 
in patients with COPD. In 2004, Mathur and colleagues reported within-
session and test re-test reliability over seven days for isokinetic strength 
testing in 20 patients with moderate to severe COPD (Mathur et al. 2004). 
Isokinetic testing of the quadriceps took place on the dominant leg for three 
trials at PAV’s of 30 and 90 deg/ sec (°/sec). The within-session test re-test 
reliability was high [intra-class correlation co-efficient (ICC) ranging from 0.95 
(90°/sec) to 0.99 (30°/sec)]. There were no significant differences between the 
three trials (p>0.05). There were also no significant differences between the 
peak torque recorded between 2 sessions, one week apart [ICC 0.85 
(30°/sec) and 0.96 (90°/sec)]. 
Equipment for testing 
Manual testing and the one repetition maximum (1RM) 
Manual testing (using the 0-5 Medical Research Council grades) is often used 








grade three and above [against gravity (Gosselink et al. 2004)]. The 1RM
measurement of strength can be used to measure isotonic strength and is a 
safe and reliable measure of strength in patients with COPD (O'Shea, Taylor, 
& Paratz 2004). To achieve the maximum, weight should be incrementally 
increased by one to five kg at intervals of one to five minutes (Gosselink, 
Troosters, & Decramer 2004). It therefore involves trial and error until the 
patient is unable to lift any more. Because of the number of repetitions 
involved in finding the true 1RM, testing can be confounded by fatigue 
(Chandler et al. 1997). This type of testing may not be suitable in very frail 
subjects or those with unstable cardiac disease because there are theoretical 
concerns that increased afterload on the heart during the lifting phase, could 
worsen left ventricular function. In individuals where there are concerns, the 
1RM test can be modified. Estimates of the 1RM can be made from multiple 
tests, say a 10RM (relative load tests) or multiple RM testing based on target 
repetitions [goal repetitions per set (Baechle, Earle, & Wathan 2008)]. 
Cable tensiometers and strain gauges 
Cable tensiometers are used to measure isometric strength, and quadriceps 
strength (QMVC: quadriceps maximum voluntary contraction) has been 
measured in this way in patients with COPD (Simpson et al.1992). To 
measure quadriceps strength with a patient in sitting and the knee at a 
90°angle; a cable is strapped to the lower leg and connected to the 












Figure 2.4 Subject positioning for measuring QMVC using a seated strain 
gauge
When the knee is extended, tension is produced in the cable which causes 
depression of the riser over which the cable runs. This leads to deflection of 
the pointer on the device and isometric strength is indicated (kg). The 
tensiometer can measure strength at a variety of joint angles and the 
equipment is portable (attached to an adapted commode chair on wheels). 
This portable device was used in the study outlined in appendix 10. The 
device can also be attached to a software programme which can measure 
QMVC over a 1 second plateau. 
The seated QMVC methodology described was proposed by Edwards in 1977 
(Edwards et al. 1977) derived from a healthy population and has been 
extensively adopted for use in patients with COPD. The coefficient of variation 






Dynamometers: mechanical and electronic 
Dynamometers measure isometric strength via the application of an external 
force which either compresses a steel spring (mechanical dynamometer) or 
moves an electronic force transducer [electronic dynamometer (Gosselink, 
Troosters, & Decramer 2004)]. HHD can test varying muscle groups by an 
assessor placing the device over the lever being tested- the device then 
displays the force produced in kg. Two methods of testing have been 
described: the ‘make’-test and the ‘break’-test. In the make-test, the maximal 
force of the subject is equal to the force of the assessor. In the break-test, the 
force of the assessor exceeds that of the subject. Higher reproducibility has 
been found during break-tests (Stratford & Balsor 1994).  
The reliability of HHD has been tested in healthy populations (including the 
elderly) and specific disease groups (Phillips et al. 2000b;Roy and Doherty 
2004;Taylor et al. 2004). In 2007, O’Shea and colleagues tested the test re-
test reliability of HHD in four muscle groups, in four women and eight men 
with moderate-severe COPD (O'Shea et al. 2007b). The ICC’s were 
measured to assess the test re-test reliability for individual and group mean 
scores. Quadriceps ICC was very good with a score of 0.87. Despite this the 
mean difference between the tests was 2.76 (±7.34 SD) kg and the group 
95% CI was -1.91 to 7.42, this increased in individual scores to -13.40 to 
18.92. Interestingly the authors commented that a group of patients with 
COPD would need to have an increase in quadriceps strength of 7.4kg (17%) 
to be 95% confident that the changes were not just due to variability in the 







look at change within an individual, because to overcome the measurement 
error, strength would need to increase by 10-19kg (34-58%) in the four muscle 
groups tested. Clearly values of this magnitude may exceed the expected 
change in these outcomes following a RT programme.  
Despite concerns around the within-subject reliability of HHD in patients with 
COPD it does represent a cheaper alternative to other more expensive modes 
of isometric testing (cost is approximately £1000), reference values are 
available (Andrews et al. 1996), it is simple to use and portable.
Hand grip dynamometers measure grip strength and have been used in 
several studies of patients with COPD. Normative data is available for hand 
grip strength in several age groups (Mathiowetz et al. 1985) and grip strength 
is a useful indicator of nutritional status (Vaz et al. 1996). 
Isokinetic dynamometry uses a computer-assisted dynamometer (trade 
names e.g. Cybex® or Kin-Com®) to measure isokinetic and isometric 
strength of various muscle groups at a variety of joint angles and contraction 
velocities (Gosselink, Troosters, & Decramer 2004). This device represents 
the ‘gold standard’ method of measuring strength and both static and dynamic 
strength were measured in this way for this thesis. The presence of an 
accommodating resistance in isokinetic testing allows for the safe measuring 
of torque (Newton metres: Nm) and work (Joules: J) at constant speed 
throughout the full ROM and therefore gives a comprehensive picture of 
muscle function. In healthy subjects, a good correlation exists between 












are available (Neder et al. 1999). See also section 2.3.1 Healthy muscle 
structure, physiology and energy metabolism which has information on 
isokinetic normal values for quadriceps strength. 
To measure knee extension in sitting, stabilisation of the upper body and thigh 
can be achieved with straps- see figure 3.2 in Chapter 3: Materials and 
Methods. This is important so that movement at the knee joint is isolated 
(Weir et al. 1996). The joint centre and axis of rotation of the machine also 
need to be aligned to produce valid measures (Rothstein et al. 1987). 
Subjects should be encouraged to make contact with the mechanical end 
stops during knee extension and flexion. Furthermore, standardised verbal 
encouragement can be provided throughout the test (Brown & Weir 2001). 
When combined with additional visual feedback, this is known to increase 
performance (Campenella et al. 2000). 
Whilst highly accurate; isokinetic dynamometry may not be widely available in 
clinical practice due to its cost (tens of thousands), size and practicality of use 
(requires training to: calibrate and set up the device, perform the test and to 
interpret the results). 
Electromyography (EMG) 
EMG measurements using surface electrodes are an indication of motor unit 
firing and therefore of the neural component of muscle strength (Broughton 





   
All of these testing methods may be limited by patient effort, learning effect 
and other extrinsic factors (e.g. arthritis). Peripheral muscle function (namely 
endurance) can also be measured via non-volitional twitch force; the 
quadriceps muscle has been investigated in this way. This involves applying 
supramaximal magnetic stimulation to the intramuscular branches of the 
femoral nerve to produce a force which is not effort dependant nor subject to 
learning effect (Swallow et al. 2007a). However this technique may be 
uncomfortable and technically more difficult to perform than some volitional 
methods. For these reasons, the technique is generally reserved for research 
use rather than clinical practice. Using this technique, quadriceps strength has 
been found to be lower in COPD patents compared to healthy controls and a 
drop in twitch force after exercise is a useful indicator of muscle fatigue (Saey 
et al. 2003b). 
2.6.2 Whole body and regional muscle mass
Body weight and body mass index (BMI: height normalised body weight) are 
the easiest and most practical measures of nutritional status. However, 
changes in weight may be due to changes in fat, muscle or both. These 
simple measurements may therefore underestimate the prevalence of 
nutritional depletion because some patients show relative reductions in 
muscle mass despite being a normal weight (Schols et al. 1991c). For this 
reason, measurements of body composition are increasingly used for the 
nutritional assessment of COPD patients. These measurements subdivide the 
body into a number of compartments. Of importance is the fat free mass 







2000). FFM is calculated as lean mass and BMD. Normal ranges for FFM 
have not been established, which have led to challenges in defined muscle 
‘wasting’ in individuals with COPD. The FFM index (FFMi) has been proposed 
as a reference criteria to assess muscle wastage in patients with COPD. This 
was first described by Baarends and colleagues and body composition was 
assessed using deuterium and bromide dilution techniques, to measure total 
body water (TBW) and extracellular water. From these measurements
patients were deemed to be wasted if their height normalised FFM was less 
than 16 kilograms per metres squared (kg/m2) in men or less than 15kg/m2 in 
women.(Baarends et al. 1997a). These criteria have since been used to 
define muscle wastage in the COPD population, using bioelectrical impedance 
as the measurement tool to assess FFM (Mostert et al. 2000;Schols et al. 
2005). 
A number of direct and indirect measures have been used in the study of 
(whole-body and regional) muscle mass. Four-site skin-fold anthropometry 
(SFA) uses callipers to measure the thickness of skin and underlying fat at the 
biceps, triceps, subscapular and suprailiac areas. SFA may be unreliable in 
the elderly due to changes in the distribution of fat (Chumlea et al. 1984) and 
due to extravascular fluid (American Thoracic Society/ European Respiratory 
Society 1999). An additional problem is that patients with COPD also have 
increased intramuscular fat compared to healthy controls (Mathur et al. 2007). 
There are also ways to estimate quadriceps CSA from measures of thigh 
circumference (Housh et al. 1995) although these measures are based on 







al. 2008). Whilst thigh circumference does offer a simple alternative measure 
in clinical practice, it may not be a sensitive enough measure of muscle mass 
(Mathur et al. 2008) and assumes that the underlying muscle is circular in 
shape and that subcutaneous tissue is evenly distributed (Mathur et al. 2008). 
This may not be the case. 
Bioelectrical impedance (BIA) is inexpensive, non-invasive, simple to use and 
portable; making it ideal for use in clinical practice. It measures FFM based on 
the differential conduction of an alternating current through body tissue. The 
information derived is converted to a volume based on the principle that the 
impedance (resistance) of a conduction system (bodily tissues) is related to its 
length and cross-sectional area. However it relies on intracellular fluid 
remaining constant which it may not in the elderly or those with a chronic 
disease. Furthermore, BIA may not be sensitive enough to detect changes in 
mass in response to interventions [e.g. RT (Nelson et al. 1996;Sipila & 
Suominen 1995)].
U/S can be used to measure the CSA and thickness of superficial muscles via 
the reflection of high-frequency sound waves from the tissues. U/S is easy to 
perform as the equipment is portable. Rectus femoris CSA, as measured by 
U/S, has recently been found to correlate well with strength (Seymour et al. 
2009) and work at our own institution has shown that U/S is sensitive to 
changes in mass in response to RT (Menon et al. 2009) in patients with 













when measured by U/S [21.1 (16.4) %] as compared to DEXA [6.4 (3.0) %], in 
this study (p=0.002). 
CT and MRI are the ‘gold standard’ tools to measure muscle mass. They can 
measure the volume and CSA of individual muscles (e.g. the vastus lateralis) 
as well as muscle groups [e.g. the quadriceps (Mathur et al. 2008)]. Reduced 
quadriceps CSA has been detected in patients with COPD compared to 
healthy controls using these methods and CSA is closely correlated with 
volume [r= .61 to 0.94 for both groups (Mathur et al. 2008;Vilaro et al. 2009)]. 
These correlations were equally strong at three specified levels of the thigh 
(30, 50 and 80% of the thigh length). CT and MRI have also been used to 
detect an increase in strength in response to training in patients with COPD
(Bernard et al. 1999;Kongsgaard et al. 2004). However these radiological 
techniques are expensive and require access to cumbersome equipment with 
trained technicians (Ross 2003a). Furthermore CT involves exposure to 
ionising radiation which is not ideal for serial measures (Mathur et al. 2008). 
To reduce this time and risk, often a single slice is used as an indicator for the 
entire muscle (Mathur et al. 2008). 
DEXA (figure 2.5) is an attractive alternative to CT and MRI, has been 
validated against deuterium dilution (a measure of total body water from urine 
or saliva samples) in patients with COPD (Engelen et al. 1998) and has been 
shown to correlate well with CT (Wang et al. 1996). DEXA measures BMD, 
bone-free lean/ FFM and fat mass via two low-energy x-ray beams which 











complete and regional analysis can be performed (Menon & Steiner 2009). 
Importantly, changes in hydration do not appear to affect the accuracy of the 
measurements (Kohrt 1995). However, the DEXA equipment is expensive, 
large and may not be routinely available in clinical practice. Furthermore, 
whilst DEXA can determine regional mass (e.g. of the thigh); it can not 
differentiate between individual muscles. Thigh and whole-body FFM were 
measured using DEXA for this thesis.
Figure 2.5 DEXA scanner
Measures of FFM in COPD patients have been compared using DEXA, SFA 
and BIA prior to the start of PR (Steiner et al. 2002). Relative to DEXA, FFM 
was overestimated by SFA and underestimated by BIA. The prevalence of 
nutritional depletion detected by DEXA, BIA and SFA was 49, 48 and 38% 
respectively. These between-method differences highlight that the tools to 







2.6.3 Physical Activity (PA) 
PA is defined as, ‘any bodily movement produced by skeletal muscles that 
requires energy expenditure and produces progressive health benefits’ (Anon 
1996). This definition is different to exercise which involves planned bodily 
movements that are repetitively performed to improve or maintain fitness 
(Caspersen et al. 1985). The health benefits of maintaining PA in healthy 
people are well documented. However it is only in recent years that we have 
realised the importance of PA in patients with COPD. It may be that part of the 
deconditioning associated with COPD is due to inactivity (Morgan 2008). 
Levels of PA are reduced in patients with COPD, when compared to healthy 
age-matched subjects (Pitta et al. 2005). This is the case even in those with 
mild disease. PA levels are also known to decrease in the days before and 
during an AE and PA levels are not regained, even at 3-months post-AE (Pitta 
et al. 2006a). Reduced PA in patients with COPD is associated with a poorer
prognosis (increased time to death) and an increased risk of hospitalisation 
(Garcia-Aymerich et al. 2006a;Pitta et al. 2006a). 
One of the aims of PR is to improve physical functioning (Hunter et al. 2006). 
To change domestic PA requires a behaviour change and a commitment to 
being more physically active (Morgan 2008). The objective monitoring of PA in 
COPD is therefore now of clinical interest particularly when we aim to 
measure changes in PA in response to rehabilitation programmes or other 
interventions. Quantifying daily PA measures a different construct to functional 
capacity (i.e. a maximal exercise test). Functional capacity relates to what 






we are observing what patients choose to do (Leidy 1994). It is important to 
differentiate between these dimensions when assessing patients with COPD, 
as habitual PA appears to have a protective benefit. We know that PA is only 
marginally correlated with the degree of airflow obstruction in this population, 
indicating that other factors are involved, such as peripheral muscle weakness 
(Garcia-Aymerich et al. 2006). 
The outcomes of interest related to PA are: step count, energy expenditure 
(EE) and metabolic equivalents (METS), amongst others. EE is the amount of 
energy (calories) that a person uses to breathe, circulate blood, digest food 
and be physically active (Davies 2007). METS are a multiple of the resting 
rate of oxygen consumption per minute. One MET is equal to that of the 
oxygen consumption at rest, which is approximately 3.5mls of oxygen/kg/min 
or one kcal of oxygen/kg/hour. Three METS would correspond to brisk walking 
(Ainsworth et al. 2000).  The ‘gold standard’ method of measuring PA is by 
direct observation (Sirard & Pate 2001). However this method is impractical 
and hugely labour-intensive. EE can also be accurately assessed used 
laboratory-based doubly labelled water (DLW) or indirect calorimetry 
techniques. These techniques are costly, confined to the laboratory and 
require skill to conduct the tests/ analyse the results. Furthermore, they are 
unable to characterise PA patterns as they only give total energy expenditure 
over a period of time (Sirard & Pate 2001). 
Traditionally, PA has been derived from questionnaires, interviews, heart rate 









more practical measures of PA and have often been validated against some 
of the ‘gold standard’ measures of energy expenditure described above.
Questionnaires or interviews are a simple and inexpensive way to measure 
PA. However, these subjective measures are open to inaccuracy and bias in 
recall (Pitta et al. 2006b). This is a particular problem in very sedentary 
patients when seemingly small changes in PA may confer large gains in 
function or health status (Morgan 2008). It has been suggested that 
questionnaires may be useful to compare groups of patients but lack the 
sensitivity to detect changes within an individual (Pitta et al. 2006b). 
PA was measured in this thesis using the adapted PA questionnaire for the 
elderly [(Voorrips et al. 1991) appendix 14]. This questionnaire was chosen as 
it is not disease-specific and could therefore be used to assess both patients 
and healthy elderly controls. The questionnaire consists of scores in 
household activities, sporting activities and leisure activities to produce an 
overall activity score of 0-35. The questionnaire is interviewer-led and asks 
about activities within the last year; a higher score indicates a greater level of 
PA. The researcher is responsible for giving an intensity code for each of the 
sporting and leisure activities. This code is based on the energetic costs of 
activities [originally based on the activity questionnaire described by Baecke 
and co-workers (Baecke et al. 1982)]. Test-retest reliability, and validity of the 
modified questionnaire, compared to two independent methods of assessing 
PA (pedometer and 24hour activity recall) in the elderly have been 
established (Voorrips et al. 1991). The questionnaire has been used to 










to healthy controls (Engelen et al. 2000;Serres et al. 1998)], rather than as an 
outcome measure of PR. In the study by Serres and co-workers, PA using this 
questionnaire was found to be significantly lower in patients (5±1) compared 
to healthy controls (10±2, for the total score. p<0.05). Furthermore, low PA 
was associated with poor muscular endurance [r=0.60, p<0.05 (Serres et al. 
1998)]. 
The Duke Activity Status Index (DASI) was another self-administered 
questionnaire used in this thesis. The DASI (Hlatky et al. 1989) was 
developed in a cardiac population and has good correlation with peak oxygen 
uptake (spearman’s correlation coefficient r= 0.80 in n= 50). Its utility and 
relationship to oxygen uptake in patients with COPD is unknown. The DASI is 
a simple, 12-item instrument that provides a patient’s self-assessment of their 
functional abilities. The DASI was validated to estimate maximal oxygen 
consumption (VO2 peak) measurements at peak exercise (Hlatky et al. 1989). 
METs can then be calculated by dividing the estimated VO2 peak by 3.5 (as 
one MET is equal to that of the oxygen consumption at rest, which is 
approximately 3.5mls of oxygen/ kg/ min). DASI scores range from 0, which 
represents an inability to carry out any of the listed activities, to 58.2, which 
represents the ability to carry out all of listed activities. 
To combat the inadequacies of questionnaires, many devices are now 
available which can measure PA more accurately (Agusti 2008;Steele et al. 
2003). These devices are either pedometers (step counters) or 





2008;Steele et al. 2003)]. Pedometers are simple, inexpensive devices which 
measure movements in a vertical plane, i.e-steps. They are widely available to 
the general population, easy to use and provide subject feedback. One 
frequently used pedometer; the Yamax digi-walker CW-700 (Yamax 
corporation, Tokyo, Japan), costs around £20. Validation against visual counts 
is generally good (in healthy adults) but they may underestimate walking at 
slower speeds (Cyarto et al. 2004;Tudor-Locke et al. 2002). Also in healthy 
volunteers, accuracy in the step count recorded (pedometer Vs visual counts), 
improves at faster walking speeds (Turner et al. 2010) This may be a problem 
in sedentary COPD patients who walk at slower speeds as the 
underestimation of steps, due to lack of sensitivity, may be de-motivating. Also 
pedometers do not detect other forms of movement in different directional 
planes, the intensity of activity or time spent doing alternative activities to 
walking (Pitta et al. 2006b). Despite these limitations, step counts have 
become a popular outcome measure. The majority of the general population 
are familiar with the public health campaign to encourage adults to reach their 
recommended 10,000 steps per day. Less than 5,000 steps per day is 
deemed ‘sedentary’ (Tudor-Locke & Bassett, Jr. 2004). 
Accelerometers are preferred, as they can quantify movement and its intensity 
(Steele et al. 2003). Accelerometers measure acceleration created by bodily 
movement which are converted to counts. More sophisticated devices can 
also measure the time spent doing mild, moderate and vigorous activity (in 











Minimod® by McRoberts, Hague, Netherlands and the Sensewear® armband 
by Bodymedia, Pittsburgh, USA - figure 2.6).   
Figure 2.6 Sensewear® activity monitor- position on subject’s arm
Most modern accelerometers are multiaxial and are therefore able to detect 
movement in more than one bodily plane. Accelerometers can store data for 
long periods of time (Pitta et al. 2006b). It is generally agreed that two days of 
recording is the minimum required for accelerometers; ideally three to five 
days of 12 waking hours achieves reliability for adults (Trost et al. 2005). Days 
should be standardised (i.e. weekdays/ weekends) as activity may differ. This 
is especially true of those who are working. The number of days that an 
accelerometer can record data varies between devices and is determined by 
battery life and storage capacity (Davies 2007). Computer software is required 
to view and analyse the data.
The disadvantages with accelerometers are the relatively expensive cost 





issues (e.g. battery level) and sensitivity to external vibrations (e.g. from being 
in a vehicle) (Patterson et al. 1993;Pitta et al. 2005;Pitta et al. 2006b). 
The ActiTrac® activity monitors, used in this thesis, [IM Systems, Baltimore 
(MD) USA] are bi-axial accelerometers. These monitors are simple to use for 
patients, with no on/off power buttons. The ActiTrac® software is also 
uncomplicated for clinicians who use it to initialise the monitors and download 
the data. Graphs can be displayed to view activity patterns over the day. 
These monitors were chosen to assess PA in this thesis because they were 
available for use at the time of the study and are also relatively inexpensive 
(approximate cost: device £400, software £230); particularly in comparison to 
other devices on the market (Approximate costs: DynaPort Minimod device= 
£830, Sensewear Armband device= £660, software= £1000). The ActriTrac® 
has been used to measure activity in healthy individuals and is a valid way of 
measuring energy expenditure under controlled conditions [as compared to 
indirect calorimetry (Welk et al. 2003)]. The correlation coefficients between 
measured and predicted EE for the ActiTrac® were r=0.94 (Welk, Almeida, & 
Morss 2003). Prior to their use in patients with COPD, it was important to 
examine whether or not the devices could detect the slow speeds of walking 
typically employed by patients. Therefore, the devices were tested at 3 
speeds of walking (slow, moderate and fast) in a healthy individual (the author 
of this thesis). More details regarding this activity monitor and testing prior to 
use in patients are provided in chapter 7. Unfortunately, the device does not 
measure steps or energy expenditure and the output may not therefore be 







Accelerometers and pedometers have been used in patients with COPD as an 
outcome measure of PR (Pitta et al. 2008), and these have been summarised 
in a review by Troosters last year (Troosters et al. 2010). In the nine studies 
assessed, there was huge variation in the improvement in PA seen after PR 
compared to baseline. This probably reflects heterogeneity in the PR 
programmes and devices used to collect PA data. The percentage change in 
PA after rehabilitation ranged from 0 (Steele et al. 2008) to 70 % (de Blok et 
al. 2006). This review highlights that changes in PA after PR are not 
guaranteed. Furthermore, we don’t know what a clinically relevant 
improvement in PA after PR would be and this is likely to differ between 
patients and patient groups.
Simple activity monitors and pedometers can also be used as a training aid or 
to monitor exercise compliance (Hunter  et al. 2006) if the devices provide 
patient feedback. One study by deBlok (de Blok et al. 2006) used a 
pedometer to provide feedback to patients about their walking during a PR 
programme and gave PA counselling advice. A control group received only 
conventional PR. For the group that had the pedometer, steps increased by 
1430 per day (or 69%) from baseline compared to controls that had an 
increase of 455 steps (or 19%). However no other secondary outcome 
measures improved in this study and patients in the experimental group 
achieved a step count after PR that still fell short of the 10,000 per day public 








2.6.4 Whole-body Exercise Performance 
Reduced exercise capacity is a well documented feature of COPD and limiting 
factors may vary and change over time (Saey & Maltais 2005). Ventilatory 
limitation (including dynamic hyperinflation and reduced oxidative capacity), 
abnormal gaseous exchange, cardiovascular limitation, skeletal muscle 
dysfunction and psychosocial problems have all been identified as factors 
which can influence exercise capacity (Gallagher 1994;Saey & Maltais 2005). 
It has been debated which of these are the primary causes (Aliverti and 
Macklem 2008a;O'Donnell & Webb 2008), however it seems reasonable that 
as the disease progresses that more of these factors will play a role in 
exercise limitation (Aliverti & Macklem 2008b). These factors can be 
measured in the context of a whole-body exercise test and a number of 
objective methods have been developed to assess exercise tolerance in 
patients with COPD. 
Generally it is lower-limb exercise capacity which is measured. The 
information gathered from these tests can also be used to determine the need 
for PR, surgery, a walking aid or AOT; prescribe an exercise programme and 
also to measure the response to treatment (Johnson 2004). 
Laboratory-based exercise tests 
The ‘gold standard’ measure of maximal exercise capacity is the laboratory-based 
cardiopulmonary exercise testing [CPET (Palange et al. 2007)]. Cycle ergometry or 
treadmill tests are the most commonly employed. These tests are usually 




usually instructed to cycle at a constant speed [often around 50 revolutions per 
minute (RPM) is sustainable] and after one minute periods, the work rate is 
increased by a specified number of Watts per minute (W/min). This is continued 
until the individual is no longer able to maintain the set speed or is limited by 
symptoms. Treadmill tests are broadly similar in so far that the individual is 
required to walk at a designated speed; the gradient then increases to represent 
an increased work load (Singh et al. 1994). These tests also allow the individual to 
be monitored closely for vital signs and observations of exercise limitation, such as 
ventilatory, cardiac or leg fatigue. For individuals who have COPD, peak oxygen 
uptake (VO2peak) is a measurement which is frequently focused upon (Palange et 
al. 2007). This is an indication of maximal exercise capacity and is defined as the 
highest value of oxygen uptake that is attained during an incremental exercise test. 
Work rate is also recorded, commonly reported in Watts (W). In a meta-analysis of 
13 trials of cycle ergometry [(Lacasse et al. 2006) 268 participants and 243 
controls], the common effect size was 8.4 W [95% confidence interval (CI) 3.4-
13.4] following PR. This equated to an 18% improvement in peak work rate from 
baseline in a similar review (Troosters et al. 2005). The minimal clinical important 
difference (MCID) for a change in W after intervention has been reported. The 
MCID represents the minimum by which the subjects improve to notice a 
difference. Data from the NETT trial suggests an MCID of 4W following pre-LVRS 
rehabilitation (Puhan et al. 2011). 
Field exercise testing 
Whilst laboratory-based exercise tests are the gold standard, they may be 








alternative. The most common field tests are the six minute walk test [6MWT (Anon 
2002)] and the incremental shuttle walking test [ISWT (Singh et al. 1992)]. 
According to the ATS Guidelines (2002), during the 6MWT the individual is 
instructed to walk as far as possible during six minutes around a 30 metre (m) 
course which is designated by two cones, and marked out at three m intervals. The 
individual is permitted to slow down, stop and rest as necessary. The operator is 
required to track the distance covered by the individual during the test. A practice 
walk is not required, but should be considered. It is important to standardise the 
test course and conduct because it is known that encouragement and course 
layout may influence the outcome.
The ISWT (Singh et al. 1992) is an externally paced field test (figure 2.7). The 
individual is provided with standardised instructions prior to commencing the test. 
They are then required to walk around a ten metre course along a flat surface, 
which is demarked by two cones placed  nine metres apart, allowing 0.5 m at each 
end for turning. The speed of walking is dictated by an audio signal which begins 
slowly, and increases at one minute intervals. The test is continued until the 
individual is too breathless or fatigued to continue, or can no longer maintain the 
walking pace. A practice walk is required as there may be a significant learning 
effect with repeat testing (Singh et al. 1992). A ‘true’ test should be performed after 
a 30 minute rest. VO2 peak during the ISWT correlates favourably with oxygen 
consumption during standard treadmill tests (Singh et al. 1994) and during the test 













test is therefore useful for measuring the distance walked to predict maximal 
oxygen uptake. 
Figure 2.7 ISWT in practice
The response to the 6MWT and the ISWT has been compared (Luxton et al. 
2008). The physiological response to the ISWT is gradual and mirrors the 
response observed in an incremental cycle test. This is not seen in the 6MWT 
where a peak response is observed within the first three minutes. 
It is currently accepted that a change of around 48m for the ISWT (Singh et al. 













Quadriceps muscle dysfunction is a key cause of exercise intolerance in 
patients with COPD, manifested by reduced muscle mass and strength. This 
problem also imposes a burden to the health system as quadriceps 
dysfunction is an independent predictor of hospitalisation and mortality. 
Importantly, the quadriceps may provide a target for therapy in an otherwise 
irreversible lung disease and changes in strength after RT are well known.  
Dietary protein has been shown to induce protein synthesis in healthy young 
adults. However there is an impaired response in healthy elderly subjects and 
merely providing dietary protein may not be effective in increasing protein 
synthesis. It may be that an anabolic stimulus, such as exercise is needed. 
The timing of supplementation in relation to RT may also be an important 
factor in the response for older people.
This thesis describes a RCT which aims to explore the role of protein 
supplementation given immediately after RT, upon functional outcomes, in 
patients with COPD. Secondary aims were to precisely explore the training 
intensity progression, fatigue profile and cardio-respiratory load imposed by 















This chapter will describe all methods employed in chapters 4-6. These 
chapters explore the main components of the randomised controlled trial 
discussed in this thesis. This includes: the main study outcomes (chapter 4), 
the profile of the RT programme (chapter 5) and the cardio-respiratory load of 
the training (chapter 6). The methodology for the reliability and sensitivity of 
the activity monitors is described in detail in chapter 7 and is therefore not 
discussed comprehensively here. This chapter will examine the study design, 
recruitment of subjects and outline the interventions compared in this thesis.  
It will also comprehensively describe the outcome measures and the methods 
of statistical analyses employed in this thesis.
3.2 Ethical approval
The study described in this thesis received ethical approval from the 
Leicestershire, Northamptonshire and Rutland Research Ethics Committee 1 
(Reference: 06/Q2501/138), Leicester City Primary Care Trust (Reference: 
0696) and was sponsored by the University Hospitals of Leicester (UHL) NHS 
Trust (Reference: 10146). Funding was provided by a Medical Research
Council experimental medicine grant and the study was registered with the 
International Standard Randomised Controlled Trial Number Register 
(Reference ISRCTN22764439). Recruitment took place between January 








Subjects were provided with written information and given at least 48 hours to 
consider the information and ask any questions. Patient information leaflets 
for COPD patients and healthy controls are shown in appendices 3 and 4. All 
subjects provided written informed consent (appendix 5) prior to participation 
in the study. Consent was taken by myself or Dr Menon. It was made clear 
that refusal to take part or withdrawal from the study would not affect any 
future care. The GP of the subjects were informed that their patient was 
involved in the study and were provided with an information leaflet outlining
the study. A copy of the consent form and patient information sheet were filed 
in the subjects’ medical notes. New notes were created for any subject who 
was not previously known to UHL NHS Trust. 
All assessments and interventions described in this thesis took place in the 
exercise laboratory and respiratory physiology department at Glenfield 
Hospital which is part of the UHL NHS Trust.
3.3 Study design
The study design was a double-blind, randomised placebo-controlled trial of 
protein supplementation throughout a RT programme. The study objectives 
were met by comparing skeletal muscle function, muscle mass and PA at 
baseline, during and after a standardised 8-week RT programme in patients 
with COPD and age-matched healthy controls. COPD patients were also 
randomised to receive a nutritional supplement or a non-caloric placebo 
during the course of the RT programme. Patients were stratified prior to 





































   
     
 
  
   
  




   
  
   
patients were recruited to each arm of the study. Patients were deemed to be 
wasted if their height normalised fat-free mass (FFM) was less than 16 kg/m2 
in men or less than 15kg/m2 in women from DEXA analysis (see section 3.8). 

















Figure 3.1 Study Design
3.4 Randomisation and blinding
A third party randomisation service was provided by the University of 
Nottingham Clinical Trials Unit (CTU). This facility was internet based and 
involved logging onto the system prior to the subjects’ first training session. 
The following subject details were entered: sex, date of birth, study number 
and whether they were wasted/ non-wasted from DEXA analysis. 







The system then provided a randomisation number which matched the 
treatment label on the supplement boxes. A person independent of the study 
(Dr Louise Sewell) received the treatment allocation list at Glenfield Hospital 
and labelled the treatment boxes accordingly. This enabled double blinding 
(subject and researcher).
Importantly, the system was set up to stratify subjects based on their gender 
and whether they were wasted/ non-wasted from DEXA analysis. Healthy 
subjects were not randomised and received a box of placebo sachets for the 
duration of the study.
3.5 Recruitment sources, inclusion and exclusion criteria 
Subjects with COPD were recruited from respiratory out-patient clinics at 
Glenfield Hospital, from local GP practices and from the respiratory specialist 
nurses working in the community. Invitation letters were also sent to those 
who had been referred for PR at Glenfield Hospital and to PR graduates who 
had completed their treatment at least one year ago. For those subjects who 
had been referred for PR, they were able to complete the study whilst 
remaining on the waiting list and went onto start PR as planned. As the study 
interventions in this thesis did not constitute comprehensive PR, we also 
offered a place in PR to those who felt that this was needed after completion 
of the study. In accordance with ethical standards, subjects only participated 
in one research study at any one time. Motivated patients, prepared to 







Inclusion criteria: COPD subjects 
Subjects were enrolled who had moderate to severe airflow obstruction on 
spirometry [GOLD stages II-IV (FEV1/ FVC ratio <70%), a diagnosis of COPD 
and a significant reduction in exercise tolerance (MRC grades III-V). Patients 
were clinically stable (no exacerbation in the previous 4-weeks) and able to 
carry out lower-limb RT. 
Exclusion criteria: COPD subjects 
Exclusion criteria were oral corticosteroid, anticoagulant and long-term oxygen 
therapy as well as type I and type II diabetes. These criteria were all due to 
potential problems in either the muscle biopsy procedure or analysis (vastus 
lateralis biopsies were taken as part of the wider study by Dr Menon). These 
criteria therefore excluded the most severe patients and may reduce the 
external validity of the findings. Those with co-morbid conditions preventing 
exercise training, such as lower-limb arthritis, were also excluded. 
Furthermore, PR graduates were asked to wait at least a year after 
completing the programme before starting the study; because the benefits of 
rehabilitation have been shown to persist for at least 12-months (Griffiths et al. 
2000;Ries et al. 2007). 
Recruitment of healthy subjects 
Age-matched healthy controls were recruited from the local population via 
advertisements including posters, bulletins on the UHL NHS Trust intranet and 














patients’ spouses enrolled. This may have introduced selection bias as they 
would have a vested interest in the results of the study. 
Inclusion Criteria: Healthy Subjects 
Healthy subjects who had no evidence of airflow obstruction on spirometry 
(FEV1 > 80% predicted) and were able to carry out lower-limb RT were 
included. A sedentary healthy cohort were required to provide comparison 
with the COPD group and therefore healthy subjects did not participate in 
regular exercise (defined as ≥ three exercise sessions per week).
Exclusion Criteria: Healthy Subjects 
Exclusion criteria were the same as for the COPD subjects. In addition, 
healthy subjects who met the criteria for FFM depletion were also excluded. 
3.6 Interventions 
Quadriceps resistance training
The RT programme lasted for eight weeks and comprised of three supervised 
thirty-minute sessions per week. Supervision was provided by a trained 
Physiotherapist (LH- author) who gave standardised instructions and all 
subjects could visualise their performance on the screen at all times. Training 






      
 
Positioning and stabilisation of the subject were standardised according to 
manufacturer guidelines. This involved the subjects sitting upright in a seated 
position. The chair monorail and back translation were adjusted so that the 
centre of the dynamometer head was in line with the subjects’ knee joint line. 
A seatbelt, thigh strap and contra-lateral limb stabiliser were used to ensure 
that movement of other body parts was limited. In addition, subjects were 
asked to fold their arms (see figure 3.2). The knee/ hip adaptor pad was then 
strapped to the distal part of the tibia at a level which was approximately five 
centimetres above the lateral maleoulus of the ankle (see figure 3.3).  
Figure 3.2 Isokinetic dynamometer subject position
The subjects’ leg was held out so that the knee was straight (0 degrees) and 





   
                
was then measured to allow the computer system to correct for gravity in its 
calculations (Chan et al. 1996). 
Subjects then performed five sets of thirty maximal knee extensions, moving 
the knee/ hip adaptor bar up and down. The contractions were isokinetic and 
concentric at a PAV of 180°/sec. Each set was separated by a minutes rest 
and both legs were trained. The work of the knee flexors to move the leg back 
to the resting position is not presented because patients were not asked to 
forcefully pull back. Additionally, subjects also received one minute of 
continuous passive movement (flexion/ extension) before and after the 
training to act as a warm-up/ cool-down. This RT protocol was known to 
restore muscle mass, post-immobilisation in healthy young men (Jones, Hill, 
Krasney, O'Conner, Peirce, & Greenhaff 2004) and was found to be tolerable 
by frail COPD patients in a pilot study (Williams, Flora, Sandland, Singh, & 
Steiner 2007). 












The basic measurements recorded were the peak torque (Newton-metres: 
Nm) and total work done (Joules: J) for each of the five sets. The highest 
value for each leg was also documented (see recording log, appendix 6).
Patients were withdrawn from training if they had a disease exacerbation 
meaning that they were unable to attend a training session for ≥ 10 days or if 
they complained of continued musculoskeletal pain.
Nutritional supplementation 
COPD patients were randomly assigned to receive either a dietary protein 
supplement or a placebo after training throughout the study period. Healthy
volunteers received the placebo only. The supplement contained 19 grams (g) 
of protein and some carbohydrate (Vitargo Gainers Gold: Swecarb, Sweden) 
and was mixed with up to 500 millilitres (mls) of cold water. The protein-
carbohydrate mix was deemed sufficient to saturate post-exercise muscle 
protein synthesis and to ensure insulin availability, above the level known to 
inhibit muscle protein breakdown in healthy young volunteers (Rennie 2007). 
The placebo was an identical volume, non-nutritive and non-caloric drink. The 
supplement and placebo looked identical both in powder form and once mixed 
with water. The only difference was that the supplement was heavier (by 45
g). For this reason, the sachets or boxes weren’t handled by researchers. The 
full ingredients of both the supplement and placebo are shown in appendices 











Supplementation took place immediately after each training session, as the 
timing of protein intake appears to be critical (Esmarck et al. 2001). All 
subjects were responsible for making their own drinks from the sachets in 
their allocated box. This ensured that the boxes weren’t handled by the study 
personnel and therefore blinding remained in tact. However subjects were 
supervised to ensure that drinks were taken in full prior to leaving the exercise 
laboratory. 
3.7 Measurement of symptoms during resistance training
Breath-by breath analysis 
Breath-by-breath measurements of gas exchange and ventilation were taken 
in a subset of subjects during one RT session; to determine the load on the 
cardio-respiratory system. This is described in detail in chapter 6.
Measurement of breathlessness 
Perception of breathless was measured before and after each RT session 
using the Modified Borg scale [(Borg 1982) appendix 8]. This is a categorical 
scale with ratio qualities and is sensitive to changes in respiratory effort 
(Jones et al. 1985). The scale ranges from 0 (“no breathlessness”) to 10 (“the 
worst breathlessness you have ever experienced”). 
Measurement of perceived exertion 
Rates of perceived exertion (RPE) were measured before and after RT using 













(“no exertion”) to 20 (“maximal exertion”). The scale takes into account 
breathlessness and muscle fatigue to give an overall score. 
Other physiological measures
Continuous monitoring of SpO2 and HR were measured throughout each RT
session using a portable pulse oximeter with finger probe (PULSOX-3: Konica 
Minolta, Osaka, Japan). Resting and post-exercise values were documented.
3.8 Outcome measures
Outcomes were assessed before and after the 8-week RT programme. Of 
note, subjects were familiarised to all tests prior to the baseline assessment to 
prevent a learning effect. The need for one practice isometric and isokinetic 
strength test, prior to baseline testing, is apparent from the data presented in 
appendices 10 and 11. Muscle strength and muscle mass were also assessed 
at 4-weeks (mid-point, prior to training sessions 12-14). These 4-week, interim 
results are presented in chapter 5 only when considering the how RT intensity 
relates to functional outcomes. The results at 4-weeks are not presented in 
chapter 4. Muscle biopsies of the vastus lateralis and blood tests were taken 
immediately prior to the first RT session, 24-hours after the first RT session, at 
4-weeks and at the end of 8-weeks by Dr Manoj Menon to explore the 
molecular mechanisms underpinning muscle growth (not discussed in this 
thesis). 


















































































































































































































































































































































































During the first visit, general clerking information was collected. e.g. 
demographics, medical history, medication list, smoking history and social 
information. In addition, height was measured in cm (to the nearest 0.1cm) 
using a wall mounted measuring stick and weight measured in kg (to the 
nearest 0.1kg) was measured using floor scales (both SECA: Hamburg, 
Germany), to calculate BMI. 
Assessment of quadriceps strength 
Both isometric and isokinetic strength of the dominant quadriceps was 
measured using an isokinetic dynamometer (Cybex II Norm: CSMi, 
Stoughton, USA). The same standardised positioning of the subject was used 
as for the RT (figure 3.2). Peak isometric strength (Nm) was measured during 
six attempts at a maximum static contraction, with the knee fixed at 70° 
flexion. As part of a methods comparison, the same procedure was also 
carried out on a seated strain gauge and with a HHD in a sub-group of 
participants (see appendix 10). The test re-test reliability of the more 
affordable, portable methods were compared to the gold standard cybex 
measure. HHD was the least reliable. Both the cybex and strain gauge had 
ICC values of 0.90 and above.
Isokinetic strength was also assessed during two sets of five knee extensions 
at an angular speed of 60°/sec. The highest peak torque (Nm) and total work 
done (J) for the best set was recorded. Furthermore, isokinetic peak torque 










     
training to produce 180°/sec results (reported in chapter 5). Resting and peak 
measures of SpO2, HR, Borg breathlessness levels and Borg RPE levels were 
taken in the same way as they were for the RT.
Assessment of total body and regional muscle Mass
Total body and thigh FFM were measured using DEXA (Lunar Prodigy: GE 
Healthcare, Chalfont St. Giles, UK). Subjects were asked to lie flat on the 
DEXA table within the boxed area for the duration of the scan (approximately 
five minutes). Straps were placed around the knees and ankles to hold them 
in position. See positioning diagram (figure 3.5). Metallic items were removed 
from the body prior to the scan. 





    
 
 
FFM (g) was calculated as lean mass + bone mineral mass. To determine the 
lean mass of the dominant thigh, a region of interest (ROI) was traced using 
custom analysis. The upper limit of this ROI was the lowest point of the ischial 
tuberosity. The lower limit was the knee joint line. The pubic symphysis and 
the most lateral part of the thigh were used as the medial and lateral limits 
[(Delmonico et al. 2008) see figure 3.6]. The total body FFM was also 
expressed as an index (FFMi: lean mass + bone mineral mass/ height). 
Subjects were deemed to have FFM depletion if their height normalised FFM 
index was below 16kg/m2 for men and below 15kg/m2 for women. As DEXA is 
primarily used in the screening of osteoporosis; subjects’ GPs were informed 
if osteoporosis or osteopenia were apparent. 
Figure 3.6 Thigh FFM ROI
Assessment of physical activity
PA was measured in a subgroup of participants using two, none disease-








The Voorips questionnaire was performed at baseline only. The DASI and the 
7-day activity monitor results were analysed before and after the 8-week RT 
programme. The methodology and results of PA monitoring are discussed in 
depth in chapter 7.
Assessment of whole-body exercise performance  
Subjects performed a symptom-limited, maximal, incremental cycle 
ergometery test. This involved patients sitting on a static bicycle whilst having 
a mouthpiece held in their mouths and a nose peg to create a seal (see figure 
3.7). The mouthpiece collected breath-by-breath measurements of gas 
exchange and ventilation during the ergometry test. Specifically, resting and 
peak measures of minute ventilation [VE (l/min)], oxygen consumption [VO2, 
mls/kg/min)], carbon dioxide production [VCO2, (l/min)] and work (W). The 
ergospirometry system used was the zAn-600 ErgoTest (ZAN Meβgeräte 
GmbH, Oberthulba, Germany). Resting and peak measures of blood 
pressure, SpO2, HR, Borg breathlessness levels and Borg RPE levels were 
also collected.
Subjects were asked to remain still for one minute whilst resting values were 
collected. They were then asked to start a cycling warm-up; there was no 
load/ resistance on the bike at this time. This warm-up lasted for one minute 
for COPD patients and two minutes for healthy controls. Subjects were then 
informed that the resistance of the cycling would gradually increase. A ramp 
protocol was utilised, ensuring a steady linear increase in load over time. For 












subjects the increase was 20 W/min. The difference in warm-up times and 
loads for patients and controls is standard practice in our laboratory; designed 
so that patients and controls perform the test for a similar duration. Subjects 
were asked to cycle at a cadence of 40-50 revolutions per minute (RPM) 
which was visible to them.
Figure 3.7 Maximal cycle ergometry test
The test ended when the subject could no longer continue due to symptom 
provocation, such as breathlessness or leg fatigue. The test could also be 
stopped by the operator if the subject was unable to maintain the required 
speed or if they believed that the subject was in any danger. The reason for 











Assessment of Lung Function  
At baseline only spirometry was performed by a trained technician in the 
Respiratory Physiology Department at Glenfield Hospital. Both COPD patients 
and healthy controls underwent these tests.
Basic spirometry was performed using the SPIRO AIR® spirometer with 
Exp’Air software (Medisoft: PAE de Sorinnes, Belgium). This involved the 
subject taking a maximal inspiration then blowing as hard and as fast as they 
could into the spirometer mouthpiece. A nose peg was also worn to prevent 
an air leak. Subjects remain seated throughout testing. FEV1 (l), FVC (l) and 
the FEV1/FVC ratio were recorded. 
3.9 Equipment calibration 
The isokinetic dynamometer, DEXA scanner, cycle ergometer and respiratory 
physiology equipment described in this methodology chapter all required 
calibration. For the isokinetic dynamometer this occurred monthly, whilst the 
DEXA, cycle ergometer and spirometry equipment were calibrated on each 
use. See appendix 12 for full calibration procedures.
3.10 Data acquisition, storage and statistical analysis 
Acquisition, analysis and storage of data 
Raw data (standard cybex output data) was collected manually and stored in 
the subjects’ study notes for the RT results and for strength, muscle mass, 








provided by the Respiratory Physiology department for all lung function 
results. These were filed in the subjects’ study notes. The activity monitor data 
was acquired, stored and analysed using the ActiTrac software (IM Systems, 
Baltimore, USA). Electronic data was automatically saved on the isokinetic 
dynamometer, DEXA scanner and cycle ergometer for future use. These three 
systems were also backed up to an external hard-drive at least monthly.
Results of all outcomes at baseline, mid-point and post-intervention were 
manually inputted into a statistical package (Statistical package for the Social 
Sciences: SPSS, version 16.0 and later version 17.0= PASW). The RT data 
from each training session was also inputted into SPSS for analysis. The data 
stored in SPSS was stored on two hard drives of a NHS computer (Dell 
Optiplex 745, Dell Inc, Austin, Texas, U.S) and three memory sticks, in 
separate locations.
Subjects’ study notes were locked in a secure filling cabinet and computer 
equipment was also secure and password protected.
Power calculation 
Statistical advice was taken from the Trent Institute for Healthcare Services 
Research at the time that the protocol was written. The main outcome 
measure chosen in this thesis was muscle strength, as this is an outcome for 
which we have previous data. Strength is also an important functional 
outcome for patients. We therefore estimated the samples size required to 
meet the study objectives using expected improvements in isometric muscle 








a 20% difference between groups or a 20% improvement in isometric 
quadriceps strength after training would be significant (Bernard et al. 
1999;Spruit et al. 2002). Using quadriceps strength data obtained at our 
institution, we would require 24 subjects in each group to complete the study 
(90% power, significance level 0.05) to show a 10.0 (SD 14.8) Nm within-
group improvement in isometric strength (Deacon et al. 2008). Allowing for a 
25% dropout rate in the COPD group (the average for the outpatient 
rehabilitation programme at Glenfield Hospital) we would need to recruit 31 
patients with COPD (per group) and 24 healthy controls.
Statistical analysis
All analysis was performed using SPSS version 16.0 and later PASW version 
17.0. An intention-to-treat analysis was planned for subjects who completed 
the RT but dropped out of supplementation. The level of statistical significance 
was set at p<0.05. All data was firstly assessed for normality to choose 
appropriate parametric and non-parametric tests. Continuous and normally 
distributed variables are presented as mean and standard deviation. 
Categorical variables and skewed data are presented as medians and inter-
quartile range or frequencies and percentages. 
The strength of association between variables was assessed using Pearson’s 
correlation coefficient for parametric data and Spearman’s rank correlation for 
non-parametric data. To compare the agreement between two methods of 




















(Bland & Altman 1986). Test re-test reliability was reported using the intra-
class correlation co-efficient (ICC). 
Comparisons within and between groups were analysed with paired and 
unpaired t-tests for parametric data and with Wilcoxon and Mann-Whitney U 
tests for non-parametric data. Appropriate post-hoc tests were chosen to 
evaluate were significant differences lay. When comparing more than two 
groups at one time point, a one-way analysis of variance (ANOVA) was 
performed (or Kruskal-Wallis for none-parametric data). When comparing 
more than two groups over time, a repeated-measures ANOVA with 
Bonferroni corrections for multiple comparisons was executed or a Friedman 
test for non-parametric data using time and group interactions. Generalised 
estimating equation (GEE) analysis was performed to compare the gradients 
of slopes. 
Advice on the statistical analysis of this study was provided by the East 
Midlands Research Design Service (RDS) and Coventry University. Detailed 













Main randomised controlled trial outcomes; the role of
supplementation as an adjunct to resistance training
4.1 Introduction 
Resistance training (RT) is recognised as a key component of modern 
Pulmonary Rehabilitation (PR) programmes and, as such, is recommended 
within several international guidelines (Nici et al. 2006;Ries et al. 2007). This 
is because of the known associations between muscle weakness, healthcare 
utilisation and mortality (Marquis et al. 2002;Swallow et al. 2007b). Several 
investigators have shown that RT can improve muscle mass and strength in 
healthy elderly people (Brown et al. 1990b;Hakkinen et al. 2000) and in those 
with COPD (Bernard et al. 1999;Spruit et al. 2002). Improvements are 
generally in the region of 20% (Bernard et al. 1999;Spruit et al. 2002). From 
literature in healthy subjects, we know that changes in muscle mass, in 
response to training, tend to fall short of the increases in strength (Jones et al. 
2004). This is because muscle force is not simply a product of muscle CSA, 
but also a number of other factors (discussed in chapter 2).  
For the benefits of RT to be translated into muscle hypertrophy, sufficient 
protein substrate is required within the muscle to enhance muscle building.
Dietary protein has been shown to induce protein synthesis in healthy young 
adults. However there is an impaired response in healthy elderly subjects and 














synthesis (Cuthbertson et al. 2006). It may be that an anabolic stimulus, such 
as exercise is needed. In addition, the timing of supplementation in relation to 
resistance exercise may also be an important factor in the response for older 
people. Data from Denmark found that muscle hypertrophy only occurred in a 
healthy elderly group receiving protein immediately after RT and not in those 
receiving the protein two hours later (Esmarck et al. 2001). The aim of this 
thesis was to translate these observations to a group with COPD as the role of 
protein in combination with RT has not been studied in this population. 
Furthermore we do not know if the results will translate into functional benefits 
for patients. This was a mechanistic study, exploring the role of protein as an 
adjunct to RT. It was not a study of dietary protein in patients, in isolation, or 
alongside generic rehabilitation.
This chapter presents results from the main RCT as described in chapter 3. 
4.2 Hypothesis and aim 
Hypothesis 
Resistance training, in combination with protein ingestion (at the time of 











To measure the functional response to the intervention at 8-weeks in terms of 
changes in muscle strength, muscle mass and whole-body exercise 
performance. 
4.3 Methods 
The methodology for the main study is described comprehensively in chapter 
3- materials and methods. Refer to chapter 3 for details regarding recruitment, 
study design, randomisation, interventions and outcome measures. The 
power calculation identified that 24 subjects were required per group (90% 
power). 
For ease of reading; the interventions and outcomes are summarised below.
Intervention groups 
Patients with COPD and healthy controls all underwent 8-weeks of quadriceps 
RT using an isokinetic dynamometer. Training consisted of three supervised, 
30-minute sessions per week. Subjects then performed five sets of 30 
maximal knee extensions. The contractions were isokinetic and concentric at 
a PAV of 180°/sec. Each set was separated by a minutes rest and both legs 
were trained. The highest recorded peak torque (Newton-metres: Nm) and 
total work done (Joules: J) from the five sets was recorded for each leg. 
Completion was defined as those attending all 24 training sessions and 















COPD subjects were also randomly assigned to receive either a dietary 
protein (with carbohydrate) supplement or a placebo at the point of training 
throughout the study period. Healthy volunteers received the placebo only, as 
the role of protein alongside RT is already established in this group (Esmarck 
et al. 2001). Supplementation took place immediately after each training 
session and all subjects were responsible for making up their own drinks with 
water, under supervision. 
Outcome measures 
Outcome measures were assessed at baseline, after familiarisation and after 
8-weeks of RT. The outcomes can be broadly classified into two categories:
Muscle function 
• body weight 
• total body fat-free mass (and FFM index) 
• thigh lean mass 
• isometric peak torque 
• isokinetic peak torque (Nm) and total work (J) at a PAV of 60°/sec 
•
Physical performance 
• physical activity (convenience sample- results in chapter 7) 







Measures of muscle function were also taken at the mid-point of training (4-
weeks). This data is reported in chapter 5 where the relationship between 
outcomes and training intensity is examined. 
4.4 Statistical analysis 
Statistical analysis was performed using the statistical package for the Social 
Sciences: SPSS, version 16.0 (and later version 17.0= PASW). The level of 
statistical significance was set at p<0.05. Results are presented for those who 
completed the course of RT. An intention-to-treat analysis was planned for 
subjects who completed the RT but dropped out of supplementation. 
However, no subjects fell into this category.
Firstly the baseline characteristics were compared between completers/ non-
completers in each group, to check for differences using an independent 
samples t-test (or chi-squared test for categorical variables). A one-way 
ANOVA with post-hoc Bonferroni tests was used to compare baseline 
characteristics and baseline outcome measures between the three groups 
(COPD supplement, placebo and controls). The equivalent test for non-
continuous variables (e.g. gender) was performed using hierarchical loglinear 
analysis. Any baseline differences between the two COPD groups or between 
completers/ drop-outs were used as covariates in subsequent analysis 
(analysis of covariance: ANCOVA). The strength of association between 
variables at baseline and after RT was evaluated using Pearson’s correlation 
coefficient for parametric data and Spearman’s rank correlation for non-








strength of a relationship, values of: ±0.2 are weak, ±0.5 are moderate and 
±0.8 are strong (Zou et al. 2003). 
Comparisons between and within-groups were analysed with un-paired and 
paired t-tests for parametric data and with Mann-Whitney U tests or Wilcoxon 
tests for non-parametric data, respectively. When comparing more than two 
groups (i.e. COPD supplement, placebo and controls) at one time point, a 
one-way analysis of variance (ANOVA) with post-hoc Bonferroni test was 
performed (or Kruskal-Wallis for non-parametric data). The effect size for 
changes in outcome measures after the intervention was calculated by 
dividing the mean difference by the standard deviation of the pre-intervention 
measurement. By calculating effect sizes, the magnitude of change can be 
judged using the following criteria: small; 0.2 to 0.5, moderate; 0.5 to 0.8 and 
large; >0.8 (Cohen 1988). 
It was hypothesised that wasted patients might respond differently to the 
intervention; patients were therefore stratified by FFM in the randomisation 
process. A post-hoc subgroup analysis of the main study outcomes was 
performed in patients with muscle wastage according to accepted FFMi 
criteria (i.e. <15kg/m2 for women and <16kg/m2 for men). 
4.5 Results 
Screening data, numbers recruited and attrition 
107 participants (81 COPD/ 26 healthy controls) were recruited to the study 






figure 4.1). The reasons for exclusion from/ none-uptake to the study are 
shown in figure 4.2. The main reasons for COPD participants not meeting 
inclusion criteria were an MRC dyspnoea grade ≤2, unable to have a muscle 
biopsy (e.g. taking warfarin) and recent exacerbations.
After consent but prior to treatment allocation/ starting training: seven patients 
with COPD and one control withdrew from the study, five participants were 
withdrawn by the researcher as exclusion criteria (3 controls) had been met 
and one patient with COPD died (reasons for withdrawal are shown in figure 
4.1). Therefore 71 patients with COPD and 22 controls started the RT 
programme. 38 patients with COPD were randomly assigned to the 
supplement and 33 to the placebo. In the supplemented COPD group, four 
participants were lost to follow-up and four discontinued the intervention. 
Therefore data from 30 subjects was available for analysis at the 8-week time 
point. For the placebo COPD group, two were lost to follow-up and two 
discontinued the intervention, leaving 29 available at the 8-week assessment. 
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Figure 4.2 Reasons for exclusion from and none-uptake to the study
There was one discontinuation in the control group (spouse of a COPD 
subject who wanted to withdraw at the same time as their partner) and no loss 
to follow-up. More patients dropped out from the supplemented COPD group 
(n=8) compared to the placebo (n=4) and control (n=1) groups. However this 
was not statistically significant (chi-squared test, p>0.05 supplement vs. other 
two groups). This can be attributed to an increased number of disease 
exacerbations in this group (n=3 vs. n=0 in the other two groups). 
There was full compliance with all patients ingesting their supplement or 
placebo drink after each RT session, under supervision of the researcher. 


















     
   
  
   
    
   
  
   
  
  
   
 
 
   
    
      
    
        
 
          




The baseline characteristics of the three groups are shown in table 4.1. 
There were no significant differences in the baseline characteristics of 
completers and non-completers in the COPD groups. Pack years smoking 
was significantly different between control completers [mean (SD) 12.8 (21.5) 
years] and the one drop out in the control group (60 pack years) who was a 
current smoker (p<0.05). There were significant differences at baseline 
between controls and both COPD groups for MRC grade, smoking status, 
pack years, lung function variables and the number with defined muscle 
wastage (table 4.1), as expected. 










Age (years) 68.6 (9.7) 67.7 (8.7) 66.5 (5.1)
Gender- number of
males (%)
24 (63) 18 (55) 11 (50)
BMI 26.7 (4.9) 26.3 (5.6) 26.8 (2.8)
MRC Dyspnoea Grade-
median (IQR)
3 (1)** 4 (1)** 1 (0)
Current smokers-
number (%)
6 (16)* 8 (24)* 4 (18)
Smoking pack years 
(years)
48.5 (42.3)** 47.8 (31.0)* 14.9 (23.3)
FEV1 (litres) 1.2 (0.4)** 1.2 (0.4)** 2.6 (0.7)
FEV1 (% predicted) 47.0 (18.4)** 47.5 (16.9)** 104.8 (21.2)
FEV1/ FVC (ratio) 39.9 (13.9)** 42.5 (11.7)** 72.1 (6.6)
Muscle wasted- no. (%) 7 (18)* 7 (21)* 0 (0)
All data are mean (± SD) unless otherwise stated.
*p<0.05; **p≤0.001 significant difference compared to control group.
However there were no significant differences between control and COPD 







      
 












     
       
      
       
    
 
  
   
  
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
differences between the two COPD groups at baseline for any variable (all 
p>0.05). 
Baseline outcome measures 
Table 4.2 displays the baseline values for the muscle function and physical 
performance variables measured in the three groups. 
Table 4.2 Baseline values for muscle function and physical performance 









Weight (kg) 72.4 (15.8) 71.2 (17.0) 73.1 (10.2)
Total body FFM (g) 48005.1 (9614.1) 47529.1 (10360.0) 48136.6 (9292.6)
Total body FFMi 17.6 (2.7) 17.5 (2.7) 17.5 (1.8)
Thigh lean mass (g) 4162.2 (975.3) 4093.8 (1139.9) 4446.3 (899.8)
Isometric strength (Nm) 111.0 (44.9)* 109.7 (47.6)* 137.7 (43.8)
Isokinetic peak torque
(Nm) at 60°/sec
81.5 (35.4) 76.4 (34.3)** 99.7 (36.3)
Isokinetic total work (J) at
60°/sec
310.5 (145.5) 283.8 (141.9)** 378.6 (149.3)
Cycle ergometry work
(W)
48.4 (21.1)** 52.3 (24.1)** 119.7 (38.3)
Cycle ergometry time
(sec)
352.0 (128.3)** 372.1 (147.8)* 467.8 (129.8)
Cycle ergometry peak
VO2 (l/min)
1.1 (0.6)** 1.1 (0.5)** 1.7 (0.5)
Cycle ergometry peak
VO2 (mls/kg/min)
15.0 (6.1)** 15.0 (5.1)** 22.8 (6.3)
Cycle ergometry peak
VCO2 (l/min)
0.9 (0.3)** 1.0 (0.5)** 1.8 (0.7)
Cycle ergometry peak
VE (l/min)
32.1 (10.7)** 32.2 (12.6)** 46.0 (17.2)
Cycle ergometry peak
RER (l/min)
1.0 (10.7)** 1.0 (12.6)** 1.0 (0.1)
All data are mean (± SD). *p<0.05; **p≤0.01 significant difference compared to
control group.
There were no significant differences between the three groups at baseline for 












subjects recorded significantly greater results in all cycle ergometry variables, 
compared to both COPD groups.
There was a significant difference at baseline between control subjects and 
COPD subjects receiving the placebo for isometric strength, isokinetic torque
and isokinetic work. COPD subjects receiving the supplement however, only 
differed from controls for isometric strength (p<0.05). There were no 
significant differences between the two COPD groups, for any outcome at 
baseline.
From DEXA analysis, osteopenia was detected in 19 males (45%) and 16 
females (55%) with COPD. Osteoporosis occurred in 5% of males (n=2) and 
10% of females (n=3) with COPD. Diagnosis was based upon the World 
Health Organization T score criteria of -1 to -2.49 for osteopenia and ≤-2.5 for 
osteoporosis (World Health Organization 1994). These patients were advised 
to see their GP and a letter detailing the findings was sent to participants’ GP 
with consent. No control subjects had evidence of bone thinning.
Baseline correlations in outcome measures
In COPD subjects there were weak but statistically significant correlations 
between FEV1 (l) and total body lean mass (r=0.39 supplement/ r=0.38 
placebo), quadriceps lean mass (r=0.44 supplement) and whole body 










Quadriceps (thigh) lean mass (g) was strongly and significantly correlated with 
both isometric strength (r=0.85) and isokinetic peak torque (r=0.85) in healthy 
controls (p<0.001) at baseline. The relationship between baseline thigh lean 
mass and isometric strength was moderate in subjects with COPD (r=0.67 
supplement, r=0.64 placebo, both p<0.001). Thigh lean mass and isokinetic 
strength was also moderately correlated in patients with COPD at baseline 
(r=0.66 supplement, r=0.65 placebo, both p<0.001). Interestingly, thigh lean 
mass was also associated with cycle ergometry performance (work). 
Correlation coefficients were 0.75 (controls, p<0.001), 0.40 (COPD 
supplement, p<0.05) and 0.74 (COPD placebo, p<0.001). Furthermore, 
isometric and isokinetic strength were shown to be moderately related to 
ergometry workload performance in all groups [controls: r=0.78 (isometric) 
r=0.79 (isokinetic); supplement: r=0.5 (isometric) r=0.60 (isokinetic); placebo: 
0.58 (isometric) 0.64 (isokinetic). All p<0.001].
Within-group changes and between group differences after the 
intervention 
Results are displayed for those completing the assessments at the 8-week 
time point. Table 4.3 summarises the within-group changes (mean change 








           




























    
 
 
   
 
   
 




   
 
   
 




   
 
   
 




   
 
   
 
   
    
 
  
   
  
   
 
   
     
   
 
   
 
   





   
 
   







   







   


















































































All data are mean change (95% CI). *p≤0.05; **p≤0.01; ***p≤0.001 significant
difference within groups. † significantly different to control subjects (p≤0.05).
All groups made significant within-group changes in thigh lean mass, 
quadriceps strength and cycle ergometry peak work/ time. Change in weight 
at 8-weeks was significantly different between controls and the placebo COPD 
group (p<0.05). All groups lost weight after RT; this was significant in the 
supplemented COPD group (p≤0.01) and controls (p≤0.001). Changes in 
whole body FFM (and the FFMi) were small in all groups (<1% change from 
baseline) and did not reach statistical significance.
Table 4.4 shows the effect sizes for the changes in outcome measures after 

























   
 
  
    
 
   
    
 
   
 
 
   
 
 
   
 
 
   
    
 
   
       
   
 
   
    
 
   
    
 
   
The only large effect size was for the change in cycle ergometry peak VO2 in 
healthy controls [according to Cohen’s definition (Cohen 1988)].










Weight (kg) -0.1 -0.0 -0.2
Total body FFM (g) 0.0 0.0 0.0
Thigh lean mass (g) 0.2 0.2 0.3
Isometric strength (Nm) 0.4 0.3 0.4
Isokinetic peak torque (Nm) 0.5 0.6 0.3
Isokinetic total work (J) 0.5 0.6 0.4
Cycle ergometry work (W) 0.5 0.3 0.4
Cycle ergometry time (sec) 0.5 0.3 0.4
Cycle ergometry peak VO2 
(mls//kg/min)
-0.1 0.4 0.8
Cycle ergometry peak VCO2 
(l/min)
1.0 1.1 0.6
Cycle ergometry peak VE
(l/min)
0.1 0.4 0.7
Effect sizes (Cohen 1988): 0.2 to 0.5 (small), 0.5 to 0.8 (moderate) and >0.8
(large)
There were no significant differences between the two COPD groups for the 
changes in all outcomes (see table 4.5). Therefore we can reject the study 
hypothesis as protein did not enhance the benefits of RT in this study. 
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Table 4.5 Mean differences (95% CI) between COPD supplement and placebo 
groups after resistance training
Mean
difference *
95% CI p value
Weight (kg) -0.5 -1.3 to 0.4 0.27
Total body FFM (g) -148.5 -645.0 to 348.0 0.55
Thigh lean mass (g) -50.3 -166.7 to 66.2 0.39
Isometric strength (Nm) 3.0 -7.0 to 13.1 0.55
Isokinetic peak torque (Nm) -2.1 -12.0 to 7.9 0.68
Isokinetic total work (J) -6.7 -51.8 to 38.4 0.77
Cycle ergometry work (W) 1.8 -5.4 to 8.9 0.63
Cycle ergometry time (sec) 11.8 -31.8 to 55.5 0.59
Cycle ergometry peak VO2 
(mls//kg/min)
-1.9 -5.0 to 1.3 0.12
Cycle ergometry peak VCO2 
(l/min)
-0.2 -1.0 to 0.7 0.72
Cycle ergometry peak VE
(l/min)
-4.4 -11.7 to 2.9 0.24
* supplement within-group change minus placebo within-group change
Measures of thigh lean mass at baseline and 8-weeks, and percentage 
change from baseline are shown in figure 4.3. Again all three groups made 
significant improvements after the intervention; this was in the order of 5%. 
Differences between the groups were not significant. 
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Figure 4.3 Percentage change from baseline in thigh lean mass in all groups
Figures 4.4 and 4.5 show the mean values for isometric and isokinetic 
strength (peak torque at 60°/ sec) respectively; before and after the 
intervention, in all groups. The percentage change from baseline is displayed 
across the top. 
All groups made significant changes after 8-weeks in both measures of 
strength Both COPD groups had greater improvements in isometric and 
isokinetic strength, compared to controls. However there were no statistically 
significant differences between the groups. All groups had larger increases in 
isokinetic (dynamic) measures of strength (torque and work), rather than 
isometric (static) measures. The trajectory of change in quadriceps strength, 




             
          
Figure 4.4 Percentage change from baseline in isometric strength in all groups






            
 
Changes in whole-body exercise performance indicate some carry over of RT 
to endurance performance. Peak cycle work improved in all three groups 
(figure 4.6- mean values at baseline and 8-weeks, and percentage change 
from baseline). The change was approximately 10 watts in each group and 
there were no significant differences between the groups. 
Figure 4.6 Percentage change from baseline in peak cycle work in all groups
Cycle time improved by around one minute in all groups. The change in peak 
VO2 was significantly lower in the supplemented COPD group compared to 
controls (p<0.05) and only reached statistical significance in control and 
placebo COPD groups (p≤0.05). There were no differences between the 













and VE only reached statistical significance in the control group (p≤0.05 VCO2 
and p≤0.01 VE). 
Correlations between changes in outcome measures after the 
intervention 
Patients with COPD who received the supplement had significant associations 
between changes in weight and changes in thigh lean mass (r=0.38, p<0.05). 
Changes in isometric strength were moderately correlated with changes in 
isokinetic peak torque (r=0.53), isokinetic work (r=0.45) and cycle ergometry 
work [(r=0.40) all p<0.05). Furthermore changes in cycle work were also 
correlated with isokinetic peak torque (r=0.60) and isokinetic work [(r=0.56) 
both p<0.01] in supplemented COPD subjects.
For the placebo COPD group, the only significant associations were between 
changes in isometric strength and changes in isokinetic peak torque (r=0.72) 
and isokinetic work [(r=0.61) both p<0.01].
In control subjects, changes in isometric strength were strongly correlated with 
changes in isokinetic peak torque (r=0.83) and work [r=0.76 (both p<0.01)]. 
Also changes in cycle ergometry work and changes in peak VO2 were 







Sub-group analysis of wasted and non-wasted patients with COPD 
Supplement and placebo groups collapsed 
A post-hoc subgroup analysis was performed to compare wasted and non-
wasted subjects with COPD with the supplementation (protein and placebo) 
groups collapsed. Twelve subjects had FFMi evidence of muscle wastage. 
The remaining 47 patients with COPD who completed the study had no 
evidence of muscle wastage. The wasted and non-wasted subgroups were 
different at baseline for weight, BMI, FFM, FFMi, isometric and isokinetic 
strength and cycle ergometry work (all significantly lower in the wasted group, 
all p≤0.05). These factors were used as covariates in the analysis. Wasted 
patients made significantly less improvement in isometric quadriceps strength 
(15.1 Nm difference between groups), isokinetic quadriceps strength (15.3 Nm 
difference between groups) and whole-body work (9.8 W difference between 
groups), compared to non-wasted patients (all p<0.05). However these results 
should be interpreted with caution, as the numbers in the wasted sub-group 
are probably too small to make meaningful comparisons.
There were no significant differences between wasted and non-wasted groups 
for any other outcome (besides quadriceps strength and cycle ergometry 
work). 
Comparing supplemented and placebo groups 
When further sub-division of the wasted and non-wasted groups occurred, 







wasted supplemented and wasted placebo groups. These groups are 
probably too small to detect significant differences and there were no 
significant differences detected between supplemented and placebo groups, 
for any outcome when divided into FFMi sub-groups. 
4.6 Discussion
This chapter reports the results of a RCT of protein supplementation in 
patients with COPD, undergoing RT. This is novel, as the role of protein as an 
adjunct to RT has not before been studied in this population. The primary aim 
was to measure the functional response to the intervention at 8-weeks in 
terms of changes in muscle strength, muscle mass and whole-body exercise 
performance. The effects in patients with COPD are compared with healthy, 
age-matched controls. This again is unique as often healthy controls are 
trained and considered separately. 
The results indicate that the study hypothesis can be rejected as there were 
no significant differences between the COPD subjects receiving the 
supplement or the placebo. Therefore supplementation sub-groups have been 
collapsed in subsequent chapters (5-8). All groups made significant within-
group improvements in quadriceps strength, thigh lean mass and whole-body 
exercise performance. We can infer from these findings that the increases in 
muscle mass, evident in all groups, indicate that RT increased net protein 
synthesis within the quadriceps muscle. This in contrast to work by 
Cuthbertson and colleagues who found that providing dietary protein was not 





2005). However this study (Cuthbertson et al. 2005) did not include a training 
programme which may be responsible for providing the necessary anabolic 
stimulus in the current study. It is not clear whether the RT programme used 
in this thesis activated protein synthesis pathways, inhibited protein 
degradation pathways or a combination of both. We know from previous 
research that RT can influence both protein synthesis and degradation 
(Phillips et al. 1997) and that there is evidence of increased whole-body 
protein turnover (increased rates of protein synthesis and breakdown) in 
patients with COPD compared to healthy controls (Engelen 2000). This may 
be clarified with the muscle biopsy analysis (performed by Dr Menon- analysis 
incomplete at the time of writing this thesis). 
In the current study, providing additional protein at the time of RT did not 
enhance the benefits of RT in patients with COPD. The reasons for the failure 
of this intervention are unclear. It may be that the stimulus or signal from RT 
swamps any additional affect of protein. Alternatively the level of protein given 
may not have been enough to show an enhanced response, above RT alone. 
It could be that improvements are dependent on the dose of protein given and 
that this will differ for each individual (i.e. varies with gender, BMI etc). Steiner 
and co-workers have previously shown that an improvement in walking 
performance was related to the amount of carbohydrate ingested during a PR 
programme (Steiner et al. 2003). In the current study the same ‘dose’ of 
protein was given to all in the supplemented group and the level did not 
change over the course of RT. This may be a limitation. However in a study by 










improved in an elderly group who received protein immediately after RT and 
not in those receiving the protein two hours later [p<0.001 between timing 
groups (Esmarck et al. 2001)]. This is despite the subjects in the Danish study 
receiving less protein (10g) than the subjects in the current study (19g).  
There was a trend towards subjects with COPD (both groups) making greater 
improvements in strength, thigh lean mass and whole-body exercise work and 
time, compared to healthy controls. However the differences between the
three groups were not statistically significant. Interestingly, data from chapter 
5 shows that the even the most disabled patients with COPD, who were 
performing RT at much lower intensities compared to healthy controls, can 
make comparable improvements in thigh mass, strength and whole-body 
exercise performance. 
It may have been that because patients with COPD had lower baseline values 
for these outcomes that they had more scope to improve. Baseline values for 
isometric and isokinetic strength (at 60°/sec) fell far short, in patients with 
COPD, of expected values in healthy older persons (as outlined in table 2.4, 
Literature Review). Alternatively, there may have been a ‘regression to the 
mean’ effect (when baseline values are highly variable, subsequent results 
are closer to the actual mean). However this effect should have been 
minimised because all subjects were familiarised to the outcome 




This RCT was adequately powered to detect differences in the functional 
outcomes within the two COPD groups, however the required sample size 
was not met in the control group (n=21 completed, n=24 needed). In future, a 
between-group power calculation may be more appropriate for this study 
design. It was perhaps ambitious to expect no drop-outs in the control group 
and to therefore not allow for attrition within the power calculation. 
Furthermore, very small numbers of wasted patients were recruited (n=12 
overall). Although the FFMi criteria are based on using BIA, this was 
unexpected, as work from our group has previously shown that around 50% of 
patients with COPD were deemed to have muscle wastage using the same 
DEXA criteria (Steiner et al. 2002). Indeed, DEXA generally detects more 
cases of FFM depletion when compared to BIA (Steiner et al. 2002). 
Therefore the results of the post-hoc sub-group analysis should be interpreted 
with caution, as it is likely that this analysis was underpowered to detect 
changes in the wasted group. None the less, the data suggests that the 
response to RT may be lower in the wasted patients and that additional 
protein was equally ineffective in both wasted and non-wasted groups. Using 
the arbitrary FFMi cut-off values was unhelpful when defining this COPD 
population. In future, it may be better to observe muscle mass as a continuous 
variable to look for obvious sub-groups. 
RT resulted in weight loss for all groups. These reductions were only 
significant in the control and placebo COPD groups. Total body lean and FFM 
mass increased; therefore changes in weight can be attributed to changes in 






rehabilitation programme for patients with COPD where exercise may result in 
a negative energy balance (Baarends et al. 1997a). Steiner and co-workers 
have previously shown that an improvement in walking performance was 
related to the amount of carbohydrate ingested during a PR programme 
(Steiner 2003) and that a lack of carbohydrate may pose a limit to the amount 
of training patients can do. The same may be true of protein during RT or 
conventional PR. If patients with COPD are in a negative protein balance prior 
to training (wasted), they may require additional protein in the diet to ensure 
muscle protein synthesis. Some underweight patients with COPD show signs 
of heightened inflammation and progressive cachexia. These patients 
respond particularly badly to nutritional support (Creutzberg et al. 2000). A 
poor treatment response in these patients may be attributed to an inadequate
assessment of their energy requirements when engaged in a rehabilitation 
programme (Baarends et al. 1997a). It may have been that some of our 
‘wasted’ patients fell into this ‘non-responder’ category and therefore reduced 
the effect of protein supplementation in the whole group.
In clinical practice, it may be important to measure lean mass/ FFM before 
and during exercise programmes for patients with COPD. The reasons for this 
are two-fold: to ensure that adequate nutritional support can be given to 
overcome the metabolic demand of exercise and, secondly, to confirm that 
exercise is not exacerbating further lean mass loss. Indeed, the stimulus of 
exercise may be shown to improve weight gain by stimulating appetite. In the 
current study, habitual diet was not measured. This is perhaps a limitation as 









normal dietary intake of protein to adjust for supplementation. This adjustment 
has been shown in previous studies of supplementation alongside 
rehabilitation in patients with COPD (Steiner et al. 2003). However this was a 
mechanistic study, examining the role of protein as an adjunct to RT. It was 
not a study of dietary protein in patients, in isolation, or alongside generic 
rehabilitation in patients with COPD. The primary hypothesis was to discover if 
providing additional protein at the time of training would lead to greater muscle 
protein synthesis and have greater effects on functional outcomes than RT 
alone.
Another potential limitation was that healthy controls only received a placebo
following training; a second group did not receive the supplement. It could 
have been interesting to examine if protein provided any additional benefit to 
RT in control subjects, as protein had no effect in the COPD patients from this 
study. However, prior to starting the study we were aware of the effects of 
supplementation and RT in healthy, elderly subjects (Esmarck et al. 2001). 
Therefore it was not deemed necessary to provide control subjects with 
protein. Controls all received a placebo drink post-exercise so that their 
transition through the training programme (e.g. session time) was identical to 
patients with COPD. This was particularly important for healthy spouses who 
trained alongside their partners with COPD.
It is likely that the improvements in muscle function and physical performance 
were meaningful for many of the subjects with COPD, despite only small or 








this was a motivated group of patients, keen to undergo exercise training. 
Therefore selection bias may have been a factor. Furthermore, the results 
may not be representative of a typical COPD population as the most severe 
patients (i.e. those of long-term corticosteroids and oxygen) were excluded. 
This was due to the biopsy procedure in the main study design.
There is no MCID established for changes in thigh mass, quadriceps strength 
or cycle ergometry outcomes in this population. This makes it difficult to 
interpret the findings, although we can compare these results to previous 
studies of RT in patients with COPD or healthy populations. The percentage 
change in thigh lean mass was approximately 5% in all groups; this is in 
keeping with the percentage of lean mass restoration observed after 
immobilisation in healthy men (Jones et al. 2004). It is, however, important to 
remember that their may have been some bias and measurement error in 
drawing the ROI for thigh mass on DEXA analysis. This could’ve been 
minimised by asking a blinded assessor to perform the drawing. The intra- 
and inter-operator variability in this measure is unknown and would be 
something to consider if using this measure again.
Changes in quadriceps strength are typical around 20% after PR in patients 
with COPD (Bernard et al. 1999;Spruit et al. 2002). Changes in isokinetic 
strength are seldom reported for the COPD population. In the current study, 
isometric and isokinetic strength exceeded 20% in the supplemented COPD 
group and the isokinetic strength change was more than 20% in the placebo 





compared to controls (percentage change <15% for isometric and isokinetic 
strength), although this was not statistically different. Also, changes in 
isokinetic strength were greater than changes in static strength (isometric) for 
all groups. This perhaps indicates that isokinetic or dynamic strength is more 
responsive to training. Alternatively, this may simply reflect a specific 
adaptation to the RT programme which was also isokinetic in nature. Previous 
studies in healthy individuals have confirmed that isokinetic peak torque 
improves at velocities above and below the training velocity (Kraemer, 
Mazzetti, Ratamess, & Fleck 2000). In this instance, although the training was 
at a PAV of 180°/sec, improvements have also occurred at the testing velocity 
of 60°/sec. Furthermore, isokinetic training can also improve measures of 
isometric strength (Kraemer et al. 2000); this is evident in the current study.
The changes in quadriceps strength, in all groups, are disconnected from 
changes in muscle mass, which were much lower after RT (around 5%). This 
highlights that other factors (besides increased mass) are involved in 
producing muscle force (Jones et al. 2004). Several authors have reported 
that neural adaptations within the muscle may account for this disconnect 
between strength and mass changes (Sale 1988). Neural adaptations are 
related to the quality and coordination of the muscular contraction and occur 
during the first few weeks of a RT programme (Moritani & deVries 1979). 
However, neural adaptations were not directly measured in the current study. 
Muscle hypertrophy (change in fibre/ muscle group size) occurs later as a 
result of long-term training (Sale 1988). Therefore, changes in thigh mass may 





reports relationships between RT intensity and the outcome measures, with 
measurements also reported at the mid-point of training (4-weeks). Therefore 
chapter 5 may help to unravel when changes in quadriceps muscle mass and 
strength occur in the time course of a RT programme.
As well as improvements in muscle strength and mass, the RT programme 
also produced significant gains in whole-body exercise performance. Changes 
in quadriceps strength were associated with changes in cycle ergometry work 
for the three groups. The change was around 10 W for peak cycle work and 
one minute for peak cycle time, in all groups. However the improvements 
were lower in the placebo COPD group (8.2 W change, 49 second change; 
not significantly different to the other 2 groups). In a meta-analysis of 13 trials 
of cycle ergometry (Lacasse et al. 2006), the common effect size was 8.4 W 
following PR. Data from the NETT trial suggests an MCID of 4 W following 
pre-LVRS rehabilitation (Puhan et al. 2011). Therefore improvements in the 
current cohort exceed these suggested threshold values for ergometry work 
rate. However the MCID of 4 W from the NETT trial is not likely to be 
representative of a typical (stable) COPD population, as all subjects were pre-
LVRS with worse disease severity. There were also significant improvements 
in peak VO2 (mls/ kg/ min) for the supplemented COPD group and control 
subjects. VE and VCO2 increases were only significant within the control 
group. These changes in whole-body exercise performance are perhaps 
surprising, given that RT is not routinely expected to influence endurance 
outcomes. However we know that lower-limb weakness contributes to whole-




improving quadriceps strength, this may have meant that subjects were able 
to sustain cycling performance for longer, in the current study. Another 
plausible explanation is that the RT programme utilised in this study, activated 
the cardio-respiratory system. Although cardio-pulmonary stress and 
metabolic load is lower in RT when compared to endurance training (Probst et 
al. 2006) we can expect any form of exercise training to active the cardio-
respiratory system to a certain extent. Particularly as the chosen speed for 
this study (180°/sec) sits in the middle of the spectrum of speeds available on 
isokinetic machines and, as such, represents the centre of the muscular 
strength to endurance continuum (Kraemer et al. 2000). Chapter 6 explores in 
more detail the cardio-respiratory load imposed by the RT programme chosen 
in the current study. 
The attrition rate for the study was in line with our outpatient PR service for 
the COPD supplement group (26%) and much lower than expected in the 
placebo group (12%). The higher drop-out rate in the supplement group was 
due to a greater number of disease exacerbations. This probably occurred by 
chance and is not thought to be related to supplementation. Furthermore, the 
drop-out rates for the three groups were not significantly different to one 
another. The uneven drop-out rates meant that the two COPD groups had 
more even numbers at the end of 8-weeks, as the two COPD groups were 
uneven at randomisation (n= 38 supplement, n=33 placebo). This was due to 
the block randomisation procedure performed, because the blocks were of 










matched at baseline and thigh mass was correlated with quadriceps strength 
and cycle ergometry work at baseline in all three groups.
In conclusion, this is the first study to explore the role of protein as an adjunct 
to RT in patients with COPD and to compare the results to a healthy, age-
matched control group. The data suggests that all groups made significant 
within-group improvements in thigh lean mass and quadriceps strength after 
RT. These changes translated into whole-body exercise performance 
improvements; indicating some functional carry over from RT and suggest that 
the RT programme activate the cardio-respiratory system. Although there was 
evidence of increased protein synthesis within the muscle (increases in thigh 
lean mass), providing additional protein at the time of training, did not
enhance the benefits. The reasons for this are unclear. Therefore, the 
universal prescription of protein alongside RT can not be routinely 
recommended for patients with COPD. In future, it may be important to adapt 
the dose and the timing of supplementation in relation to training to observe 
whether amending these factors can improve the outcome. As protein did not 
augment the benefits of RT, the supplement and placebo groups are 
collapsed from this point forward. 
Post-hoc sub-group analysis in wasted patients revealed that the response to 
RT may be lower in this group. However, providing additional protein was 
equally ineffective in both wasted and non-wasted groups. Using the arbitrary





      







Training intensity trajectory and fatigue profile of the
resistance training programme. How does training
intensity relate to functional outcomes?
5.1 Introduction 
Chapter 4 reported the main outcomes from the RCT of RT and protein 
supplementation given at the time of training. As protein did not enhance the 
benefits of RT, the COPD sub-groups are pooled in this chapter. Interestingly, 
chapter 4 showed that patients with COPD made comparable improvements 
to healthy controls. This is despite anecdotally appearing to perform RT at a 
lower absolute intensity. The unique RT programme chosen in this RCT 
provided a novel opportunity to precisely explore the training intensity 
progression, fatigue profile and cardio-respiratory load imposed by the 
training; comparing patients with COPD to healthy controls. The cardio-
respiratory load of the training is discussed in chapter 6.
Unlike endurance training or comprehensive PR, we do not know what the 
optimum ‘dose’ of RT is, to derive maximum benefit in terms of muscle 
strength and mass. The ‘dose’ comprises of training intensity and duration 
(Zuwallack et al. 2006). The relationship between RT intensity and outcome 
measures, such as strength has been poorly described in the COPD 
population. Ideally, the optimum ‘dose’ of training should depend on the 





of outcomes during training (Ries et al. 2007). However the serial 
measurement of outcomes may be impractical in the context of a training 
programme. It is not apparent whether changes in muscle strength and mass, 
following RT, track the same trajectory as improvements in exercise tolerance 
and HRQoL derived from endurance training or comprehensive PR. Although 
we do know that progressive RT in healthy adults does improve maximal 
strength in a dose-dependant pattern (Steib, Schoene, & Pfeifer 2010). In the 
current study, there was the opportunity to observe the trajectory of change in 
training intensity and to relate this to outcome measures, recorded at 4 and 8-
weeks. 
Muscle fatigue is an important area of research as it is essential for daily living 
tasks and exercise performance. However, the term ‘fatigue’ has been poorly 
defined in the literature. The fatigue index (FI) is a common parameter 
described in and calculates the amount of muscle fatigue using the following 
equation: final force/ initial force x 100 (Thorstensson & Karlsson 1976). This 
index reflects the amount of force decay. The capacity to resist muscle fatigue 
during exercise is known as ‘fatigue resistance’ (FR). Generally, fatigue and 
FR are measured during strength testing (one session). However it may be 
important to look at these factors successively, during a RT programme. 
There is some data available in healthy (young and old) individuals to suggest 
that RT can improve FR (Campos et al. 2002;Izquierdo et al. 2006;Kemmler et 
al. 2004;Salvador et al. 2009). Furthermore, training until fatigue is thought to 
enhance strength outcomes (Abdalla, McGregor, & Strutton 2007;Izquierdo et 








methods, have focused on peak torque (maximal strength) as an outcome, 
rather than work (cumulative). Therefore the fatigue characteristics of 
isokinetic work remain largely unknown in healthy and diseased populations. 
There is some discrepancy in the literature regarding the effects of ageing on 
muscle fatigue. Some investigators suggest that older people experience 
greater muscle fatigue than younger counterparts (Cupido, Hicks, & Martin 
1992;Petrella et al. 2005) whilst others argue that older people are more 
fatigue resistant than the young because ageing muscle relays more heavily 
on oxidative rather than glycoltic pathways and therefore lactate production is 
reduced (Lanza, Russ, & Kent-Braun 2004). Muscle fatigue, and particularly 
the FI, is seldom reported in studies of patients with COPD. However one 
study has shown that fatigue is reduced after a neuromuscular electrical 
stimulation (NMES) training programme (Neder et al. 2002). 
This chapter aims to describe the training intensity trajectory and fatigue 
profile of this unique RT programme in patients with COPD. The benefit of 
using isokinetic dynamometry is that the profile of training has been accurately 
recorded over the 8-week training period in terms of total work performed and 
peak torque (at 180°/sec). Therefore training progression and force decay 
during training can be observed and related to changes in outcome measures 
at 4 and 8-weeks. In addition, a healthy age-matched control group also 
underwent the same training programme alongside patients with COPD. This 
allows for direct comparison of the training profiles in each group. This is 















Three aims were formulated to establish, and compare, the training profile in 
patients with COPD and healthy age-matched controls. They were:
1. To observe the trajectory of change in isokinetic total work (J: at 180 °/sec 
PAV) and peak torque (Nm) performed over the 8-week training period.
2. To investigate the within-session fatigue profile of total work and peak 
torque (at 180°/sec) over 5 training sets, by calculating the force decay                
[fatigue index (FI)] over the 8-week training period.
3. To analyse the relationship between training intensity and changes in 
outcome measures at four and 8-weeks. 
5.3 Methods 
The methodology for the RCT discussed in this thesis is described in detail in 
chapter 3. This includes recruitment of subjects, details of the intervention and 
outcome measures assessed. Chapter 4 outlines the main outcomes of the 
RCT. As protein supplementation did not have augment the effects of RT, the 
results presented in this chapter are pooled for supplemented and placebo 
COPD groups. 
Trajectory of RT 
To observe the trajectory of improvement in RT over the training period, work 






5 sets of 30 maximal knee extensions (concentric) at a PAV of 180°/sec, 
during each training session. There were 24 training sessions over the 8-
week training period (3/ week). The highest peak torque was recorded from 
the 30 repetitions making up each of the 5 training sets. Work was cumulative 
over 30 repetitions. For simplicity, the data for the right leg only has been 
reported for all subjects (95.2 % of subjects were right leg dominant), however 
training took place bilaterally and data from the left leg is reported in appendix 
13. The average torque and work per week is also shown in the graphs (i.e. 
training sessions 1-3 = week one, 4-6 = week two etc). 
Fatigue Profile 
The fatigue index (FI) was calculated to measure the decay in isokinetic work 
and peak torque (180°/sec) over the 5 sets of 30 repetitions. FI was calculated 
as set 5/ set 1 x 100. The FI was plotted as the average over weeks 1-8 as 
described above. The absolute decline in work and torque between sets 1 and 
5 (average per week), is also reported. Again, data from the right leg only is 
presented. 
Relationship between training intensity and changes in outcome 
measures
To assess the changes in quadriceps strength over the 8-week training 
period, both isometric and isokinetic strength (at the testing velocity of 
60°/sec) of the dominant leg was measured using an isokinetic dynamometer 
at baseline (after familiarisation), at week four (training sessions 12-14) and at 








(Nm) was measured during six attempts at a maximum static contraction, with 
the knee fixed at 70° flexion. Isokinetic strength was also assessed during two 
sets of five knee extensions at a PAVof 60°/sec. The highest peak torque 
(Nm) and total work done (J) for the best set was recorded. Thigh lean mass 
was measured using DEXA (g) at the same time points. Correlations between 
training loads and outcome measures are reported.
5.4 Statistical Analysis 
The data is presented per-protocol, for subjects’ data available at each time 
point (i.e. per training session/ per week for patients still engaged in RT).  
Firstly graphs were produced to observe the trajectory of change in 
isokinetic total work and peak torque and (at 180 °/sec angular speed) over 
the 8-week training period; comparing patients with COPD and healthy 
controls. A repeated measures ANOVA was performed with Bonferroni 
corrections for multiple comparisons, to analyse within and between-group 
changes in work and work over weeks one to eight. Generalised estimating 
equation (GEE) analysis, also known as ‘cross-sectional time-series analysis’ 
was executed to calculate whether or not the graph slopes for training 
intensity (work and torque) in COPD subjects and controls were significantly 
different from one another (group x time interaction with Wald confidence 











The fatigue profile was assessed by plotting the FI and the absolute decline 
in work and torque (averaged each week), using a repeated measures 
ANOVA, as described above. 
The changes in outcomes (isometric strength, isokinetic strength at 60°/sec 
and thigh lean mass) between baseline and 4-weeks/ 8-weeks were 
compared within-groups and between groups using paired and independent t-
tests, respectively. Also the correlation between training intensity and 
changes in outcomes at weeks four and eight were observed with scatter 
plots and associations analysed using the Pearson’s correlation coefficient. 
The strength of any associations is as described in chapter 5 (i.e. weak/ 
moderate/ strong). 
5.5 Results 
70 patients with COPD [mean (SD) age 68.6 (9.1) years, BMI 26.7 (5.4), FEV1 
44.8 (15.2) % predicted, 42 male] and 22 healthy age-matched controls [mean 
(SD) age 66.6 (5.1) years, BMI 26.8 (2.9), FEV1 103.4 (15.9) % predicted, 12 
male] were enrolled as part of a RCT of protein supplementation (PS) 
alongside RT and started the training programme. There were 11 drop-outs in 
the COPD group (nine by 4-weeks) and 1 in the control group (lost between 
weeks four and eight). The main results of the RCT are provided in chapter 4. 
This chapter presents per-protocol data, for subjects’ data available at each 





           
        
   
   
   
   
   
   
   
   
 
 
The number of subjects per week is outlined in table 5.1.









Table 5.1 Number of patients’ data analysed per week of training
Trajectory of RT 
Figure 5.1 shows the training progression in total work performed averaged 
over weeks one to eight in both groups. Healthy controls performed RT at 
significantly higher workloads than patients with COPD at all time points





         






Figure 5.1 Training intensity progression of total work performed at weeks one
to eight in patients with COPD and healthy controls
Both groups had significant within-group improvements in work performed at 
four and 8-weeks compared to baseline. Workload improvement plateaued in 
the healthy control group after 4-weeks (no significant improvement between 
weeks 4-8). However COPD subjects continued to have significant 
improvements in training workload between four and 8-weeks (p≤0.001). GEE 
analysis found that the gradient of the slopes were not significantly different 
from one another in statistical terms (p=0.06), although there was a trend 
towards significance. Therefore, one can conclude that work load progression 








        
   
 
Figure 5.2 shows the equivalent figure for the progression in training peak 
torque over 8-weeks. The trajectory shown is similar to work progression 
shown in figure 5.1. Again, healthy controls produce higher peak torque 
values than patients with COPD at all time points (p≤0.05). Both groups 
displayed significant improvements in peak torque performed at four and 8-
weeks compared to baseline. Peak torque improvement plateaued in the 
healthy control group after 4-weeks (no significant improvement between 
weeks 4-8). However COPD subjects continued to have significant 
improvements in peak torque between four and 8-weeks (p≤0.001). 
Figure 5.2 Training intensity progression of peak torque performed at weeks






            
          
 
 
       
      
 
  
      
 
   
   
 
  








GEE analysis revealed that the progression slopes for patients and controls 
were not significantly different to each other (p>0.05). Again the rate of torque 
progression was significant within, but not between groups. 
Table 5.2 shows the mean percentage change in isokinetic training work and 
torque from baseline at four and 8-weeks, in patients and controls.
Table 5.2 Mean percentage change in isokinetic total work and peak torque
during the 8-week resistance training programme, in patients with COPD and
healthy controls
Values are mean (SD) COPD Subjects Healthy Controls
Percentage change in work weeks 1-4 20.4 (27.2) 11.7 (16.8)
Percentage change in work weeks 1-8 32.4 (32.8) 12.3 (15.5) *
Percentage change in torque weeks 1-4 10.0 (20.4) 8.7 (12.2)
Percentage change in torque weeks 1-8 19.0 (25.4) 12.3 (15.5)
* p<0.05 between group difference
The results indicate that the majority of the progression in training work and 
torque occurs within the first 4-weeks, for both groups. The percentage 
changes in isokinetic work exceeded changes in torque at both time points for 
patients with COPD. For healthy controls this was only the case for weeks 1-
4. There was a statistically significant between-group difference for the 
percentage change in isokinetic work in weeks 1-8 (12.3% for controls, 32.4% 
for patients with COPD, p<0.05). 
Fatigue Profile 
Figure 5.3 shows the plot of FI for isokinetic work, averaged each week for the 
8-week training programme. 
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Figure 5.3 Mean fatigue index (FI) for work over 8-weeks in patients with COPD
and healthy controls
There were no significant differences between the two groups, at any time 
point for FI. However there was a trend towards a difference between the 
groups at weeks one (patients have a higher FI) and seven [controls have a 
higher FI (both p=0.06)]. A high FI indicates high fatigue resistance (FR), i.e. 
an increased ability to sustain muscular contraction/ lower fatigue rate.
Interestingly, the groups appear to cross over at week four. Prior to this, 
patients have a greater FI and are therefore more fatigue resistant compared 
to controls. By the end of the 8-week programme, controls appear to develop 
FR, whilst patients with COPD do not. To put this into context, figure 5.4 




      









Figure 5.4 Absolute decline in isokinetic work between sets 1 to 5 averaged per
week in patients with COPD and healthy controls
The absolute decline in work is comparable between the two groups for weeks 
one to six. However healthy controls were performing at consistently higher 
training work loads than patients with COPD during these RT sessions (see 
figure 5.2). There is a significant difference between groups for work load 
decline at weeks seven and eight (p<0.05) as healthy controls became more 
fatigue resistant. The work load decline was significantly reduced for controls 
at 4-weeks [mean decline (±1SE) 35.0 (30.8) J] and 8-weeks [22.7 (23.3) J], 






            
   
 
 
For patients with COPD the absolute decline in work does not dramatically 
reduce, [mean change in work decay (±1SE) from baseline to 8-weeks -8.6 
(7.1) J- figure 5.4] and their FI is lower (figure 5.3- at 4 and 8-weeks compared 
to baseline). These observations were not statistically significant, compared to 
baseline within the COPD group. However, patients were producing 
progressively higher workloads compared to baseline over the 8-week period, 
where as there was a plateau in the performance of control subjects at 4-
weeks (figure 5.1). 
Figure 5.5 presents the FI for isokinetic torque, averaged each week for the 8-
week training programme. 
Week
Figure 5.5 Mean fatigue index (FI) for torque over 8-weeks in patients with







         
     
 
There were no significant differences between or within-groups for torque FI 
over time [(all p>0.05) figure 5.5]. The FI for torque remained at approximately 
90% for both groups over 8-weeks. This is in contrast to the FI for work which 
was lower and showed definite changes over the 8-week training period. 
Figure 5.6 shows the absolute decline in torque between sets 1 to 5, 
averaged each week for both groups. There were no significant differences for 
the average torque decay between groups, at any time point (all p>0.05). 
Figure 5.6 Absolute decline in isokinetic torque between sets 1 to 5 averaged 
per week in patients with COPD and healthy controls
Within-group changes in torque decline were only significant for control 









(1.7 SE) Nm (p<0.05). The change in torque decline for patients with COPD 
was minimal and actually increased slightly between weeks 1 to 8 by 1.6 (1.3 
SE) Nm.
Relationship between training intensity and changes in outcome 
measures
Mean values and percentage change from baseline are shown in table 5.3 for 
the outcome measures: isometric strength, isokinetic strength (at 60°/sec) and 
thigh lean mass, which were measured before and after four, and 8-weeks of 
RT. Controls were significantly stronger than patients with COPD at baseline 
for both isometric and isokinetic strength (p<0.05). Both groups made 
significant improvements in all outcomes at four and 8-weeks, compared to 
baseline. 
Table 5.3 shows that the greatest proportion of the improvements occurred 
within the first four weeks of RT for both groups. There were no statistically 
significant differences between groups for the changes at 4 or 8-weeks. Both 
groups made significant within-group changes from baseline at weeks 4 and 
8. The only significant improvement between weeks four and eight was for 
thigh mass in healthy controls (p≤0.05). Percentage changes in the measures 
of strength exceeded changes in thigh mass in both groups at 4 and 8-weeks. 
Patients with COPD had larger percentage improvements in quadriceps 
strength (isometric and isokinetic) compared to healthy controls, at weeks four 
and eight; although this did not reach statistical significance.
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Table 5.3 Mean values and percentage change from baseline for isometric 
strength, isokinetic strength (at 60°/sec) and thigh lean mass, at 4 and 8-weeks
in patients with COPD and healthy controls
The intensity of isokinetic work and torque (from figures 5.1 and 5.2), over the 
8-week training period were correlated with changes in the outcome measures 
shown in table 5.1. For isokinetic training work (180°/sec), there were only 
significant associations with isokinetic peak torque (60°/sec: r=0.48, p=0.000, 
figure 5.7) in patients with COPD and with isometric strength for healthy 
controls (r=0.55, p=0.012, figure 5.8). These were positive correlations. i.e. 
greater training work progression was associated with larger improvements in 




      
      
  
      
        
 
Figure 5.7 Scatterplot to show the relationship between training work intensity 
and changes in isokinetic peak torque between baseline and 8-weeks in
patients with COPD
Figure 5.8 Scatterplot to show the relationship between training work intensity 











For patients with COPD, there were some weak and moderate correlations 
between training torque changes (180°/sec) and isometric strength (r=0.33, 
p=0.012), as well as isokinetic peak torque (60°/sec: r=0.61, p=0.002, figure 
5.9). Again these were positive correlations. There were no statistically 
significant correlations between changes in training torque and the outcome 
measures, at 8-weeks, for healthy controls. 
Figure 5.9 Scatterplot to show the relationship between training torque
intensity and changes in isokinetic peak torque between baseline and 8-weeks
in patients with COPD
A clear outlier is identified in figures 5.7 and 5.9. Data entry was checked and 
this was deemed to be a genuine, valid response. Therefore the outlier has 
remained in the figures. However, with the outlier removed the r value in figure 











mass were not correlated with either measure of training progression (work or 
torque), in both groups.
The cardio-respiratory load and symptoms associated with the RT programme 
are explored in chapter 6.
5.6 Discussion
The aim of this chapter was to precisely explore the training intensity 
trajectory and fatigue profile of an isokinetic RT programme, observing the 
variables of work and peak torque. Another objective was to analyse the 
relationship between RT intensity and changes in outcome measures at four 
and 8-weeks. This is important as the relationship between RT intensity and 
outcome measures, such as strength has been poorly described in the COPD 
population. This is the first study to explore these factors in such detail serially 
during an 8-week training programme, in patients with COPD.  Furthermore 
the results have been compared to a healthy age-matched control group, 
training at the same time; this again is novel.
The results in this chapter and also in chapter 4 suggest that COPD patients, 
who are exercising at lower absolute workloads compared to healthy controls, 
can make comparable gains in muscle strength and mass. Controls subjects 
were performing the RT programme at higher absolute intensities for both 
isokinetic work and torque at weeks 1 to 8; compared to COPD subjects. 
There were significant improvements within both groups for training intensity 








week 1. Control subjects appeared to show a plateau in their rate of training 
progression after 4-weeks for both work and peak torque. Subjects with 
COPD however continued to demonstrate significant improvements in training 
intensity progression beyond 4-weeks. Despite this, there were no statistically 
significant differences between the two groups for training intensity 
progression. Indeed, the gradient of the training intensity slopes were similar 
for both work and torque in both groups (GEE analysis p>0.05). One may
speculate that, if training were to continue in the COPD group, they too would 
eventually demonstrate a plateau in performance and may even reach the 
levels of normal subjects.
Despite lower absolute values for isokinetic work and torque in patients 
compared to controls during RT; COPD subjects had greater percentage 
improvements in work and peak torque (relative to their baseline), when 
compared to healthy controls at 4 and 8-weeks. This was statistically 
significant between the groups for changes in training work progression 
(weeks 1-8). Moreover, percentage improvements in isokinetic training work 
exceeded changes in peak torque for both groups. This suggests that 
Isokinetic work may be a more sensitive measure to change after RT, than 
peak torque. This highlights the importance of measuring work which is 
cumulative rather than merely reporting peak torque (maximal force), as 
significant improvements may be missed. 
In addition, isokinetic work as an output appears to be more susceptible or 




chapter shows that the FI for peak torque did not really change over the 8-
week training period and remained at around 90% in both groups. The 
absolute decay in peak torque (from set 1 to set 5) also showed only minimal 
change over the 8-week training programme. It could be that because peak 
torque represents maximal strength, it may not be likely to change by a large 
magnitude on a session by session basis. In contrast, the fatigue profile for 
isokinetic work demonstrated definite changes during the RT course. Healthy 
controls experienced less fatigue in isokinetic work production as the RT 
programme progressed. This is evident due to an increased FI (significant 
between weeks 4-8) and a significant reduction in the absolute work decline 
(from set 1 to set 5) in this group at weeks 4 and 8 compared to baseline. The 
FI improved by around 10% from week 1 to week 8 and the reduction in 
absolute work decline was an average of 20 Joules by week 8 compared to 
week 1 of RT. In other words, healthy controls were able to demonstrate 
better fatigue resistance and experienced less fatigue as the RT programme 
progressed. These findings are comparable to others who have shown that 
RT can improve FR (Campos et al. 2002;Izquierdo et al. 2006;Kemmler et al. 
2004;Salvador et al. 2009). These changes were not apparent in the COPD 
group as their resistance to fatigue did not improve with training for both work 
and torque. 
Whilst one would expect subjects with COPD to fatigue to a greater extent 
(and more rapidly) than healthy controls (Allaire et al. 2004;Swallow et al. 
2007a), it remains unknown why the elderly control group in the current study 




did not. This is a novel finding. In the only previous study to evaluate the FI 
after training in patients with COPD, the authors did see a significant 
improvement in FR after NMES (Neder et al. 2002). However it is difficult to 
compare the findings in this study to the current study because the RT 
modalities were different and the knee extensor testing velocity was slower in 
the NMES study (PAV of 70°/ sec). Although muscle fatigue, and particularly 
the FI, is seldom reported in studies of patients with COPD we do have some 
data from healthy individuals to which we can compare the results of the 
current study. In a study of healthy elderly subjects, who underwent the same 
RT protocol as described in this thesis, subjects demonstrated an average 
percentage decline of 22% in sets 2-5 compared to set 1, during a single 
testing session (Rawson 2010).The healthy control group in the current study 
had a fall in fatigue index of approximately 28% at the start of the training 
programme (100%: no fatigue, minus 72%: FI in week 1). The study by 
Salvador and colleagues examined the percentage change in FI after an 8-
week RT programme in healthy young subjects. The change in FI was -17% in 
men and -31% in women, using the alternative FI were a lower score is better. 
Unfortunately we do not know what would constitute a clinically significant 
improvement in FI and this makes the interpretation of the findings difficult.
One may hypothesize that because control subjects showed a plateau in their 
progression of training work and torque (after 4 weeks), that they merely 
became more efficient at performing the same 5 sets of 30 repetitions task 
each session. i.e. they were not producing any greater force in the last few 
weeks but their decay in force was reduced. Were as, the patients with COPD 





4-weeks. Therefore these subjects were producing greater muscle force (in 
terms of torque and work) but as consequence, displayed greater fatigue 
(lower FI and greater absolute decline in work and torque between sets 1 to 5, 
as training progressed). Because of skeletal muscle dysfunction in patients 
with COPD, changes in muscle function and FR may take longer to occur. 
One could imagine that had the RT programme continued beyond 8-weeks, 
subjects with COPD may have also reached a plateau in training progression 
and therefore may have shown reductions in fatigue. These speculations are 
supported, to a certain extent, by literature in healthy subjects which suggests 
that muscle fatigue is related to production of greater peak muscle force 
initially (Pincivero, Gandaio, & Ito 2003), as the FI is a ratio based on the initial 
force generated. Therefore men are more likely to display greater fatigue than 
women because their initial force is superior (Pincivero, Gandaio, & Ito 2003). 
Correspondingly, if patients with COPD were producing greater isokinetic 
work and torque values (in relative terms: % improvement from their baseline) 
than healthy controls towards the end of the 8-week programme; then one 
may expect their level of fatigue to be greater. Furthermore, we know that 
fatigue in itself has a positive effect on strength as an outcome measure 
(Abdalla, McGregor, & Strutton 2007;Izquierdo et al. 2006). Therefore if 
patients with COPD displayed more fatigue during training, this may account 
for their continued progression in training-related strength outputs. It is 




If we consider that the decline in muscle function seen with normal ageing 
might be more pronounced or accelerated in patients with COPD, this may 
also account for some of the differences in the fatigue profile of the two 
groups. We are aware from the literature, that there is some debate as to 
whether older people are more or less fatigue resistant, compared to younger 
subjects. One argument is that older people are more fatigue resistant than 
the young because ageing muscle relays more heavily on oxidative rather 
than glycoltic pathways and therefore lactate production is reduced (Lanza, 
Russ, & Kent-Braun 2004). A recent study by Rawson et al. analysed the 
fatigue for old (mean age 66 years) and young healthy men using the same 
isokinetic RT protocol described in this thesis (Rawson 2010). This protocol 
took place on one testing session. The authors of this study concluded that 
older men demonstrated enhanced FR during their chosen testing protocol 
and commented that this type of testing favours the oxidative preferences of 
ageing muscle, as intermittent contractions favour the replenishment of 
oxygen within the muscle. However, we know that patients with COPD who 
have skeletal muscle dysfunction have reduced oxidative capacity within the 
muscles. This is because of a relative reduction in the proportion of type I 
(oxidative) fibres and an increased proportion of type IIb (glycolytic) fibres, as 
well as a lower fibre-to-capillary ratio and reduced oxidative enzymes (Allaire 
et al. 2004;Hurley et al. 1986;Whittom et al. 1998). Therefore the patients with 
COPD in the current study may have been lacking the capacity within the 
muscles to replenish oxygen during the RT programme. One may wonder 
weather healthy controls were able to do this, as their muscles have the usual 





accounts for their reduced fatigue evident over the training period. It is likely 
that if the training programme variables were altered; such as contraction 
speed, number of repetitions and rest intervals, that this would have 
influenced FR. For instance we recognise that elderly subjects experience 
more fatigue than younger people when the speed of contraction is at a high 
PAV, but not at slower speeds or during static contractions (Callahan & Kent-
Braun 2011). It is also apparent that isometric testing is better at evoking 
fatigue than isokinetic testing in healthy subjects (Corin, Strutton, & McGregor 
2005). We do not know if the same is true in subjects with COPD because the 
current study did not investigate fatigue during the isometric quadriceps 
testing. The aim of this chapter was to explore fatigue over the time course of 
a RT programme, rather than to observe fatigue during a single assessment. 
In future, one may wish to explore which types of training and assessment 
protocols are the best at evoking fatigue in patients with COPD. 
Data in chapter 4 demonstrated that the RT programme led significant within-
group improvements in quadriceps strength, thigh lean mass and whole-body 
exercise performance in all groups, regardless of supplementation. In this 
chapter the outcomes of muscle strength (isometric and isokinetic: 60°/sec) 
and thigh lean mass have been further explored by observing an interim 
measurement after 4-weeks of RT. The data shows that both groups made 
significant within-group improvements in all outcomes and there were no 
significant differences between the groups. The greatest proportion of the 
improvements occurred within the first four weeks both groups, in all 





progression in work and torque occurred in the first four weeks; controls 
plateau after this point in terms of training progression. Again it is clear that 
there was a transfer effect from training because peak torque improved at a 
speed below (60°/sec) the training velocity (180°/sec) and isometric strength 
also improved. Also, improvements in isokinetic strength measures again 
exceeded static measures, in both groups at 4 and 8-weeks. There were 
some associations between training intensity (work/ torque) and the measures 
of isometric and isokinetic strength (60°/sec) after 8-weeks in both groups. 
These were positive, suggesting that increased training intensity leads to 
improved gains in muscle strength which are ‘dose-dependant.’ Also the 
association between peak torque progression in training was greater with 
isokinetic rather than isometric strength and probably reflects the specific 
adaptation to the training which was also isokinetic. 
In addition we can once more observe this disconnect between the changes 
in muscle mass, which are much lower than changes in muscle strength for 
both groups. These findings replicate what is reported in previous literature 
(Jones et al. 2004). One might have expected that the muscle mass changes 
would not be apparent until the 8-week measure, as muscle hypertrophy 
(change in fibre/ muscle group size) is known to occur later as a result of long-
term training (Sale 1988). However, in the current study, there was a 
significant increase in muscle mass by week 4; at which point the majority of 
the improvement had occurred. Between baseline and week 4, thigh lean 
mass improved by 4.5% in patients with COPD and by 4.1% for healthy







increased by a further 0.9% in patients and 1.4% in controls (p<0.95 between 
week 4 and 8 in controls only). This is unusual as mass changes generally 
occur later and most likely dispels the theory put forward in chapter 4, that
changes in thigh mass may have been greater if the RT were to continue 
beyond 8-weeks. Interestingly changes in muscle mass showed no correlation 
with RT intensity. 
In this chapter, limits were set to be able to present the information coherently. 
For instance, by reporting the right leg only and by observing the averages 
per training week. This may be a limitation as important within-session and 
between leg variations could have been overlooked. However the results for 
the left leg are reported in appendix 13 and mirror the findings from the right 
leg. The progression in work and torque training output, were similar for both 
legs. Furthermore, it may have been appropriate to assess the outcome 
measures at further time points throughout the RT programme. Important 
adaptations may have occurred prior to the 4-week assessment and serial 
measures each week would have been preferred. However, this was not 
undertaken due to time constraints for the assessor and concerns about 
fatigue in the individuals undergoing RT, as extra assessments could 
theoretically negatively influence training output. 
In conclusion, this is the first study to precisely explore training intensity 
progression and fatigue/ force decay during a RT programme in patients with 







RT programme chosen provided a unique opportunity to explore these factors 
in detail by measuring both isokinetic work and peak torque. 
The data shows that, whilst patients with COPD perform RT at much lower 
absolute intensities (compared to healthy controls), they can still make 
comparable improvements in muscle strength and mass. Both groups were 
able to significantly improve training intensity for both work and torque over 
the 8-week training period. The trajectory of progression was similar in both 
groups. 
Fatigue is rarely reported in COPD literature and when it is, the term has been 
defined in various ways. To my knowledge, only one previous study has 
examined how fatigue changes after training in patients with COPD, this was 
following 6-weeks of NMES training (Neder et al. 2002). Clinicians do not 
have an MCID value established for FI changes and therefore we do not know 
what would represent a clinically significant improvement in FI. These factors 
create a challenge when interpreting the results. The current study has 
revealed that healthy controls became more FR (display less fatigue) over 8-
weeks with the chosen RT protocol. However subjects with COPD did not. 
Further study is required to explore fatigue in more detail in subjects with 
COPD, by altering training and assessment variables (including isometric 
protocols) to establish which are the best to evoke fatigue.
The work presented in this chapter implies that isokinetic work is a more 
sensitive measure to change following RT, compared to peak torque.. This 


















torque as significant improvements may be missed. Work was also found to 
be more sensitive to fatigue. The fatigue characteristics of isokinetic work 
remain largely unknown in healthy and diseased populations as peak torque 
is normally just reported. Future research should continue to explore work as 












Cardio-respiratory load imposed by the resistance
training programme
6.1 Introduction 
Chapter 4 reported the main outcomes from the RCT of RT and protein 
supplementation given at the time of training. As protein did not enhance the 
benefits of RT, the COPD sub-groups are pooled in this chapter. Interestingly, 
one of the findings of chapter 4 was that the RT programme led to appreciable 
improvements in whole-body exercise performance, assessed using cycle 
ergometry. This suggests some functional carry over of the benefits of RT and 
may indicate central adaptations to training. This chapter aims to describe the 
ventilatory load imposed by the chosen RT programme and the symptomatic 
response to training. The data presented compares the responses in patients 
with COPD, to healthy age-matched controls. This data compliments chapter 
5 by analysing a further component of the RT programme. 
In addition to the improvements in muscle mass and strength derived from 
RT; this type of training may also offer advantages for patients with severe 
COPD, where ventilatory limitation is often the main contributor to exercise 
intolerance (O'Donnell 2001). There is a school of thought, that for more 
disabled patients with COPD; RT of small muscle volumes may allow for 







Theoretically, RT should not activate the cardiopulmonary system to the same 
extent as whole-body exercise (Simpson et al. 1992). Probst and co-workers 
have shown that cardiopulmonary stress is lower during RT when compared 
to endurance training at the start, middle and end of a 12-week training 
programme (Probst et al. 2006). This was observed in both objective (e.g. 
minute ventilation, oxygen uptake derived from a portable breath by breath 
system) and subjective (i.e. symptom scores) parameters. More recently, 
Sillen et al found that the metabolic response was significantly lower still with 
NMES compared to RT during a single session (Sillen et al. 2008). However, 
the authors concluded that both NMES and RT resulting in acceptable 
metabolic responses and symptom scores for patients (Sillen et al. 2008). 
Whilst the two afore mentioned studies have measured the cardio-respiratory 
response to conventional quadriceps RT (multigym, isotonic training), the 
response has not been explored for isokinetic training. The isokinetic RT 
protocol described in this thesis utilised a training velocity of 180°/sec. This 
PAV represents the middle of the spectrum of speeds available on isokinetic 
machines and, as such, represents the centre of the muscular strength to 
endurance continuum (Kraemer et al. 2000). We know from chapters 4 and 5 
that this type of training can significantly improve muscle strength and thigh 
mass. However one may also speculate that this type of training activates the 
cardio-pulmonary system, as changes in whole-body exercise performance 













Two aims were formulated to assess and compare the cardio-respiratory load 
imposed by the RT programme in patients with COPD and healthy age-
matched controls. 
1. To assess the breath-by-breath response to one RT session in a 
convenience sample of subjects by measuring parameters of ventilation and 
gas exchange (compared to a maximal CPET at baseline). 
2. To observe symptom scores (Borg) and physiological variables (HR and 
SpO2) in response to RT during the 8-week training period.
6.3 Methods 
The methodology for the RCT discussed in this thesis is described in detail in 
chapter 3. This includes recruitment of subjects, details of the intervention and 
outcome measures assessed. Chapter 4 outlines the main outcomes of the 
RCT. As protein supplementation did not have augment the effects of RT, the 
results presented in this chapter are pooled for supplemented and placebo 
COPD groups. 
Breath-by-breath sub-group analysis
A convenience sample of 14 patients [mean (SD) age 70.8 (7.9) years, FEV1 
1.2 (0.2) l, 7 male] and 11 healthy controls [age 65.6 (6.0) years, FEV1 2.5 






     
     
 
gas exchange during one of their RT sessions (5 sets of 30 maximal knee 
extensions). Subjects wore a mouth piece attached to the same 
ergospirometry system used for the CPET (figure 6.1), as described in chapter 
3. This analysis took place between training sessions 8-12 (range) and the 
five training sets on the right leg were chosen for analysis. The recorded 
outcomes were: peak oxygen uptake (VO2: mls/kg/min) and minute ventilation 
(VE: l/ min) for each individual, on each of the 5 RT sets. These values were 
compared to the baseline CPET (cycle ergometry) values.
Figure 6.1 Breath-by-breath analysis of ventilation and gas exchange during 
one resistance training session, using the ergospirometry system
Symptomatic response to RT 
Perceptions of breathlessness (score 0-10) and RPE (score 6-20) were 
measured using Borg scales (Borg 1982) throughout the entire 8-week 













analysed per week). Other physiological responses (HR and SpO2) were also 
recorded before training and after each training session. Patients were asked 
to rate their Borg scores based on how they felt at ‘peak’ exercise. These 
values were averaged each week (i.e. training sessions 1, 2 and 3= week 1 
etc). 
6.4 Statistical analysis 
Breath-by-breath sub-group analysis
The ventilation outcomes (VO2 and VE achieved) during the single RT session 
are presented as a percentage of the maximal CPET at baseline. Actual 
values achieved during each set are also reported. Independent and paired t-
tests were used to look at differences between and within groups, 
respectively. 
Symptomatic response to RT
Symptom scores were averaged for weeks one, four and eight of training. A 
repeated measures ANOVA was performed to analyse within and between-
group changes in these outcomes between weeks 1, 4 and 8. 
6.5 Results 
Breath-by-breath sub-group analysis
Table 6.1 shows the mean (±SD) percentage of VO2 (mls/ kg/ min) and VE (l/ 
min) achieved on each set, during a single RT session, in patients and healthy 









     
     
    
 
  
    
 
  
    
 
  
   
 
  




    
 
  
    
 
  
    
 
  
    
 
  
    
 
  
             
achieved on the baseline cycle ergometry test (CPET), described in chapter 3. 
In COPD subjects, the percentage of VO2 and VE increased with each set
(from 49.1 to 60.1%: VO2 and from 57.6 to 72.2%: VE). The VO2 increase was 
significant between sets 1 and 2 [49.1 to 54.8% (p<0.05)]. Controls worked at 
the highest percentage of their VO2 and VE on set 3 (52.3%: VO2, 65.3%: 
VE), values were reduced in sets 4 and 5. Overall, COPD subjects worked at 
higher percentages of their maximal VO2 and VE compared to controls during 
all 5 sets; although this wasn’t statistically significant.  
Table 6.1 The percentage of maximum VO2 and VE achieved for sets 1-5, during
one RT session, compared to maximal cycle ergometry testing at baseline
Values are mean (± SD)
COPD Subjects (n=14) Healthy Controls (n=11)
%VO2 achieved set 1 49.1 (16.3) 45.7 (15.3)
%VO2 achieved set 2 54.8 (16.9)* 50.4 (13.9)
%VO2 achieved set 3 58.9 (17.6) 52.2 (14.3)
%VO2 achieved set 4 60.0 (17.9) 50.4 (14.3)
%VO2 achieved set 5 60.1 (17.7) 51.4 (10.5)
%VE achieved set 1 57.6 (16.7) 49.8 (17.7)
%VE achieved set 2 66.1 (19.2) 62.1 (15.7)
%VE achieved set 3 70.3 (17.3) 65.3 (17.7)
%VE achieved set 4 71.6 (19.9) 62.6 (15.7)
%VE achieved set 5 72.2 (20.5) 63.6 (17.7)
* p< 0.05 between sets 1 and 2 for % VO2 achieved in patients with COPD
Figures 6.2 A and B show the actual VO2 and VE values achieved on each 





           
      
 
VO2 on set 2 (p<0.05), where the value was significantly higher for control 
subjects. 
Figure 6.2A and B Mean actual VO2 (A) and VE (B) achieved during sets 1 to 5 











Controls achieved an average quadriceps work load over these five training 
sets of 1032.6 J compared to 750.9 J in patients. This difference was 
statistically significant (p<0.05). 
Chapter 4 reports the CPET outcomes after the RT intervention; there were 
significant improvements in CPET work and some ventilation parameters after 
RT for whole groups (of COPD patients and controls). CPET changes in this 
subgroup of 14 patients and 11 controls were significant for peak work [mean 
change (±SD) 8.5 (7.9) W for patients and 8.5 (6.2) W for controls, both 
p<0.05], but not for ventilation/ gas exchange parameters.
Symptomatic response to RT 
Symptom scores (Borg breathlessness and RPE) were recorded immediately 
before and after each training session, as were measures of HR and SpO2 in 
both groups. Table 6.2 shows the average values of these parameters in 
weeks one (sessions 1-3), four (sessions 10-12) and eight (sessions 22-24) in 
both groups. 
The results in table 6.2 indicate some significant differences in symptom and 
physiological variables between patients with COPD and healthy controls. 
Borg breathlessness scores were higher in patients with COPD, before and 
after exercise, at all time points (p≤0.01 compared to controls). Resting HR 
was higher in patients with COPD compared to controls at all time points 
(p≤0.05). As expected, SpO2 values were significantly lower in patients 




        
             
 
 
   
 
      
 
     
   
 
    
  
 
     
  
 
   
  
 
     
   
 
   
   
 
    
  
 
   
  
 
     
   
   
 
   
  
 
     
  
 
   
  
 
     
   
 
    
   
 
    
  
 
     
  
 
     
     
(p≤0.05). There was no de-saturation in SpO2 evident during RT for subjects 
with COPD. However those on LTOT had already been excluded from the 
study. SpO2 actually improved in the COPD group after training compared to 
baseline, in week one (≤0.001).  
Table 6.2 Symptom scores and physiological parameters before and after




COPD Subjects Healthy Controls Significant difference
between groups
Week 1: Start of training
Pre Borg 0.5 (0.8) 0.0 (0.0) p≤0.001
Post Borg 3.0 (1.7) $ 1.8 (1.1) $ p≤0.01
Pre RPE 6.0 (0) 6.0 (0) NS
Post RPE 14.3 (1.9) $ 14.2 (2.6) $ NS
Pre SpO2 (%) 94.0 (4.2) 96.3 (1.5) p≤0.05
Post SpO2 (%) 94.6 (4.3) $ 96.8 (1.0) p≤0.05
Pre HR 81.8 (11.8) 72.7 (11.2) p≤0.01
Post HR 98.3 (14.7) $ 95.4 (13.4) $ NS
Week 4: Mid-point
Pre Borg 0.7 (0.8) 0.0 (0.0) p≤0.001
Post Borg 3.2 (1.7) $ † 2.0 (1.3) $ p≤0.01
Pre RPE 6.0 (0) 6.0 (0) NS
Post RPE 13.9 (2.1) $ 13.9 (2.6) $ NS
Pre SpO2 (%) 94.3 (4.4) 96.7 (0.8) p≤0.05
Post SpO2 (%) 94.6 (4.4) 96.7 (1.2) p≤0.05
Pre HR 84.1 (11.6) † 75.1 (9.5) p≤0.001
Post HR 100.9 (16.2) $ 97.4 (14.5) $ NS




   
 
     
   
 
   
  
 
     
  
 
   
  
 
     
   
 
   
   
 
   
  
 
    
  
 
     
 
         
        







Week 8: End of training
Pre Borg 0.6 (0.8) 0.0 (0.0) p≤0.001
Post Borg 2.9 (1.4) $ 1.6 (1.3) $ p≤0.001
Pre RPE 6.0 (0) 6.0 (0) NS
Post RPE 13.4 (2.1) $ † 12.8 (2.9) $ NS
Pre SpO2 (%) 94.4 (4.5) 96.9 (1.3) p≤0.05
Post SpO2 (%) 95.2 (2.1) 96.7 (1.0) p≤0.05
Pre HR 82.5 (12.5) 76.5 (9.9) † p≤0.05
Post HR 100.1 (15.6) $ 97.7 (15.4) $ NS
NS not significant; $ p≤0.001 significant within-session (pre to post) change 
within-group; † p≤0.05 significant within-group change compared to week 1; ≠
p≤0.05 significant within-group change compared to week 4.
Borg breathlessness and RPE scores increased after RT, at all time points. 
These changes were significant in both groups (p≤0.001). Post-RPE (after 
RT) was lower in week eight compared to week one for patients with COPD 
(p≤0.05).  
The RT programme caused significant increases in heart rate (compared to 
pre training), each week for both groups (p≤0.001).  
6.6 Discussion
The aim of this chapter was to describe the cardio-respiratory load imposed 
by the RT programme used in the RCT, described in this thesis. Typically RT 










endurance training. However the changes in whole-body exercise 
performance, ventilation and gas exchanges variables, evident in chapter 4, 
imply that the RT protocol was able to sufficiently activate these central 
systems. 
The data in the current chapter supports this notion that the RT protocol was 
able to sufficiently activate the cardiopulmonary system and may be 
responsible for central adaptations to training.
Typically, COPD patients were working at higher percentages of their peak 
VO2 and VE (in relation to their maximal baseline CPET) compared to healthy
controls during the assessment of ventilation and gas exchange during a 
single RT session. However this did not reach statistical significance probably 
due to the low sample size (type II error). Controls were working at higher 
actual VO2 and VE levels and were producing more quadriceps isokinetic 
work than COPD patients for each of the five RT sets (p<0.05 between 
groups). 
Two previous studies have examined the cardio-respiratory response to RT. 
The study by Sillen and colleagues compared quadriceps RT [3 x 8 repetitions 
(70% of 1RM) to NMES and also evaluated their results in comparison to a 
maximal CPET (Sillen et al. 2008). This allows for easy comparison to the 
current study. Peak VO2 (% of maximum from CPET) was 57% after RT and 
34% after NMES (p<0.001 between RT and NMES). These findings are 









ranged from 49.1% to 60.1% after RT, in patients with COPD. Peak VE (% 
max voluntary ventilation) was also comparable after RT in both the study by 
Sillen et al [58% (Sillen et al. 2008)] and in the current study were the range 
was 57.6% to 72.2% for patients with COPD. 
The second study by Probst and co-workers (Probst et al. 2006) is difficult to 
compare to the current study as the ventilation data is reported over a 12-
week training period rather than a single session. Furthermore, the results are 
presented as actual values rather than related to a percentage of maximum. 
Actual values for VE (l/min) after leg press exercise ranged from 22 (week 
one) to 26 (week 12). These findings are similar to the current study as 
patients with COPD had actual VE values of approximately 21 l/min after sets 
3-5 of RT.
There were limitations with the sub-group breath-by-breath analysis 
presented; primarily that the sample size was too small to detect significant 
differences between the groups. Also, the ventilatory requirements of this 
training protocol were not directly compared to different modes of exercise. 
For instance, it would be interesting to see where this novel RT regime sits on 
the spectrum between typical endurance (e.g. walking) and RT (e.g. 3 sets of 
8 repetitions at 70% of 1 RM). In addition; although ventilatory and gas 
exchange measurements were taken at a standardised training session 
number (8-12 out of 24 total sessions), it may have been interesting to take 
serial measures over the 8-week training period and to re-calibrate from a new 





load of the training changed in both groups, during the 8-week training period. 
Finally, measures of lactate would have been of interest to compliment the 
results and one could have tracked the recovery of ventilatory parameters if 
the device had remained on the subject during the recovery period.
Thinking about the symptoms associated with the RT programme, the data 
shows that the training was well tolerated in both groups. The maximum Borg 
breathlessness score after RT for patients was 3.2 (moderate) at week 4 and 
RPE was highest at week one (14.3). There were no significant differences 
between patients and controls for Borg scores after RT, therefore patients with 
COPD did not perceive the training to be any harder than healthy controls. 
However, control subjects were performing the RT at a much higher intensity 
(see chapter 5). There is some evidence to suggest that patients with COPD 
become desensitised to the perception of training intensity as their reported 
RPE at week 8 was 13.4. This is significantly lower than at week one (14.3). 
Borg scores after RT in the study by Sillen et al (Sillen et al. 2008) were 
similar to the current study, 3 for breathlessness and 3 for RPE (using the 
modified 0-10 Borg scale). What was not measured was the motivation for the 
exercise session and post-training enjoyment or satisfaction which can be 
measured using questionnaires. This is perhaps a limitation, as motivation can 
have a bearing upon effort and ultimately the outcomes of training (Seynnes 
et al. 2004). Therefore these unmeasured (confounding) factors may impact 
upon outcomes in chapters 4, 5 and 6. However, one assumes that a persons’ 
motivation is reflected in their effort during training. This was ‘somewhat hard’ 






may be interesting in future to observe the training progression and outcome 
responses in those patients with a lower perceived effort. 
There was no evidence of oxygen de-saturation after RT in the current study; 
however those on LTOT had already been excluded from the study. There 
were significant HR changes after training in both patients and healthy 
controls, for weeks 1, 4 and 8. If we consider that subjects with COPD had a 
mean HR after training of around 100 bpm, this relates to 66% of their 
maximum heart rate [220 minus mean age of the group (68 years)]. Using the 
same formula, control subjects were working at 63% of their maximum heart 
rate. A HR of 65 to 85% of maximum relates to the target training zone for 
cardio-respiratory fitness and fat burning (Tanaka, Monahan, & Seals 2001); 
therefore training at this level can be expected to bring about central 
adaptations. Subjects in the study by Probst and co-workers also had a HR 
approaching 100 bpm after leg press exercise [99, 99, 104 at weeks 1, 6 and 
12 respectively (Probst et al. 2006)]. However the HR changes after RT were 
significantly lower than walking, cycling (week 1 and 6 only) stair climbing and 
arm cranking. 
In conclusion, the data outlined in this chapter shows that the RT protocol was 
able to sufficiently activate the cardiopulmonary system; this was evident by 
subjects working at high proportions of their maximum VO2, VE and HR. This 
may explain the significant changes in whole-body exercise performance, 
reported in chapter 4, which would be typically seen with traditional endurance 

































strength and mass (chapter 4). The chosen RT programme was performed 
comfortably by patients as Borg breathlessness scores remained at an 
acceptably low level after training and no oxygen de-saturation occurred.  
Whilst it may be that in the most severe patients, we can not overcome 
ventilatory limits; this RT protocol offers an attractive alternative training 
option. As the RT programme was able to influence both strength and 
endurance outcome measures (chapter 4) it is likely that the protocol sits fairly 












Reliability properties of the ActiTrac® accelerometers 
and changes in physical activity after resistance 
training
7.1 Introduction 
This chapter describes a pilot study to assess the test re-test reliability, 
reproducibility and sensitivity of the ActiTrac® activity monitors to establish 
their suitability for use in patients with COPD. Previous work in healthy 
subjects has shown that these monitors are reliable when compared to 
indirect calorimetry (Welk, Almeida, & Morss 2003). It was important to identify
whether these monitors were reliable and sensitive enough to detect different 
speeds of walking prior to their use in patients with COPD for the main RCT. 
This is particularly important for slow speeds of walking, typical of patients 
with COPD. Therefore the monitors were tested in a healthy individual 
(author) in a pilot study, prior to their use in patients.
A secondary aim of this chapter was to explore whether RT led to changes in 
physical activity (PA), as detected by the ActiTrac® monitors and a none 
disease-specific questionnaire in patients with COPD. As protein did not 
enhance the benefits of RT (see chapter 4), the COPD sub-groups are pooled 
in this chapter. 
Levels of physical activity (PA) are known to be reduced in patients with 








Spruit, Probst, Decramer, & Gosselink 2005). Reduced PA in patients with 
COPD is associated with a poor prognosis and an increased risk of 
hospitalisation (Garcia-Aymerich et al. 2006). One of the aims of Pulmonary 
Rehabilitation (PR) is to improve physical functioning and to increase 
domestic activity in patients with COPD (Hunter et al. 2006).The objective 
monitoring of physical activity in COPD is therefore of clinical interest, 
particularly when we aim to measure changes in PA in response to 
rehabilitation programmes. Several studies have explored changes in PA after 
PR (Troosters et al. 2010) and there is huge variation in the improvements 
reported. This probably reflects heterogeneity in the PR programmes and 
devices used to collect PA data. The percentage change in PA after 
rehabilitation ranged from 0 (Steele et al. 2008) to 70 % (de Blok et al. 2006). 
This review highlighted that changes in PA after PR are not guaranteed. We
also know that PA is only marginally correlated with the degree of airflow 
obstruction in this population, indicating that other factors may be involved, 
such as peripheral muscle weakness (Garcia-Aymerich et al. 2006). 
One of the objectives of this thesis is to explore the role of RT (in isolation, i.e. 
outside of the context of conventional PR), upon physical performance in 
patients with COPD. RT would be expected to increase muscle mass and 
strength. However the translation of improvements in strength to daily PA is 
inconclusive (O'Shea et al. 2009). Clearly, for increases in strength and mass 
to be meaningful, they must translate into functional benefits for patients. 














activities may be easier to perform and, as a consequence, PA would 
increase. 
Traditionally, PA has been derived from questionnaires, interviews and more 
recently accelerometers (Pitta et al. 2006b). In this thesis, three measures of 
PA are explored: the ActiTrac® accelerometer, the adapted PA questionnaire 
for the elderly (baseline only) and the DASI.
7.2 Aims
There were two primary aims in this chapter; to evaluate the reliability 
properties of the ActiTrac® accelerometers, prior to their use in patients with 
COPD and to assess changes in PA after RT. 
ActiTrac® pilot study 
The aims of this pilot study were to assess the ActiTrac®  activity monitors 
for: 
1. Test re-test reliability of each monitor over five tests, at a given speed 
2. Between monitor reproducibility at a given speed
3. The ability to discriminate between different speeds of walking  
This was performed in a healthy individual (the author), prior to their use in 
patients with COPD. 
Change in PA after RT 













1. To describe PA levels at baseline, comparing patients with COPD to 
healthy age-matched controls using the adapted PA questionnaire for 
the elderly 
2. To assess whether PA levels improved after RT in a sub-group of 
patients with COPD, using an accelerometer and the DASI
3. To observe the relationship between predicted VO2 max from the DASI 
and measured peak VO2 from cycle ergometry after RT. 
7.3 Methods 
ActiTrac® pilot study 
The ActiTrac® activity monitor (IM Systems, Baltimore, USA) is a lightweight 
device (34g) and has a biaxial accelerometer with sensitivity to detect 
movement as slight as 0.012g. The intensity of activity is expressed in 
reference scale data counts of 0-250 (acceleration per unit time). The device 
is simple to use, with no power buttons. There is a ‘mark’ button on the 
monitors if one wants to indicate specific bursts of activity. The ActiTrac® 
software is used to initialise the monitors and download data. The monitors 
are relatively inexpensive (approximate cost: device £530, software £260); 
particularly in comparison to other devices on the market (discussed in 
chapter 2, section 2.6.3 Physical activity). 
Before each session the activity monitors are initialised (labelled and clock 
set) via the computer interface so that subsequent activities can be 










epochs (number of data points per hour); this was chosen based upon 
manufacturer’s guidelines. No feedback is given to the wearer of the monitor. 
The monitors were labelled on the outside with numbers 1-5. At different 
times, five different monitors were attached to a waist belt on the right hip of a 
healthy subject (LH, author- figure 7.1) who performed five; 20-minute walks 
at three different speeds in five minute sections. These walks were performed 
in a random order. 
Figure 7.1 ActiTrac® monitor placement
The walking course was a standard 10m shuttle walk test [SWT (Singh et al. 
1992)] area on a hard, flat surface. Three speeds of the endurance shuttle 
walk test [ESWT (Revill et al. 1999)] were chosen and these constant speeds 
were determined by audio signal [1.78 kilometres per hour (kph) = slow, 
3.6kph= moderate, 5.54kph= fast]. The mark button was pressed at the start 






         
 
Average activity counts (acceleration per minute), for each five minute bout 
were extracted for analysis using the ActiTrac® software [version 8.5.5: IM 
Systems, Baltimore (MA) USA- example of screenshot figure 7.2]. The range 
of these counts is from 0-250 acceleration counts per minute. Data can also 
be expressed as milli-g acceleration units. 
Figure 7.2 Example of screenshot from the ActiTrac® software
Change in PA after RT 
At baseline only, the adapted PA questionnaire for the elderly (Voorrips et al. 
1991) was completed by both groups. This questionnaire is not disease-
specific and was chosen to allow comparison between patients with COPD 
and healthy controls. The questionnaire has previously been used to describe 
patients with COPD (Engelen et al. 2000;Serres et al. 1998). The 
questionnaire is interviewer-led and asks about household sporting and 






35. A higher score indicates a greater level of PA. The researcher is 
responsible for giving an intensity code for each of the sporting and leisure 
activities. This code is based on the energetic costs of activities [originally 
based on the activity questionnaire described by Baecke and co-workers 
(Baecke, Burema, & Frijters 1982)]. Test-retest reliability, and validity of the 
modified questionnaire, compared to 2 independent methods of assessing 
physical activity (pedometer and 24hour activity recall) in the elderly have
been established (Voorrips et al. 1991). A copy of the questionnaire and 
scoring system is shown in appendix 14. 
PA was measured in a subgroup of 20 patients with COPD before and after 
the RT programme using the ActiTrac® accelerometer and the DASI. The 
ActiTrac® was given to the wearer subject for 7 days before and 7 days after 
training. Subjects wore the same monitor number pre and post-RT, as the 
monitors were found to not be interchangeable (see pilot study results). Prior 
to each seven day monitoring period, the activity monitors were initialised 
(labelled and clock set) via the computer interface. All monitors were initialised 
at x1 sensitivity, with one minute epochs; as described above. Patients were 
asked to wear the monitors for a 12-hour period each day (e.g. 9am to 9pm). 
Patients received no feedback from the monitors. Average activity counts 
were reported (0-250 acceleration counts per minute range). The mean 
acceleration per minute was averaged over 7 days. Compliance with the 







      




The DASI was also completed by this subgroup (see appendix 16). The DASI 
asks individuals whether or not they can perform 12 activities at that moment 
in time and was therefore used to determine if changes in PA occurred during 
the intervention period. Additionally, from the DASI, VO2 max (mls/ /kg/ min) 
can be estimated using the following equation:
V02 max = 0.43 X DASI + 9.6 
The DASI (Hlatky et al. 1989) was developed in a cardiac population and has 
good correlation with peak oxygen uptake (r= 0.80). It’s utility and relationship 
to oxygen uptake in patients with COPD is unknown. The relationship 
between VO2 max estimates from the DASI and peak VO2 from the 
incremental cycle ergometry test at 8-weeks were therefore compared.
Changes in muscle strength, mass and whole-body exercise performance are 
also reported for the sub-group of 20 subjects to aid comparison between the 
functional outcome measures.
7.4 Statistical Analysis  
ActiTrac® pilot study 
As the data was not normally distributed, non-parametric statistical tests were 
utilised. Descriptive statistics are presented to display within-monitor variation 
over the five tests, at three different speeds [mean ± SD, 95% CI, median with 







variation of distribution, independent of the units of measurement. It is 
calculated by dividing the standard deviation by the mean and is expressed as 
a percentage. The non-parametric Kruskal-Wallis test (with post-Hoc Mann-
Whitney U tests) was used to assess between monitor reproducibility and to 
see if all monitors could distinguish between the three speeds of walking.
Change in PA after RT 
An independent t-test was used to compare the two groups for baseline PA 
levels using the adapted PA questionnaire for the elderly. Paired t-tests 
evaluated changes in PA from the ActiTrac® and DASI, within the COPD sub-
group. Furthermore the changes in muscle strength, mass and whole-body 
exercise performance (peak work) are reported for the sub-group of 20 
subjects with COPD. Again within-group changes were assessed using a 
paired t-test. The effect size for changes in PA after the intervention was 
calculated by dividing the mean difference by the standard deviation of the 
pre-intervention measurement. By calculating effect sizes, the magnitude of 
change can be judged using the following criteria: small; 0.2 to 0.5, moderate; 
0.5 to 0.8 and large; >0.8 (Cohen 1988). 
To explore the relationship between VO2 estimates from the DASI and the 
cycle ergometry test, at 8-weeks, Pearson’s correlation coefficient was 
calculated. The strength of any associations is as described in chapter 5 (i.e. 
weak/ moderate/ strong). Also, the difference between the two VO2 values 











   
  
  
   
  
  
   
  
  
   
  
  
   
7.5 Results 
ActiTrac® pilot study 
Table 7.1 shows descriptive statistics and within-monitor variation over the 5 
tests. Monitor 1 had the worst reproducibility. In general, standard deviation 
(SD) and interquartile range (IQR) increased as speed increased. 
Table 7.1 Descriptive statistics and within-monitor variation for the ActiTrac®
Average activity counts (acceleration/minute) 
Monitor Speed Mean (SD) 95%CI Median (IQR) CV
1 Slow 41.0 (12.1) 26.0-56.0 39.0 (21.0) 29.5
1 Moderate 90.0 (15.7) 70.5-109.5 88.0 (30.0) 17.4
1 Fast 128.6 (20.2) 103.6-153.6 121.0 (38.0) 15.7
2 Slow 25.4 (2.5) 22.3-28.5 24.0 (5.0) 9.8
2 Moderate 46.0 (1.5) 45.0-48.6 47.0 (3.0) 3.3
2 Fast 97.0 (4.2) 91.7-102.3 96.0 (8.0) 4.3
3 Slow 27.8 (2.4) 24.8-30.8 29.0 (4.0) 8.6
3 Moderate 57.2 (3.0) 53.5-60.9 56.0 (5.0) 5.2
3 Fast 83.8 (11.9) 69.0-98.6 79.0 (21.0) 14.3
4 Slow 24.2 (0.8) 23.2-25.2 24.0 (2.0) 3.3
4 Moderate 60.4 (2.9) 56.8-64.0 60.0 (5.0) 4.8
4 Fast 97.4 (12.5) 81.8-113.0 95.0 (21.0) 12.8
5 Slow 25.0 (3.0) 21.3-28.7 24.0 (5.0) 12.0
5 Moderate 59.8 (3.8) 55.1-64.5 60.0 (8.0) 6.4






           
Coefficient of variation (CV) was highest for slow speeds in monitors 1, 2 and 
5. Kruskal-Wallis analysis indicated that there were significant differences 
between the five monitors at speeds 1.78km/hr (p≤0.01), 3.6km/hr and 
5.54km/hr (both p≤0.001). Post-hoc Mann-Whitney tests (with no adjustment 
for type I errors) revealed that these differences lay between monitor 1 with all 
other monitors, at each speed. Monitor 1 systematically overestimated and 
was returned to the manufacturer as faulty. However, there were no significant 
differences between monitors 2-5, at each speed (p>0.05).
Furthermore, all monitors could distinguish between the 3 speeds of walking 
[all p≤0.01 (figure 7.3)].  





         





   
    
 
    
 
    
 
    
 
 




Change in PA after RT 
Table 7.2 displays the mean scores from the 3 separate domains of the 
adapted PA questionnaire for the elderly and totals scores, in both healthy 
controls and patients with COPD, at baseline. Data reflects PA within the 
previous year and is reported for all subjects who completed a baseline 
assessment (n= 71 COPD, n= 22 controls). The results in table 7.2 indicate 
that control subjects were significantly more active than patients with COPD 
for household, leisure and total scores. However there were no significant 
differences between the groups for sporting activities.
Table 7.2 Adapted physical activity questionnaire for the elderly: scores for all







Household 1.4 (0.0) 1.9 (0.0) 0.00
Sport 0.7 (0.3) 1.3 (0.6) NS
Leisure 4.4 (0.5) 7.2 (1.1) 0.02
Total 6.5 (0.6) 10.3 (1.2) 0.01
Values are mean (±1 SE). NS: not significant
For household activities; control subjects always did light housework (e.g. 
dusting, washing dishes) in 77.3 % of cases and heavy housework (e.g. 
washing floors, hovering) in 50.0% of cases. All control subjects prepared 
their own meals and did their own shopping. Most used a car to go out 
shopping (63.6%), although 4 subjects used public transport (e.g. the bus) 
and 4 walked to collect their shopping (18.2% in both cases). Only one control 







physically capable of climbing stairs. Controls climbed stairs more than 10 
times a day in just under half of cases (45.8%). Most control subjects did not 
perform a sport (i.e. a regular commitment or as part of a team) but all had at 
least one physically active leisure hobby. The top four leisure activities 
reported by controls were: walking, gardening, dancing and swimming.
5.1% of patients with COPD did not do any light housework and 28.8% never 
did any heavy housework. 50.8% did their own light housework (± assistance 
from their spouse). In 10.2% of cases, patients never prepared their own 
meals and relied upon spouses, family or agencies (e.g. ‘Meals on Wheels’). 
25.4% of patients with COPD never climbed stairs; although around two thirds 
of these subjects lived in a bungalow or ground-floor flat. The frequency of 
stair climbing was less in patients compared to controls; only 8.5% climbed 
stairs more than 10 times in a day. 5% of patients never went out to do the 
shopping. In those that did, the car was the preferred means of transport 
(71.2%). Very few patients walked to collect their shopping (6.8%). No 
patients with COPD were engaged in regular sport, although five subjects 
attended a local ‘keep fit’ class once a week. Patients reported more 
sedentary hobbies such as knitting, sewing (seated upper limb movements), 
cooking and painting (standing upper-limb movements). However walking and 
gardening were the top two leisure activities enjoyed by patients with COPD, 
as they were in healthy controls. However patients generally scored lower in 
these activities compared to controls because hours per week and intensity 





       
           
 
   
   
     
     
     
     
     
   
      
   
     
   
      
    
     
   
      
       
     
   
      
 
   
 
 
Additional PA measures were performed in a convenience sample of 20 
patients with COPD, before and after RT. Table 7.3 shows the changes in PA, 
isometric quadriceps strength, thigh mass and cycling performance after RT 
for the sub-group. The data in table 7.3 demonstrates that changes in PA 
were not significantly different than baseline values after 8-weeks of RT, in 
patients with COPD. There were however statistically significant 
improvements in the other outcomes (isometric quadriceps strength, thigh 
mass and cycling performance) after RT. Changes in strength, thigh mass and 
cycling work supports the findings in chapter 4 for the entire COPD group.
Table 7.3 Changes in physical activity after resistance training in comparison 
to other outcome measures in a subgroup of 20 patients with COPD
Baseline Week 8
DASI [mean (SD)] 23.7 (16.4) 24.1 (13.2)
Mean change from baseline (95% CI) ------------------- 0.4 (-11.2-12.1)
ActiTrac® [mean (SD)] – acceleration/ min 11.4 (9.9) 12.5 (9.9)
Mean change from baseline (95% CI) ------------------ 1.1 (-3.0-5.2)
Isometric strength [mean (SD)] – Nm 81.3 (28.2) 103.1 (41.9)
Mean change from baseline (95% CI) ------------------ 21.8 (10.2-33.4)**
Thigh lean mass [mean (SD)] – g 3487.6 (951.2) 3701.7 (949.8)
Mean change from baseline ------------------ 214.1 (48.2-380.1)*
Peak cycle work [mean (SD)] – W 46.4 (21.4) 59.1 (24.1)
Mean change from baseline (95% CI) ------------------ 12.8 (3.7-21.9)*













The effect sizes for the change in DASI score and ActiTrac® counts were very 
small (0.02 and 0.11 respectively). The effect sizes for quadriceps strength 
and cycle work were moderate (0.77 strength, 0.60 work). The thigh mass 
change effect size was small (0.23).
There was a moderate correlation between VO2 max as calculated by the 
DASI (19.9ml /kg/ min) and peak VO2 (16.0mls/ kg/ min) from cycle ergometry 
(r=0.59, p<0.01) at week 8. Furthermore, the difference between the peak
VO2 values derived by the two methods was not statistically different.
7.6 Discussion
There were two primary aims in this chapter; to evaluate the reliability 
properties of the ActiTrac® accelerometers and to assess changes in physical 
activity after RT. 
The results of the pilot study showed that the ActiTrac® activity monitors are 
reliable in the same wearer, on consecutive occasions. With the exception of 
monitor 1, there were no significant differences in the average activity 
recorded by the monitors (p>0.05). Therefore the individual characteristics of 
the activity monitors mean that they are not interchangeable. For this reason, 
in the study of COPD subjects, all patients were required to wear the same 
monitor to measure PA at consecutive time points (i.e. pre and post 
intervention). Also monitor 1 was returned to the company and not used by 







All monitors could distinguish between slow, moderate and fast speeds of 
walking. It is important that monitors can detect a range of speeds to 
accommodate patients with a variety of walking speeds. In particular, the 
sensitivity to detect slow walking speeds is important for patients with COPD 
who tend to walk slower than healthy people of the same age due to 
breathlessness. 
This data from the pilot study suggests that the ActiTrac® monitors are 
reliable, reproducible and that they are sensitive to changes in walking speed. 
They were therefore deemed to be a feasible, simple to use and relatively 
inexpensive device; suitable to monitor daily activity in patients with COPD 
who were engaged in the RCT described in this thesis.
Data in this chapter, confirms that patients with COPD have lower PA levels 
compared to age-matched healthy controls. This is evident from significantly 
lower household, leisure and total scores from the adapted PA questionnaire 
for the elderly, collected at baseline. These findings echo that of several 
others, as PA is reduced even in those with mild COPD (Pitta, Troosters, 
Spruit, Probst, Decramer, & Gosselink 2005). The total scores in the current 
study are similar to those reported by Serres and colleagues: 5 (±1) in COPD 
subjects and 10 (±2) in control subjects [p<0.05 between groups (Serres et al. 
1998)]. There were no significant differences between the groups for the 
sporting domain. However this may be expected as healthy subjects who 
participated in regular exercise (defined as ≥ three exercise sessions per 







subjects and healthy controls within the household domain can be attributed 
to control subjects preparing their own meals, using the stairs more often per 
day and 50% carrying out heavy housework. It could be that the questionnaire 
responses were related to gender roles rather than physical capabilities. For 
instance, several men reported that their wives had always done all of the 
cooking and cleaning. They would therefore score 0 for answering ‘never’ on 
these questions; despite being physically capable of these activities. Both 
groups used a car as their preferred means of transport to collect shopping, 
rather than walking, cycling or using public transport. 
Patients with COPD generally discussed more sedentary leisure time activities 
compared to control subjects. However walking and gardening were the top 
two leisure activities enjoyed by both patients with COPD and healthy 
controls. However patients generally scored lower in these activities 
compared to controls because they were not able to walk for a long period or 
could only manage to pot plants rather than dig/ mow the lawn, for example. 
Therefore hours per week and intensity codes were much lower. 
PA did not change after the 8-week RT programme described in this thesis. 
This was the case for both objective (ActiTrac®) and subjective (DASI) 
measures of PA were the effect sizes were 1.1 and 0.4 respectively. The 
reasons for this remain unclear. One possibility is that increases in strength 
are not routinely translated into changes in PA when RT is performed in 
isolation. The results may reflect the nature of the intervention which did not 
include any endurance training, education or PA advice. As quadriceps 





improve after RT; it appears that these improvements are not translated into 
daily PA when the educational component of PR is missing. Whilst there 
continues to be limited research about the impact of education on PA, expert 
opinion suggest that there are important benefits of patient education to 
enhance behaviour change (Ries, Bauldoff, Carlin, Casaburi, Emery, Mahler, 
Make, Rochester, Zuwallack, & Herrerias 2007). Future work should explore 
how important changes in muscle strength and mass, associated with RT, can 
be translated into other measures (including PA) with the use of education or 
advice. 
Another plausible explanation is that changes in PA take longer to become 
apparent, compared to the other outcome measures. As improved PA 
requires a long-term behaviour change, this may be facilitated by a longer 
treatment exposure (Ries et al. 2007). Therefore the PA outcomes may have 
shown significant changes if the programme were to continue beyond 8-
weeks and measured at a later follow-up assessment (e.g. 6 and 12-months). 
Finally, it could have been that the measures of PA were too crude to detect 
changes in PA. Whilst the monitors were sensitive enough to distinguish 
between walking speeds in the pilot study, they unfortunately lack the 
sophistication of other devices in terms of being able to detect time in different 
positions, energy expenditure (i.e. task difficulty) and does not report step 
counts. Whilst the monitors did detect movement in two planes, one can not 
be certain that this was walking or another purposeful activity. It may be that 








Furthermore, the ActiTrac® reports PA in reference units (acceleration per 
minute) which may not be as meaningful to clinicians as EE (calories) or 
METS. These are more commonly used terms which relate better to PA 
intensity. This reduces the external validity of the device as it is difficult to 
routinely translate the findings to clinical practice and to compare PA 
outcomes from other studies using different devices. Furthermore, these 
arbitrary units are not useful for patients to use when trying to understand their 
progress following an intervention. In addition they could not be used by 
patients as a motivating factor or compliance aid for exercise training, as they 
give the wearer no feedback. These limitations are clearly a consideration 
when selecting a device for use in patients with COPD. 
The ActiTrac® devices however, are more reasonably priced than other 
current devices on the market and may provide an affordable alternative when 
wishing to describe PA in the COPD population. If the area of interest is the 
outcome of rehabilitation or other interventions, more sophisticated devices 
would be preferred.
The relationship between estimated VO2 max from the DASI and actual VO2 
recorded at peak exercise (incremental cycle ergometry) was found to be 
moderate (=0.59, p<0.01). However this relationship is not as strong as the 
relationship between the DASI and peak oxygen uptake in a cardiac 
population [correlation coefficient r= 0.80 (Hlatky et al. 1989)]. Further work is 
required to examine the agreement between peak VO2 derived from the DASI 



















agreement eith commonly employed field exercise tests (e.g. the ISWT). It 
may be that if the agreement is satisfactory (using Bland-Altman analysis) 
then the DASI could be used as a surrogate for a CPET or field walking test 
when the performance of these tests are impossible or impractical (e.g. in 
small community venues). 
In conclusion, the data presented in this chapter has shown that the 
ActiTrac® activity monitors are reliable in the same wearer, reproducibly on 
consecutive occasions and can distinguish between slow, moderate and fast 
speeds of walking. These are important properties to consider when using 
accelerometers to describe populations or as an outcome measure.
The results in this chapter confirm that levels of PA are significantly lower in 
patients with COPD compared to healthy age-matched controls. Whilst 
quadriceps strength, thigh lean mass and whole-body exercise performance 
improved after the 8-week RT programme, PA did not change. This was the 
case for both objective and subjective measures of PA. This suggests that 
changes in strength are not routinely translated into PA improvements; there 















The aim of this thesis was to explore the role of protein ingestion as an 
adjunct to RT and the effects on skeletal muscle function in patients with 
COPD and addresses gaps in the existing field of knowledge. Although RT is 
a key component of PR, the effects of this therapeutic combination (RT and 
protein supplementation) have never before been studied in this population. 
The study hypothesis was that: RT, in combination with protein (at the time of 
training), will have greater effects on functional outcomes than RT alone. The 
main outcomes of the trial are reported in chapter 4. In addition, sub-studies 
were described which examine a number of other questions relating to the 
isokinetic RT measurements and outcomes of RT in more detail.  
8.1 Main findings 
The main outcomes of the RCT are reported in chapter 4 and enable us to 
reject the study hypothesis. Protein did not augment the effects of RT as both 
COPD groups made significant improvements in all outcomes and there were 
no significant differences between the groups. These are novel findings as the 
effects of this therapeutic combination have never before been studied. 
Interestingly, despite patients with COPD exercising at lower absolute training 
intensities compared to healthy controls (chapter 5); they still made 








The increases in muscle strength and thigh lean mass, evident in all groups 
(chapter 4); support the idea that the RT programme was able to cause a net 
protein increase within the quadriceps muscle. It is unclear whether the RT 
programme increased protein synthesis, reduced degradation or a 
combination of the two. However the addition of protein did not enhance these 
effects and this was the case for both wasted and non-wasted sub-groups. 
The reasons for the apparent failure of the intervention are uncertain. It may
have been that the response from RT swamps any additional effect of the 
protein or that the ‘dose’ of protein was not large enough. The response to 
protein may be dose-dependant and vary between individuals.
Despite being underpowered to detect significant changes in the wasted 
group, there was a suggestion that the wasted group responded less well to 
RT, compared to the non-wasted group (chapter 4). If these patients were in 
a negative protein balance prior to training (wasted), they may have required 
additional protein (in the diet or further supplementation) to ensure muscle 
protein synthesis. A poor treatment response in these patients may be 
attributed to an inadequate assessment of their energy requirements when 
engaged in the RT programme (Baarends et al. 1997a) as habitual diet was 
not recorded. It may have been that some of the ‘wasted’ patients fell into this 
‘non-responder’ category and therefore reduced the effect of protein 
supplementation in the whole group.
Improvements in muscle mass and strength from RT were found to transfer to 








variables (e.g. VO2 max). The impressive changes of around 10 watts after RT
(chapter 4), within each group, would typically be expected after endurance 
training (Lacasse et al. 2006) and suggests that the RT programme activated 
central systems. This is supported by findings in chapter 6, where it was 
apparent that patients with COPD were working at higher percentages of their 
maximal VO2 (60%) and VE [72% (compared to a baseline CPET)] during RT, 
compared to healthy controls. This was despite control subjects training at 
significantly higher intensities. Furthermore, the HR for patients with COPD 
after RT was within the target HR training zone for cardio-respiratory fitness 
(66% of maximum). 
Chapter 5 reports the data pertaining to the RT programme. The results 
showed that control subjects were working at higher absolute intensities for 
both work and torque at all time points, compared to patients with COPD. 
However the relative improvement in training progression (as a percentage
from baseline) was greater in the COPD group. Although there appears to be 
a plateau at 4-weeks for training progression in control subjects, there were 
no significant differences between the groups for the training progression 
gradients. What was apparent was that control subjects became more FR 
during the 8-week programme, whilst COPD subjects did not. The reasons for 
this are unknown. However we may speculate that control subjects (who
showed a plateau in training performance after 4-weeks) merely became more 
efficient at doing the same RT protocol towards the end of the programme. 
For patients with COPD, FR to this type of exercise may take longer to 






oxidative capacity within the muscle and may therefore have been lacking the 
capacity (Allaire et al. 2004) to replenish oxygen within the muscles, during 
the RT programme. One may wonder weather healthy controls were able to 
do this, as their muscles have the usual oxidative preferences seen in normal 
elderly muscle (Lanza, Russ, & Kent-Braun 2004). 
Changes in strength (around 20%) were found to be disconnected from 
changes in thigh muscle mass [(around 5%) chapters 4 and 5] and support 
previous findings that other factors, besides increased mass, are involved in 
producing muscle force (Jones et al. 2004). Although not directly measured, it 
is likely that neural adaptations accounted for a large proportion of the 
changes in strength. Neural adaptations occur within the first few weeks of 
training. One might have expected that the muscle mass changes would not 
be apparent until the 8-week measure, as muscle hypertrophy (change in 
fibre/ muscle group size) is known to occur later as a result of long-term 
training (Sale 1988). However, in the current study, there was a significant 
increase in muscle mass by week 4; at which point the majority of the 
improvement had occurred (chapter 5). Therefore changes in thigh mass 
would be unlikely to be any greater, even if the RT were to continue beyond 8-
weeks. Interestingly changes in muscle mass showed no correlation with RT 
intensity (chapter 5). 
Data presented in chapter 5 also showed that the majority of improvements in 
strength also occurred within the first four weeks, for both groups. This is in 








and torque occurred in the first four weeks (chapter 5). There were some 
weak to moderate associations between training intensity (work/ torque) and 
the measures of isometric and isokinetic strength (60°/sec) after 8-weeks of 
training in both groups. These were positive, suggesting that increased 
training intensity leads to improved gains in muscle strength which are ‘dose-
dependant.
Chapter 7 evaluated the measurement properties of the ActiTrac® activity 
monitors. The data showed that these accelerometers were reliable in the 
same wearer on consecutive occasions. They are also sensitive to detect 
varying walking speeds. In this chapter it was also evident that COPD patients 
had lower levels of baseline PA compared to our age-matched control group 
(based on questionnaire data). However PA levels in patients with COPD did 
not change after the 8-week RT programme. This was the case for both 
objective (ActiTrac®) and subjective (DASI) measures and may indicate that 
changes in PA take longer to occur after RT, the measures were too crude to 
detect the change or simply that improvements in strength are not 
automatically translated into PA increases.
8.2 Implications for clinical practice 
The routine recommendation of protein supplementation as an adjunct to RT 
in patients with COPD, can not be advocated based on the findings of this 





The RT protocol described in this thesis would not constitute conventional RT 
typically employed in clinical practice. Isokinetic testing is rarely used in the 
evaluation of strength for patients with COPD and has not been used as a RT 
device in this population. However, the isokinetic protocol presented a unique 
opportunity to precisely explore the training intensity progression, fatigue 
profile (chapter 5) and cardio-respiratory load (chapter 6) imposed by the 
training; comparing patients with COPD and healthy controls. This enabled us 
to gather a detailed picture of RT in patients with COPD and to explore the 
relationship between RT intensity and outcome measures, such as strength 
which has previously been poorly described in the COPD population. The 
direct comparison of the training profiles in each group was also distinctive, as 
healthy populations are usually considered separately.
The changes in strength, thigh mass and whole-body exercise performance 
(chapter 4) after RT were of small to moderate effect size but are likely to be 
clinically meaningful for patients. Unfortunately there is no established MCID 
for changes in thigh mass, quadriceps strength or cycle ergometry ventilation 
outcomes in this population. This makes it difficult to interpret the findings, 
although the results are comparable to previous studies in healthy subjects 
and those with COPD. As the isokinetic RT programme described was able to 
influence both strength and endurance outcome measures (chapter 4) it is 
likely that the protocol sits fairly centrally on the continuum between 
resistance and endurance training. The training was able to sufficiently 
activate the cardio-pulmonary system (chapter 6) whilst symptom scores 







alternative training option for breathless patients who perhaps can not sustain 
continuous aerobic training.
Changes in muscle strength were associated with training intensity, 
suggesting that strength improves in a ‘dose-dependant’ manner. Thigh lean 
mass was not correlated with training intensity and is perhaps not the most 
sensitive measure to use in this case. As most of the improvements in 
strength and thigh muscle mass occurred within the first 4-weeks (chapter 5); 
it may be that 4-weeks of RT is sufficient. Sewell and co-authors have 
previously reported that a four and seven-week PR programme were 
equivalent at the comparable time points of seven weeks and 6-months for 
SWT performance and HRQoL (Sewell et al. 2006). With ever constrained 
resources in the NHS, it may be important to demonstrate that we can 
produce significant improvements in RT outcomes within a short period of 
time. This would allow the distribution of limited resources to more patients, 
without compromising on quality.
Changes in isokinetic strength exceeded isometric strength changes in all 
groups (chapter 4). This is perhaps unsurprising, given that the training was 
also isokinetic in nature. However this may also suggest that isokinetic 
strength is more sensitive to change after RT and highlights the importance of 
measuring dynamic as well as static measures of strength. If only isometric 
strength is reported after training, important training adaptations may be 







was greater with isokinetic rather than isometric strength and probably reflects 
the specific adaptation to the training which was also isokinetic (chapter 5). 
Furthermore, it was also noticed that changes occurred at the isokinetic 
testing velocity of 60°/sec even though training took place at 180°/sec. This 
transfer effect is in keeping with previous findings. This is encouraging as the 
slow velocity of 60°/sec would be difficult for patients to sustain during a 
training session. The 180°/sec training speed was known to target type II 
fibres (Jones et al. 2004) and the speed allowed for the acceptable completion 
of 5 sets of 30 maximal knee extensions in our frail COPD population, whilst 
still improving maximal strength at slower velocities.
Data presented in chapter 5 highlighted that isokinetic work appears to be a 
more sensitive measure to change after RT and more susceptible to fatigue, 
compared to peak torque. This highlights the importance of measuring work 
which is cumulative rather than merely reporting peak torque (maximal force), 
as significant improvements may be missed. Furthermore, the test re-test 
reliability is equally very good for both isokinetic torque and work measures 
(see appendix 11). 
In chapter 4, the recruitment of wasted subjects proved challenging, with only 
12 subjects recruited who had FFMi evidence of muscle wastage. Therefore 
arbitrary FFMi cut-off values (less than 16 kg/m2 in men or less than 15kg/m2
in women) were unhelpful in defining muscle wastage for this population. For 
this reason it may be more appropriate in clinical practice to observe muscle 








spread of data. However it should be remembered that the FFMi cut-offs were 
based on BIA, rather than DEXA analysis and these methods are not 
interchangeable.
Although measuring FFM creates a challenge, I believe that the loss of lean or 
FFM is important to measure in the context of any rehabilitation programme 
for patients with COPD, where exercise may result in a negative energy 
balance. We know from work by Steiner and co-workers that an improvement 
in walking performance was related to the amount of carbohydrate ingested 
during a PR programme (Steiner et al. 2003) and that a lack of carbohydrate 
may have posed a limit to the amount of training patients could perform. The 
same may be true of protein during RT or conventional PR. The reasons for 
measuring FFM are two-fold: to ensure that adequate nutritional support can 
be given to overcome the metabolic demand of exercise and, secondly, to 
confirm that exercise is not exacerbating further lean mass loss. Indeed, the 
stimulus of exercise may be shown to improve weight gain by stimulating 
appetite. In the current study, habitual diet was not measured. This is perhaps 
a limitation and something to consider in outpatient rehabilitation programmes, 
particularly if there is a dietician available. In a busy outpatient environment, 
FFM could be measured using some of more portable measures, such as BIA, 
if DEXA is inaccessible. 
The ActiTrac® activity monitor appears to be reliable in the same wearer, on 
consecutive occasions and able to detect walking speeds, based on findings 







detect slow speeds of walking, typically utilised by disabled patients with 
COPD. As the monitors are relatively inexpensive and simple to use, 
compared to others available on the market, they may provide an affordable 
alternative when wishing to describe PA in the COPD population. However the 
ActiTrac® lacks the sophistication of other devices and reports PA in arbitrary 
reference units which may not be meaningful to clinicians or patients requiring 
feedback. Furthermore, the individual characteristics of the activity monitors 
mean that they are not interchangeable and therefore the same monitor 
should be worn by the same individual on repeat testing. 
The finding that improvements in strength do not routinely translate into PA 
benefits (chapter 7) is perhaps unsurprising, as the effects of RT on PA are 
inconclusive in this population. The results may reflect the nature of the 
intervention which did not include any endurance training, education or PA 
advice. As quadriceps strength, thigh mass and whole-body exercise 
performance did significantly improve after RT; it may be that these 
improvements are not routinely translated into daily PA when the educational 
section of PR is missing. This is important for PR practice as the educational 
component is likely to have a large impact upon lifestyle choices. This has not 
fully been explored and it is difficult to assess the impact of education alone 
as it is generally combined with exercise during PR programmes. 
Furthermore, as improved PA requires a long-term behaviour change, this
may be facilitated by a longer treatment exposure or only become apparent 





may have shown significant changes if the programme were to continue 
beyond 8-weeks and if PA were measured at a later follow-up assessment. 
The VO2 max estimated from the DASI questionnaire, used in chapter 7, has 
a moderate correlation with the actual VO2 measured by a CPET (r=0.59). 
This simple questionnaire may therefore offer an alternative when a SWT or 
CPET are impractical. 
8.3 Suggestions for future work 
In this study, protein did not augment the effects of RT, however the role of 
protein in the COPD population is worthy of future study. There was some 
suggestion in chapter 4 that wasted patients responded less well to RT; 
however the effects of protein were equally as ineffective in wasted and non-
wasted sub-groups. However there was insufficient study power to draw 
meaningful conclusions in the wasted group. Future work should explore the 
role of protein supplementation, particularly in wasted patients, during RT or 
conventional rehabilitation programmes. The titration of the correct dose of 
protein and the timing of protein in relation to training (e.g. during training) 
may be important variables to consider. As stated in section 8.2 the routine 
measurement of lean/ FFM before, during and after PR warrants 
consideration, as a negative energy balance during training may further 
exacerbate FFM loss and could limit the amount of training an individual can 
do. An understanding of the causes of energy imbalance and its relationship 






interest to clinicians and could help to identify those in need of nutritional 
support. 
The FFMi cut-off categories chosen in this study were unhelpful when defining 
muscle wastage in this population. Anecdotally it seemed that some 
individuals had a low BMI yet they failed to meet the FFMi wasting criteria. 
Furthermore, some individuals appeared to have wasted thigh muscles but as 
the FFMi is a total body measure, the wastage may not become apparent 
when other body compartments have preservation of FFM. As muscle 
wastage is an important problem for patients with COPD, other ways of 
defining muscle wastage are required. A composite measure or index of 
skeletal muscle dysfunction may be preferable which takes into consideration 
several factors, such as BMI, FFM, muscle strength and systemic 
inflammation. This type of index, in a similar way to the BODE, could then 
risk-stratify patients and help to identify those in need of different types of 
support (e.g. nutrition, RT). Alternatively, as the quadriceps muscles are 
predominately affected in patients with COPD, future research could develop 
FFM criteria based on thigh or quadriceps mass. This would involve 
generating normal values from measures taken in healthy individuals in the 
first instance. Future work could also evaluate the intra- and inter-observer 
variability in measuring the thigh ROI on DEXA analysis.
The data presented in this thesis confirms the effectiveness of RT in patients 
with COPD. However, most of the outcome measures described in this thesis, 







whether the results are clinically meaningful at an individual and group level, 
using these values. In future, it might be beneficial to derive MCID values for 
important outcomes after RT in patients with COPD, such as strength and 
quadriceps muscle mass, as has been the case for the outcomes of 
endurance training (e.g. ISWT). Furthermore it would be appropriate to 
explore the relatively sensitivity of outcome measures following RT, in the 
short and long-term. 
The data regarding muscle fatigue is sparse in the COPD population, yet 
fatigue and FR are greatly important for exercise and daily task performance. 
In future, one may wish to explore which types of training and assessment 
protocols are the best at evoking fatigue in patients with COPD. Furthermore, 
it may be important to track how fatigue impacts upon exercise performance 
and whether FR occurs over time with different modes of training. 
The relationship between RT intensity and outcome measures, such as 
strength has previously been poorly described in the COPD population. 
Ideally, the optimum ‘dose’ of training should depend on the individuals’ needs 
and the ongoing measurement of outcomes during training (Ries et al. 2007). 
Although the serial measurement of outcomes may be impractical in the 
context of a PR programme, it may of benefit in the long-term. In chapter 5 it 
was found that the majority of improvements in muscle strength and mass 
occurred within the first 4-weeks, beyond this additional improvements were 
minimal. Therefore the repeated measurement of outcomes during an 










individuals until they had made a pre-defined improvement in an outcome 
measure (e.g. MCID, % improvement, until there was 0 change from week to 
week) rather than fixing the programme length. This would enable limited 
resources to be shared between more individuals, without the quality of the 
programme being affected. In addition, it may be worthwhile training patients 
with their specific deficits in mind. For instance, if muscle weakness is a key 
problem then the PR programme should centre heavily upon RT. This is 
important as patients with muscle weakness may be done a disservice by 
generic PR programmes which concentrate on endurance training.
In future it would be interesting to see where the novel RT regime describes, 
sits on the spectrum between typical endurance and RT. It may be that we 
can tailor RT to suit individual needs based upon ventilatory parameters and 
comfort regarding respiratory symptoms. In addition, ventilatory and gas 
exchange measurements were only taken during a single RT session in this 
study (chapter 6); it would also be interesting to observe if the ventilatory load 
of training changes during the course of a RT programme. Finally, measures 
of lactate would have been of interest to compliment the results in chapter 6
and measures of ventilation during the recovery phase after training warrant 
further exploration.
8.4 Concluding remarks
Skeletal muscle dysfunction is a key cause of exercise intolerance in patients 
with COPD, manifested by reduced muscle mass and strength, particularly 





health system as quadriceps dysfunction is an independent predictor of 
hospitalisation and mortality. Importantly, the quadriceps may provide a target 
for therapy in an otherwise irreversible lung disease and changes in strength 
after RT are well documented. Protein supplementation has been successfully 
used as an adjunct to RT in healthy populations. This thesis describes the first 
study to explore the role of this therapeutic combination in patients with 
COPD. 
The overriding message from this thesis is that protein supplementation can 
not be routinely recommended as an adjunct to RT for patients with COPD. 
However it may have a role for those with evidence of muscle wastage and 
this warrants further research, as the current study was underpowered to 
detect significant improvements in this group. The dose of protein and the 
timing in relation to training may be important variables to manipulate. In any 
case, all groups made significant improvements in quadriceps strength and 
thigh mass after RT but protein did not augment the outcome. Subjects with 
COPD made comparable improvements to healthy age-matched controls, 
despite training at much lower intensities and experiencing more fatigue. 
Moreover, the RT programme was able to sufficiently activate the cardio-
pulmonary system and led to significant improvements in whole-body exercise 
performance. PA did not change after the 8-week RT programme; suggesting 
that changes after RT are not routinely translated to increased habitual PA, 



































The isokinetic RT programme used in this thesis provided a unique 
opportunity to precisely explore the training intensity progression, fatigue 
profile and cardio-respiratory load imposed by the training; comparing patients 
with COPD and healthy controls. The findings from this work provide some 
important considerations for clinical practice (section 8.2) and require further 
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Appendix 3
PATIENT INFORMATION SHEET 
Molecular Approaches to Reversing Skeletal Muscle
Wasting in COPD. The Role of Resistance Training and
Protein Supplementation.
Principal Investigator: Dr Michael Steiner
Co-Researchers:  Prof Sally Singh 
Dr. Michael Morgan
Dr Manoj Menon
Ms Linzy Houchen 
You may contact: Dr. Michael Steiner 
0116 256 3450
This study is sponsored by the Medical Research Council. 
You are being invited to take part in a research study. Before you decide 
it is important for you to understand why the research is being done and what 
it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask us if there is anything that is not clear 
or if you would like more information.  
What is the purpose of this study?
A large number of people in the UK have long term breathing problems 
due to lung diseases such as Chronic Obstructive Pulmonary Disease 
(COPD). Patients with these conditions experience breathlessness when they 
try to exercise or perform physical tasks. In many patients this is made worse 
by weakness and wasting of the leg muscles. However, little is known about 
the underlying reasons for muscle wasting in patients who suffer with COPD. 
It is known that certain genes are involved in regulating the size and strength 
of the leg muscles in healthy humans. Recent research has shown that these 
genes are important in the increase in muscle bulk seen after exercise training 
in healthy people, particularly when exercise is combined with additional 
dietary protein intake. However, we don’t know if these genes are important in 
muscle wasting in patients who have COPD. We know that exercise training is 
effective in improving symptoms for patients with COPD. However the 
mechanisms by which these improvements are brought about are largely 
unknown. 
The aim of this research is to study the effects of a programme of 
exercise training and dietary supplementation on functioning of these genes in 
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patients who suffer with COPD. We will compare these effects in similar aged 
healthy volunteers. 
This knowledge will help us understand why muscle wasting happens in 
patients with lung diseases such as COPD. This is important because if we 
can understand how our genes regulate these changes in muscle bulk we 
may be able to develop new treatments to address this problem in patients 
with chronic diseases such as COPD. 
Why have I been chosen?
Members of the pulmonary rehabilitation research team are conducting 
this study in collaboration with Prof Paul Greenhaff at the University of 
Nottingham. Patients with COPD who are going to attend the outpatient 
pulmonary rehabilitation programme or who are attending out patients at 
Glenfield Hospital are being invited to participate. We are also inviting similar 
aged healthy individuals who do not have lung disease to participate.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to 
take part you will be given this information sheet to keep and be asked to sign 
a consent form. If you decide to take part, you are still free to withdraw at any 
time and without giving a reason. This will not affect the standard of care you 
receive. 
What will happen to me if I take part?
The purpose of this research study is to determine the effects of a 
programme of leg exercise training combined with dietary supplements. If you 
agree to participate, you will therefore be asked to undertake an eight-week 
programme of leg (quadriceps muscle) training.
Because we don’t know whether taking additional dietary supplements 
is helpful, patients will be put into two groups and then compared. The groups 
are selected by a computer, which has no information about the individual – 
i.e. by chance. One group will receive a dietary supplement drink and the 
other group will receive an inactive dummy drink (called a placebo). Neither 
you nor your doctor will know in which treatment group you are (although, if 
your doctor needs to find out he/she can do so).
In order to find out what the effects of these treatments is, you will be 
asked to attend the hospital for additional assessments before the start of the 
exercise programme, in the middle of the programme and at the end. Some of 
these assessments will require a specific visit to hospital. Others will be 
performed on a day you are attending anyway as part of the exercise 
programme. 
Your involvement in the study will last 10 to 12 weeks. The study 
overall will be running for around three and a half years.
Exercise Programme 
You will be asked to attend Glenfield Hospital three times a week to 
exercise both legs on a piece of equipment called a “Cybex”. This will involve 
extending your leg as hard as you can on the Cybex. We will ask you to do 
Patient Information Sheet version 4, 04/06/2007
Ref: 15 Appendix 3.doc
280
























this 15 to 30 times (also called “repetitions”). There will be up to five bouts of 
these repetitions. You will be able to rest between these bouts. 
Dietary Supplement 
Depending on which group you are put in you will be asked to drink a 
dietary supplement or a placebo immediately after each bout of exercise 
during the exercise programme.
Assessment Visits 
Visit 1 
During this visit a doctor will discuss the study with you, take a medical 
history and examine you. You will also complete a questionnaire which asks 
about your daily physical activity. You will then be asked to perform breathing 
tests, which involves taking deep breaths, holding your breath and blowing 
down a tube. We will also measure your height and weight. We will also ask 
you to have a practice run at exercise on a bike and on the Cybex. 
Visit 2 
We will ask you to perform an exercise test on a special bicycle to 
establish your exercise ability. During the exercise we will record your heart 
and oxygen levels and you will breathe in and out of a mouthpiece. The bike 
will get gradually harder to pedal until you ask to stop. You will then be asked 
to perform a test to measure strength in your thigh muscle. This will involve 
sitting on a chair and extending your leg (which is attached to a lever) as hard 
as you can for a few seconds against a resistance. 
You will also have a DEXA Scan. This measures the amount of fat, 
muscle and bone in your body. The scan is painless and requires you to lie 
flat for a few seconds. 
The exercise programme will start one to two weeks after visit 2. 
During this time you may be asked to wear an activity monitor at home for 7 
days. This will count the times that you are active throughout the day and can 
be hidden under your clothing.
 Visit 3 
On the first day you attend for the exercise programme we will take a 
small sample of muscle from your thigh. This is called a muscle biopsy. Local 
anaesthesia is used to numb the area and a special needle is inserted 
through a small incision in the skin into the thigh muscle. We will also obtain 
a sample of blood from a forearm vein. Your first exercise session of the 
programme will be performed after these tests.
 Visit 4 
The day after your first exercise session we will take another muscle 
biopsy from your thigh. We will also take another blood test.
 Visit 5 
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Before one of your exercise sessions in the 4th or 5th week of the 
programme we will take another muscle biopsy, blood test, and another DEXA 
Scan. 
Visit 6 
We will ask you to attend Glenfield Hospital after the exercise 
programme has been completed. We will take another muscle biopsy and 
another blood test. We will then ask you to repeat the test of muscle strength 
and the cycle test. You will have a final DEXA Scan and be asked to complete 
the physical activity questionnaire again. If you wore an activity monitor before 
the training programme we will ask you to wear one again for another 7 days 
at home. 
We would like to see whether the benefits of the strength training programme 
are maintained. We will therefore invite you to visit us 6 months after you have 
finished the training programme to re-test your muscle strength. This visit will 
be optional.
Travel Arrangements 
The study involves a number of visits to hospital. Travel by taxi for all 
these visits will be provided for you if you need or wish it. 
What will happen to samples I donate as part of this study?
Muscle and blood samples you provide during the study will be stored 
and analysed at Nottingham University under the supervision of Prof Paul 
Greenhaff. Some of the analysis will take place after the study has been 
completed and samples may be stored for up to five years. Any remaining 
tissue will be destroyed at the end of the study and will not be used for any 
other purpose or future research. The samples you donate will not be tested 
for genetic diseases or other conditions.
What do I have to do?
Other than detailed above, you will not have to make any changes to 
your medication or lifestyle.
What are the possible benefits of taking part?
We would expect you to benefit from improvements in muscle strength 
as a result of the exercise programme although this may not occur in all 
participants. If the dietary supplement proves beneficial you may benefit also 
from this if you are placed in the active treatment group. 
We hope the information we get from this study will be helpful in 
understanding the problem of muscle wasting in patients with COPD and 
developing new treatments for this problem.
What are the possible disadvantages and risks of taking part?
You may find the muscle biopsy uncomfortable. Your thigh may ache for 
a day or two after the biopsy. If the biopsy site is uncomfortable we can 
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provide painkillers for you. There is a very small risk that the site of biopsy 
could bleed or become infected. 
The DEXA scans involve a very small exposure to x-rays. This is 
equivalent to a fraction of that involved in having a standard chest X-ray. A 
greater exposure would occur naturally from the environment if you were to 
take a two week holiday in Cornwall.
There is a very small risk of injury from performing the exercise. 
What if something goes wrong?
If you are harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it. Regardless of this, if you wish to complain, or have any concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints 
mechanisms would be available to you.
Will my taking part in this study be kept confidential?
Yes. Your personal details and all information collected about you during 
this study will be held in strictest confidence. People organising the trial may 
see your medical records but in no circumstance will personal details be made 
available to the public. We will inform your GP that you are taking part in the 
study. Any information about you that leaves the hospital will have your name 
and address removed so that you cannot be recognised. If the results of the 
study are published you will not be identified in the report. 
Who has reviewed the study?
All research that involves NHS patients or staff, information from NHS 
medical records or uses NHS premises or facilities must be approved by an 
NHS Research Ethics Committee before it goes ahead. Approval does not 
guarantee that you will not come to any harm if you take part. However, 
approval means that the committee is satisfied that your rights will be 
respected, that any risks have been reduced to a minimum and balanced 
against possible benefits and that you have been given sufficient information 
on which to make an informed decision.
If you have any questions please do not hesitate to contact:
Dr Manoj Menon Tel 0116 258 3652
Dr. Michael Steiner Tel 0116 256 3450
Thank you for reading this information leaflet. 
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HEALTHY VOLUNTEER INFORMATION SHEET 
Molecular Approaches to Reversing Skeletal Muscle
Wasting in COPD. The Role of Resistance Training and
Protein Supplementation.
Principal Investigator: Dr Michael Steiner
Co-Researchers:  Prof Sally Singh 
Dr. Michael Morgan
Dr Manoj Menon
Ms Linzy Houchen 
You may contact: Dr. Michael Steiner 
0116 256 3450
This study is sponsored by the Medical Research Council. 
You are being invited to take part in a research study. Before you decide 
it is important for you to understand why the research is being done and what 
it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask us if there is anything that is not clear 
or if you would like more information. 
What is the purpose of this study?
A large number of people in the UK have long term breathing problems 
due to lung diseases such as Chronic Obstructive Pulmonary Disease 
(COPD). Patients with these conditions experience breathlessness when they 
try to exercise or perform physical tasks. In many patients this is made worse 
by weakness and wasting of the leg muscles. However, little is known about 
the underlying reasons for muscle wasting in patients who suffer with COPD. 
It is known that certain genes are involved in regulating the size and strength 
of the leg muscles in healthy humans. Recent research has shown that these 
genes are important in the increase in muscle bulk seen after exercise training 
in healthy people, particularly when exercise is combined with additional 
dietary protein intake. However, we don’t know if these genes are important in 
muscle wasting in patients who have COPD. We know that exercise training is 
effective in improving symptoms for patients with COPD. However the
mechanisms by which these improvements are brought about are largely 
unknown. 
The aim of this research is to study the effects of a programme of 
exercise training and dietary supplementation on functioning of these genes in 
patients who suffer with COPD. You are being asked to take part because we 
need to compare these effects in healthy people of a similar age. 
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This knowledge will help us understand why muscle wasting happens in 
patients with lung diseases such as COPD. This is important because if we 
can understand how our genes regulate these changes in muscle bulk we 
may be able to develop new treatments to address this problem in patients 
with chronic diseases such as COPD. 
Why have I been chosen?
Members of the pulmonary rehabilitation research team are conducting 
this study in collaboration with Prof Paul Greenhaff at the University of 
Nottingham. You have been invited to participate as a healthy subject who 
does not have lung disease. Patients with COPD who are attending out- 
patient departments at Glenfield Hospital are also being invited to participate. 
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to 
take part you will be given this information sheet to keep and be asked to sign 
a consent form. If you decide to take part, you are still free to withdraw at any 
time and without giving a reason. This will not affect the standard of care you 
receive. 
What will happen to me if I take part?
The purpose of this research study is to determine the effects of a 
programme of leg exercise training combined with dietary supplements. If you 
agree to participate, you will therefore be asked to undertake an eight-week 
programme of leg (quadriceps muscle) training. Healthy volunteers who agree 
to participate will not need to take the supplements.
In order to find out what the effect of the training programme is, you will 
be asked to attend the hospital for additional assessments before the start of 
the exercise programme, in the middle of the programme and at the end. 
Some of these assessments will require a specific visit to hospital. Others will 
be performed on a day you are attending anyway as part of the exercise 
programme. 
Your involvement in the study will last 10 to 12 weeks. The study 
overall will be running for around three and a half years.
Exercise Programme 
You will be asked to attend Glenfield Hospital three times a week to 
exercise both legs on a piece of equipment called a “Cybex”. This will involve 
extending your leg as hard as you can on the Cybex. We will ask you to do 
this 15 to 30 times (also called “repetitions”). There will be up to five bouts of 
these repetitions. You will be able to rest between these bouts. 
Assessment Visits 
Visit 1 
During this visit a doctor will discuss the study with you, take a medical 
history and examine you. You will also complete a questionnaire which asks 
about your daily physical activity. You will then be asked to perform breathing 
tests, which involves taking deep breaths, holding your breath and blowing 
down a tube. We will also measure your height and weight. We will also ask 
you to have a practice run at exercise on a bike and on the Cybex. 
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We will ask you to perform an exercise test on a special bicycle to 
establish your exercise ability. During the exercise we will record your heart 
and oxygen levels and you will breathe in and out of a mouthpiece. The bike 
will get gradually harder to pedal until you ask to stop. You will then be asked 
to perform a test to measure strength in your thigh muscle. This will involve 
sitting on a chair and extending your leg (which is attached to a lever) as hard 
as you can for a few seconds against a resistance. 
You will also have a DEXA Scan. This measures the amount of fat, 
muscle and bone in your body. The scan is painless and requires you to lie 
flat for a few seconds. 
The exercise programme will start one to two weeks after visit 2.
During this time you may be asked to wear an activity monitor at home for 7 
days. This will count the times that you are active throughout the day and can 
be hidden under your clothing.
Visit 3 
On the first day you attend for the exercise programme we will take a 
small sample of muscle from your thigh. This is called a muscle biopsy. Local 
anaesthesia is used to numb the area and a special needle is inserted 
through a small incision in the skin into the thigh muscle. We will also obtain 
a sample of blood from a forearm vein. Your first exercise session of the 
programme will be performed after these tests.
 Visit 4 
The day after your first exercise session we will take another muscle 
biopsy from your thigh. We will also take another blood test.
 Visit 5 
Before one of your exercise sessions in the 4th or 5th week of the 
programme we will take another muscle biopsy, blood test, and another DEXA 
Scan. 
Visit 6 
We will ask you to attend Glenfield Hospital after the exercise 
programme has been completed. We will take another muscle biopsy and 
another blood test. We will then ask you to repeat the test of muscle strength 
and the cycle test. You will have a final DEXA Scan and be asked to complete 
the physical activity questionnaire again. If you wore an activity monitor before 
the training programme we will ask you to wear one again for another 7 days 
at home. 
We would like to see whether the benefits of the strength training programme 
are maintained. We will therefore invite you to visit us 6 months after you have 
finished the training programme to re-test your muscle strength. This visit will 
be optional.
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The study involves a number of visits to hospital. Travel by taxi for all 
these visits will be provided for you if you need or wish it. 
What will happen to samples I donate as part of this study?
Muscle and blood samples you provide during the study will be stored 
and analysed at Nottingham University under the supervision of Prof Paul 
Greenhaff. Some of the analysis will take place after the study has been 
completed and samples may be stored for up to five years. Any remaining 
tissue will be destroyed at the end of the study and will not be used for any 
other purpose or future research. The samples you donate will not be tested 
for genetic diseases or other conditions.
What do I have to do?
Other than detailed above, you will not have to make any changes to 
your medication or lifestyle.
What are the possible benefits of taking part?
We would expect you to benefit from improvements in muscle strength 
as a result of the exercise programme although this may not occur in all 
participants. We hope the information we get from this study will be helpful in 
understanding the problem of muscle wasting in patients with COPD and 
developing new treatments for this problem.
What are the possible disadvantages and risks of taking part?
You may find the muscle biopsy uncomfortable. Your thigh may ache for 
a day or two after the biopsy. If the biopsy site is uncomfortable we can 
provide painkillers for you. There is a very small risk that the site of biopsy 
could bleed or become infected. 
The DEXA scans involve a very small exposure to x-rays. This is 
equivalent to a fraction of that involved in having a standard chest X-ray. A 
greater exposure would occur naturally from the environment if you were to 
take a two week holiday in Cornwall.
There is a very small risk of injury from performing the exercise.
What if something goes wrong?
If you are harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it. Regardless of this, if you wish to complain, or have any concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints 
mechanisms would be available to you.
Will my taking part in this study be kept confidential?
Yes. Your personal details and all information collected about you during 
this study will be held in strictest confidence. People organising the trial may 
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see your medical records but in no circumstance will personal details be made 
available to the public. We will inform your GP that you are taking part in the 
study. Any information about you that leaves the hospital will have your name 
and address removed so that you cannot be recognised. If the results of the 
study are published you will not be identified in the report. 
Who has reviewed the study?
All research that involves NHS patients or staff, information from NHS 
medical records or uses NHS premises or facilities must be approved by an 
NHS Research Ethics Committee before it goes ahead. Approval does not 
guarantee that you will not come to any harm if you take part. However, 
approval means that the committee is satisfied that your rights will be 
respected, that any risks have been reduced to a minimum and balanced 
against possible benefits and that you have been given sufficient information 
on which to make an informed decision.
If you have any questions please do not hesitate to contact:
Dr Manoj Menon Tel 0116 258 3652
Dr. Michael Steiner Tel. 0116 256 3450
Thank you for reading this information leaflet. 
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Appendix 5
Participant Identification Number for this trial:
CONSENT FORM
Molecular Approaches to Reversing Skeletal Muscle
Wasting in COPD. The Role of Resistance Training and
Protein Supplementation.
Principal Investigator: Dr Michael Steiner
Co-Researchers:  Prof Sally Singh 
Dr. Michael Morgan
Dr Manoj Menon
Ms Linzy Houchen 
Please initial box
1. I confirm that I have read and understand the information sheet 
dated 04/06/2007 (version 4) for the above study and have had the 
opportunity to ask questions □
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. □
3. I understand that sections of any of my medical notes may be looked at 
by responsible individuals from regulatory authorities where it is 
relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. □
4. I agree to take part in the above study. □
Name of Patient Date Signature
Researcher Date Signature
1 for patient; 1 for researcher; 1 to be kept with hospital notes
Consent Form Version 4, dated 04.06.2007 




















































   
   
   







































































































































































































































































Ingredients in the Placebo are: water, dextrin (starchfibre), aroma, acidifier 








    
 
















                              




             
          
 
Appendix 8
THE BORG BREATHLESSNESS SCORE
0 NOTHING AT ALL









9.0 VERY, VERY SEVERE (ALMOST
MAXIMAL)
10 MAXIMAL
(N.B. There is no ‘right’ or ‘wrong’ way with this scoring. It is just
how you feel at the time. It is helpful for us to know how difficult











   
 
    
 
   
 






   
 




HOW HARD WAS IT?

















   








   
 
Appendix 10
A comparison of 3 methods to measure 
isometric quadriceps strength
Introduction: The measurement of skeletal muscle strength is important in 
the assessment of RT programmes in patients with COPD. The test re-test 
reliability of repeated measures taken within the same session is important to 
establish to ensure that learning and fatigue effects are accounted for.
Aim: The purpose of this study was to evaluate the test-retest reliability of 
three measures of isometric quadriceps strength in patients with COPD and 
healthy controls. 
Methods: The data from16 patients with COPD [mean (SD) age 68.6 (8.2) 
years, FEV1 47.8 (23.0) % predicted,13 male] and 11 healthy subjects [mean 
(SD) age 66.4 (4.7) years, FEV1 97.3 (25.7) % predicted, 6 male] was
available for analysis. Isometric peak force was measured using the 
microFET2 handheld dynamometer (HHD), a seated strain gauge (SG: Kern) 
and the Cybex II Norm isokinetic dynamometer. The knee angle was fixed at 
70° flexion for all testing methods. All were performed at least three times on 




























The HHD and SG measure strength in Kg. This was converted to Newtons (N) 
to allow comparison with the Cybex. The intra class correlation co-efficient 
(ICC) was calculated for all three measures. 
Results: Table1 shows the mean values for isometric strength for all testing 
methods, on both tests, mean difference between the two tests and the ICC.
Conclusions: The ICC was high for all isometric strength measures and very 
high for the SG and the Cybex [according to previously reported values  
(Munro 2001)]. The HHD was slightly less reliable on repeat testing. There 
does not appear to be a significant learning effect and the results were 
comparable between patients and healthy controls.
Method Mean(SD) 
Test 1 Test 2 
Mean difference 
between Tests 1 
and 2 (95% CI) 
ICC
COPD HH (N) 167.2(34.7) 169.2(29.0) 2.1 (-20.3-16.1) .714
SG (N) 267.8(54.3) 273.4(60.1) 5.6 (-33.2-22.0) .909
Cybex (Nm) 124.7(43.7) 132.4(47.5) 7.7 (-20.5-5.1) .931
Healthy HH (N) 160.1(29.0) 172.6(28.5) 13.0 (-27.2-2.2) .854
SG (N) 273.4(54.3) 288.5(97.4) 15.1 (-65.4-35.2) .905




      






Report: test re-test reliability of isokinetic methods to
measure quadriceps muscle function
Introduction: Isokinetic testing is a sophisticated method to assess muscle 
function and relates closely to functional movements; more so than isometric 
testing and has been extensively reported in musculoskeletal rehabilitation 
(Mathur, Makrides, & Hernandez 2004). However isokinetic testing is 
unfamiliar to most individuals and is rarely used in the assessment and 
training of individuals with COPD. Only 16 out of 139 articles relating to RT in 
patients with COPD used an isokinetic dynamometer to measure dynamic 
strength (Robles, Mathur, Janaudis-Fereira, Dolmage, Goldstein, & Brooks 
2011). This systematic review found that most of these studies measured 
quadriceps strength at 60°/sec. 
Reliability results from isokinetic testing in the healthy population can not be 
easily transferred to patients with COPD who have weaker muscles and are 
more prone to fatigue (American Thoracic Society/ European Respiratory 
Society 1999). Test re-test reliability of repeated measures taken within the 
same session is important to establish to ensure that learning and fatigue 
effects are accounted for. The test re-test reliability of isokinetic muscle 
testing has therefore been explored in patients with COPD. In 2004, Mathur 
and colleagues reported within-session and test re-test reliability over seven 








COPD (Mathur, Makrides, & Hernandez 2004). Isokinetic testing of the 
quadriceps took place on the dominant leg for three trials at PAV’s of 30 and 
90 °/sec. The within-session test re-test reliability was high [intra-class 
correlation co-efficients (ICCs) ranging from 0.95 (90°/sec) to 0.99 (30°/sec)]. 
There were no significant differences between the three trials (p>0.05). There 
were also no significant differences between the peak torque recorded 
between two sessions, one week apart [ICC 0.85 (30°/sec) and 0.96 
(90°/sec)]. However this study did not observe the reliability at the testing 
velocity of 60°/sec, chosen in this RCT. Furthermore, the authors did not 
report the test re-test reliability of work. Isokinetic work may have different test 
re-test properties compared to peak torque. 
Aims: The aim of this chapter was to assess the test re-test reliability of the 
chosen isokinetic testing protocol (60°/sec) in patients with COPD; 
considering both peak torque and total work variables, analysed within one 
session. A secondary aim was to compare the reliability between patients with 
COPD and healthy, age-matched controls. 
Methods: Testing of the dominant quadriceps took place on an isokinetic 
dynamometer (Cybex II Norm, CSMi, Stoughton, MA, USA) as described in 
chapter 3 (materials and methods). Subjects performed two sets of five knee 
extensions at 60 °/sec. Knee ROM was set between 10-80° flexion. The 
highest peak torque (Nm) and total work (J) were recorded. Repeat testing









minutes, on the same day. These measures took place on the familiarisation 
session, prior to baseline testing and the start of RT. 
Statistical Analysis: A repeated measures analysis of variance (ANOVA) 
with post-hoc Bonferroni testing was used to identify any significant 
differences between the peak torque and total work done on the three tests. 
The F statistic, along with its degrees of freedom (df) are reported.  
Agreement between tests 1, 2 and 3 (for torque and work) was calculated 
according to the method of Bland and Altman, with the magnitude of 
differences expressed as the mean difference (d) and the limits of agreement 
calculated from 2 standard deviations (SD) of the differences. 
Finally ICCs were also calculated for torque and work. ICC values of 0.70 to 
0.89 were accepted as high reliability, values of 0.90 and above represented 
very high reliability (Munro 2001). 
Results: A sample of 57 subjects with COPD [39 male, mean (SD) age 68.6 
(8.9) years, FEV1 45.6 (15.6) percent predicted, BMI 27.0 (5.3)] and 17 
healthy age-matched controls [9 male, mean (SD) age 67.0 (4.5) years, FEV1 
103.4 (15.9) percent predicted, BMI 27.7 (2.6)] completed three strength 
assessments on a familiarisation visit, prior to starting the RT programme.  
Mean values and percentage differences between tests are shown in table 1 
for both isokinetic torque and work, for both groups. For COPD patients, there 
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were significant differences between the three tests for isokinetic peak torque, 
F (df 2, 112) = 4.36. Post-hoc tests revealed that the significant differences 
were between tests 1 & 2 and tests 1 & 3 (both p<0.05), but not between tests 
2 & 3 (p>0.05). For isokinetic work in COPD patients there were also 
significant differences between the tests, F (df 2, 100) = 7.57. Sphericity was 
violated for work; therefore a Greenhouse-Geisser correction was made. 
Again post-hoc tests revealed that the significant differences were between 
tests 1 & 2 and tests 1 & 3 (both p<0.01), but not between tests 2 & 3 
(p>0.05). 
Table 1. Mean values for isokinetic torque and work on 3 testing occasions for
patients with COPD and healthy controls
Test 1 Test 2 Test 3
COPD Subjects
Mean (SD) isokinetic torque (Nm) 80.0 (31.9) 83.8 (34.0)* 83.6 (35.7)*
Mean percentage change between tests (95%CI) ------------------- 5.2 (1.6-8.8) -0.6 (-4.4-3.2)
Mean (SD) isokinetic work (J) 286.4 (121.4) 308.8 (137.5)** 312.4 (147.2)*
Mean percentage change between tests (95%CI) ------------------- 8.2 (3.2-13.2) 2.1 (-5.4-9.6)
Healthy Subjects
Mean (SD) isokinetic torque (Nm) 97.9 (30.0) 98.8 (30.8) 99.2 (33.5)
Mean percentage change between tests (95%CI) ------------------- 2.2 -0.6
Mean (SD) isokinetic work (J) 373.1 (130.2) 375.2 (124.9) 377.2 (139.4)
Mean percentage change between tests (95%CI) ------------------- 1.3 -0.5







When performing the repeated measures ANOVA for isokinetic torque in 
healthy subjects, sphericity was violated. Therefore, degrees of freedom were 
corrected using Greenhouse-Geisser estimates of sphericity. The results 
showed no significant differences between the 3 tests, F (df 1.47, 23.50) = 
0.19 (p> 0.05). Similarly, there were no significant differences between the 
three tests for isokinetic work in healthy subjects; F (df 2, 32) = 0.08 (p>0.05). 
The mean of the individual differences (d) in isokinetic torque and work 
between tests (test 2 minus test 1 etc) and limits of agreement [± 2 SD of the 
differences (d)], are shown in figure 1 for subjects with COPD. 
Acceptable limits of agreement for this type of testing are unknown. Inspection 
of the Bland and Altman plots suggests that the differences are sporadic and 
do not become more variable at high or low torque/ work values. 
The ICC values for isokinetic torque were 0.98 for patients with COPD and 
0.97 for healthy controls. For isokinetic work, the ICC values were 0.97 for 
patients with COPD and 0.98 for control subjects.
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Figure 1 Bland and Altman plots of the difference between tests 1 & 2 and tests
2 & 3 for isokinetic torque (A and B) and work (C and D) for patients with COPD
Conclusion: For patients with COPD, the results show statistically significant 
differences between tests 1 and 2 but not between tests 2 and 3 for both 
isokinetic torque and work. However the percentage change between repeat 
tests was relatively small in comparison to changes in isokinetic strength 
evident after the 8-week RT programme (see chapter 4). Inspection of the 
Bland and Altman plots suggests that the differences between tests were 









rates. Acceptable limits of agreement for this type of testing are unknown.
These results suggest that subjects with COPD should perform at least one
familiarisation test prior to baseline testing when using this unfamiliar strength 
testing method. This would be considered best practice. 
For healthy subjects, there were no significant differences between repeat 
tests for both peak torque and work. The cause of this apparent stability is 
unknown, particularly when the testing method would also be unfamiliar to 
most healthy individuals also. As with all types of strength testing, the results 
may be effort dependant. One may speculate that perhaps patients with 
COPD would be more tentative on the first testing occasion due to fears over 
breathlessness and perceived exertion of the task. This may account for the 
greater difference between tests one and two in patients with COPD, 
compared to healthy controls. 
The ICC values were very high for both torque (0.98) and work (0.97) in 
patients with COPD. Therefore the test re-test reliability for torque and work 
are similar. The ICC value for torque presented here, is similar to that 
reported within a single session by Mathur and co-workers (Mathur, Makrides, 
& Hernandez 2004); 0.95 (90°/sec) and 0.99 (30°/sec). Furthermore, there 
were no significant differences between ICC values for patients with COPD 















The isokinetic dynamometer (Cybex II Norm: CSMi, Stoughton, USA) was 
calibrated every month in accordance with manufacturer’s guidelines. This 
involved placing 100lbs of weight onto the knee/hip adapter arm which was 
set at a specific length. The weight was then dropped and the system shows 
the amount of torque that it should read when 100lbs is dropped. Following 
this weight drop, the system adjusts its internal conversion factors. ‘Success’ 
will be displayed if the calibration is ok. If there is an error, the calibration 
should be repeated before contacting CSMi for technical support.
DEXA Scanner 
The DEXA scanner was calibrated daily with a Quality Assurance (QA) test; 
as suggested by the manufacturer. This involved placing a calibration block 
under the laser light of the DEXA scanner arm. The block consists of tissue-
equivalent material with three bone-simulating chambers of known bone 
mineral content. The remainder of the test runs automatically; testing the 
detector status, bone mineral density of the block and system status. The 
software automatically returns to the QA screen once the test is completed. A 
green light indicates a pass and is a sign that the system is ready to measure
patients. A red light indicates a fail. In this scenario the test should be 







Gas calibration was performed everyday, in line with manufacturer 
recommendations. Prior to calibration the system had to be switched on for a 
minimum warm-up time of 20 minutes. The gas calibration involved opening 
the gas bottle and connecting the gas-suction tube to the calibration port on 
the front panel of the Zan 600. Gas mixture I (bottle gas) is compared to gas 
mixture II (ambient air). The actual values are displayed together with the 
expected values before the calibration is complete.
Volume calibration is performed before each individual test, in accordance 
with manufacturer guidelines. To do this, the flow sensor is connected to a 3l 
calibration syringe. The piston of the syringe is moved from end to end for six 
strokes and the results of the calibration are shown. If the calibration volume 
equals the syringe volume then the calibration is successful. If the deviations 
are too large, the test is repeated before contacting the manufacturer for 
support. 
In addition, a biological quality control test was carried out monthly starting 1 
year prior to the study start and during the study; using a young human male 
subject. After several practice tests, baseline tests were performed over a 
short period of time. All tests were then compared to these baseline values. 
The test involved a maximal incremental cycle ergometry test using a ramp 








Respiratory Physiology Equipment  
The SPIRO AIR® equipment was calibrated every morning for volume, FRC 
and transfer factor. A green light is displayed as a pass for all three tests. If a 
fail occurs, the calibration should be re-done before contacting the 
manufacturer for assistance. A healthy, young biological control used the 
equipment every 3-weeks as a further quality control measure. 
The blood gas analyser uses a two point calibration to check expected and 
actual concentrations of O2, carbon dioxide CO2 and pH. This occurs 
automatically every two hours. A further quality control is completed every 2-
weeks where 3 known levels (low – high) of O2, CO2 and pH are analysed by 
the system. These should be within 2 SD of what is expected.
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Resistance training progression for the left leg
This appendix shows the equivalent graphs and tables for the left leg that are
displayed for the right leg in chapter 5.
They are: total work progression, peak torque progression, percentage progression 
in training variables, fatigue indexes for total work and peak torque and absolute 
total work and torque decline over the 8-week training period. 
Figure 1. Training intensity progression of total work performed at weeks one to 




       





               
           
 
 
       
      
 
   
      
 
   
      
 
  












Figure 2. Training intensity progression of peak torque performed at weeks one to 
eight in patients with COPD and healthy controls
Table 1. Mean percentage change in isokinetic total work and peak torque for the left
leg during the 8-week resistance training programme, in patients with COPD and
healthy controls
Values are mean (SD) COPD Subjects Healthy Controls
Percentage change in work weeks 1-4 25.4 (28.6) 10.7 (14.9) *
Percentage change in work weeks 1-8 43.1 (50.3) 15.6 (17.2) *
Percentage change in torque weeks 1-4 9.3 (18.5) 7.8 (11.2)
Percentage change in torque weeks 1-8 19.8 (27.7) 13.5 (12.8)
* p<0.05 between group difference
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Figure 3. Mean fatigue index (FI) for work over 8-weeks in patients with COPD and
healthy controls
Figure 4. Absolute decline in isokinetic work between sets 1 to 5 averaged per week
in patients with COPD and healthy controls
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Figure 5. Mean fatigue index (FI) for torque over 8-weeks in patients with COPD and
healthy controls
Figure 6. Absolute decline in isokinetic torque between sets 1 to 5 averaged per









Findings: The results for the left leg, presented in this appendix, broadly mirror the 
findings in chapter 5 (right leg). The training progression trajectories for total work 
(figure 1) and peak torque (figure 2) are a similar pattern to figures 5.1 and 5.2 
(right leg, chapter 5). The absolute values are also similar. Again, healthy controls 
performed RT at significantly higher workloads and torque values compared to 
patients with COPD at all time points (p≤0.05) and this division between controls 
and COPD patients remained throughout. Both groups had significant within-group 
improvements in work and torque performed at four and 8-weeks compared to 
baseline. However there was a plateau in the healthy control group after 4-weeks 
(no significant improvement between weeks 4-8) for both outcomes. COPD 
subjects continued to have significant improvements in training workload and 
torque production between four and 8-weeks (p≤0.01). 
The results in table 1 indicate that the majority of the progression in training work 
and torque for the left leg occurs within the first 4-weeks, for both groups. The 
percentage changes in isokinetic work exceeded changes in torque at both time 
points for patients with COPD. The magnitude of changes was generally the same 
as in table 5.1 (chapter 5, right leg). Although percentage improvements in the left 
leg for work performed exceed the changes in the right leg for patients with COPD 
(left leg weeks 1-8= 43.1%, right leg weeks 1-8= 25.4%). There was a statistically 
significant between-group difference for the percentage change in isokinetic work 
in weeks 1-4 (10.7% for controls, 25.4% for patients with COPD, p<0.05).and 







Figures 3 and 4 display the FI and absolute decline for work produced in the left 
leg. There were no significant differences between the two groups, at any time 
point for FI and work decline. The FI remained at around 90% in patients with 
COPD but improved in control subjects over the 8-week period, suggesting 
improved FR in this group. The mean absolute workload decline each week was 
greater for the left leg (figure 4), when compared to the right leg (figure 5.4, chapter 
5). 
Figures 5 and 6 outline the FI and absolute decline for torque produced in the left 
leg. At week one patients with COPD had a significantly higher torque FI
compared to healthy controls (p<0.05). Differences between groups were not 
apparent at any other time point for FI and for torque decline. Furthermore, torque 
declines each week were much lower for the left leg (figure 6) when compared to 









   
   
   
   
   
   




















Wearing your Activity Monitor 
We ask you to wear your activity monitor for 7 consecutive days during waking 
hours. This will measure the times that you are active throughout the day. 
Please wear your monitor at the following times each day: 








• You do not need to switch the monitor on just attach it to your belt or belt 
hook when you get dressed in the morning. If you remember, press the ‘mark’ 
button each morning when you first put the monitor on. 
• Take the monitor off each evening and again, if you remember, press the 
‘mark’ button each evening when you take the monitor off.
• Aim to wear the monitor for approximately the same number of hours each 
day. For example, 9am to 9pm. 
• The monitor is lightweight and shouldn’t interfere with your everyday activity, 
just carry on with your daily routine as normal. 
• Take off the monitor if you have a bath/shower or when washing. Try not to 
get the monitors wet. 
Please return the monitor when you attend for your next visit or if this is your last 
visit, the monitor will be collected from your house on……………………. at ……..
Thank you for your commitment to this research study. If you have any problems or 




     
 
 
         















































































       
Appendix 16
Duke Activity Status Index (DASI)
Please answer the questions below by circling the appropriate
response Yes or No.
Can you:
Weight
1. Take care of yourself, that is, eat, dress, bathe or use 
the toilet?
2.75 Yes/No 
2. Walk indoors, such as around your house? 1.75 Yes/No 
3. Walk a one mile or two on level ground? 2.75 Yes/No 
4. Climb a flight of stairs or walk up a hill? 5.50 Yes/No 
5. Run a short distance? 8.00 Yes/No 
6. Do light work around the house like dusting or washing 
dishes? 
2.70 Yes/No 
7. Do moderate work around the house like vacuuming, 
sweeping floors or carrying groceries?
3.50 Yes/No 
8. Do heavy work around the house like scrubbing floors 
or lifting or moving heavy furniture? 
8.00 Yes/No 
9. Do garden work like raking leaves, weeding or pushing 




Have sexual relations? 5.25 Yes/No 
11 
. 
Participate in moderate recreational activities like golf, 
bowling, dancing, doubles tennis or throwing a cricket 




Participate in strenuous sports like swimming, singles 
tennis, football? 
7.50 Yes/No 
V02MAX = 0.43 X DASI + 9.6
316
317
